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Abstract 
 
The pseudokinase TRIB2 is a potent AML oncogene, capable of inducing transplantable AML with 
a relatively short latency in murine models. Functionally, the oncogenicity of TRIB2 has been 
linked to its degradation of C/EBPα, a transcription factor necessary for regulation of HSCs, 
myeloid differentiation and is identified mutated in ~10-15 % of cytogenetically normal AMLs. 
Previously, we have demonstrated that elevated TRIB2 mRNA expression is associated with a 
subset of C/EBPα dysregulated AML patients.  
Here, using in vivo ubiquitination assays I determined TRIB2 exerts its effect through K48 specific 
ubiquitin-dependent proteasomal degradation of C/EBPαp42. Peptide array analysis identified the 
specific amino acids involved in the direct binding of these two proteins. Site-directed mutagenesis 
of these amino acids demonstrated that the direct binding of TRIB2 and C/EBPα was required for 
TRIB2-mediated C/EBPαp42 ubiquitination. C/EBPαp42 may exist as a dimer or a monomer; 
however differential dimerisation perturbs terminal myeloid differentiation. TRIB2 binds both 
monomeric and dimeric C/EBPαp42 but ubiquitination assays revealed it preferentially mediates 
ubiquitin-dependent degradation of dimeric C/EBPαp42, suggesting dimeric C/EBPαp42 provides a 
structurally preferential confirmation for TRIB2-mediated ubiquitination of C/EBPαp42. In order to 
determine if a post-translational modification of C/EBPαp42 was a trigger for TRIB2-mediated 
binding and degradation, I assessed the phosphorylation status of C/EBPα, often a modification 
involved in C/EBPα ubiquitination. I determined TRIB2 decreased the levels of phosphorylated 
Serine 21 (S21) C/EBPα through preferential binding to the phosphorylated S21 form of 
C/EBPαp42 and mediating increased ubiquitination. Further molecular elucidation of the 
TRIB2:C/EBPαp42 proteolytic relationship identified C/EBPαp42-K313 as the site of ubiquitin 
conjugation on C/EBPα and subsequent annotation of this region revealed it is mutated in ~10 % of 
C/EBPα mutAMLs. 
Using the clinically available proteasome inhibitor Bortezomib I investigated the targeted inhibition 
of the TRIB2 degradation function to induce cell death in AML cells. In TRIB2 overexpressing 
AML cell lines, and in AML patient samples identified to have elevated levels of TRIB2, I have 
demonstrated that high TRIB2 expressing samples are more sensitive than low TRIB2 expressing 
samples to cell death induced by proteasomal inhibition. 
I propose TRIB2 mediates is leukaemogenic effects through functioning as an adaptor protein, 
facilitating the formation of a multiprotein complex COP1:TRIB2:C/EBPα resulting in ubiquitin-
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dependent C/EBPαp42 degradation. Dimeric P-Ser21-C/EBPαp42 provides a structurally 
favourable confirmation for enhanced TRIB2-mediated ubiquitination. As C/EBPαp42 plays a key 
role in both stem cell function and myeloid differentiation in AML, the targeted inhibition of 
TRIB2-mediated C/EBPαp42 degradation may provide therapeutic avenues in AML.  
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1.1.1 The early stages of haematopoiesis and the production of the haematopoietic 
stem cell. 
Haematopoiesis and the origins of leukaemic disease are developmentally intertwined (Orkin and 
Zon, 2008). Haematopoiesis describes the process of developing and maintaining an unlimited 
blood supply from embryogenesis throughout adult life. Dysregulation of this process results in 
haematopoietic malignancies termed leukaemia (from the ancient Greek leukos "white", and αἷμα 
haima "blood"), with leukaemic subtypes defined by the blood lineage affected. Haematopoiesis is 
highly evolutionary conserved in all vertebrates; studies of murine models have taught us much of 
what we know of the human haematopoietic system. The lifelong ability to homeostatically produce 
blood is dependent on the self-renewal and differentiation capacity of haematopoietic stem cells 
(HSCs). HSCs sit atop of the hierarchy of blood lineage. A pool of HSCs are formed early in 
embryogenesis and migrate to different anatomical niches under temporal control which support the 
intrinsic characteristics and properties of the HSC. During organogenesis simultaneous de novo 
generation of HSCs and stockpiling to create a pool for post-natal life is required. The sequential 
sites of human haematopoiesis during embryogenesis are the embryonic yolk sac, the aorta-gonad-
mesonephros (AGM), the placenta, the foetal liver and the bone marrow (summarised in Fig1.1). 
 
Fig 1.1 Anatomical localisation of embryonic haematopoiesis. The embryonic yolk sac, the 
AGM, the foetal liver and placenta are the sites of haematopoiesis during embryogenesis adapted 
from (Mikkola and Orkin, 2006). 
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Early in embryogenesis post gastrulation, mesodermal precursor cells become the early 
haematopoietic precursor cells in the embryonic yolk sac. It was been long proposed that these 
early precursor cells termed ”hemangio-blast” cells have the ability to form either the blood cells or 
the vascular endothelial cells (Sabin, 1917). Differential transcription factor expression controls this 
early stage of haematopoiesis termed the “primitive stage”. The embryonic yolk sac produces 
immature erythroid cells which migrate to the foetal liver and mature into differentiated erythroid 
cells necessary to oxygenate tissues required to support rapid embryogenesis (Li et al., 2003, 
Ferkowicz et al., 2003, McGrath and Palis, 2005). The yolk sac also forms a foetal-maternal 
transport system prior to development of the placenta (McGrath and Palis, 2005). There is as of yet 
no definitive answer regarding the role of the yolk sac in HSC production (reviewed by (Mikkola 
and Orkin, 2006, Orkin and Zon, 2008)). It is suggested that the AGM is the sole site of HSC 
production (Muller et al., 1994, Cumano et al., 1996, Medvinsky and Dzierzak, 1996, Cumano et 
al., 2001). Alternatively it is also reported that HSC production by the AGM alone is not sufficient 
to maintain the pool of HSCs but later in embryogenesis the yolk sac forms a supportive niche for 
HSC expansion (Moore et al., 1970, Kumaravelu et al., 2002). The AGM is formed by the median 
migration of the lateral mesoderm to the endoderm. HSCs accumulate within the ventral wall. From 
here the HSCs migrate to the foetal liver for expansion and differentiation (Ema and Nakauchi, 
2000). Once the bone marrow is established HSCs migrate to the bone marrow where they remain 
in a quiescent state for post-natal life. The placenta is not categorised as a haematopoietic organ 
however haematopoietic activity has also been detected within the placenta (Ottersbach and 
Dzierzak, 2005, Gekas et al., 2005). Accumulation of HSCs have been identified within the 
placenta, suggesting the placenta either acts as a de novo site of HSC production or it provides a 
niche for HSC storage and expansion just upstream of the foetal liver blood supply (Orkin and Zon, 
2008). Schematic of sequential haematopoiesis summarised in Fig 1.2 (adapted from (Mikkola and 
Orkin, 2006)). 
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Fig 1.2 Schematic of sequential haematopoiesis. Haematopoiesis initiates as a hemangio-blast 
which generates vascular and blood cells. Primitive red blood cells are produced in the yolk sac. De 
novo HSC genesis occurs in AGM, HSCs are circulated to the placenta, foetal liver and yolk sac for 
expansion. Expanded HSCs migrate to established bone marrow for post-natal life adapted from 
(Mikkola and Orkin, 2006). 
 
1.1.2 HSCs and haematopoietic lineage commitment  
There are intrinsic differences between the HSC within the foetal liver and those located within the 
bone marrow. During embryogenesis foetal liver HSCs are cycling quite frequently and rapidly in 
order to generate a HSCs pool (Bowie et al., 2006). This is contrary to adult HSCs within the bone 
marrow which are normally found in G0, a metabolically inactive quiescent state (Cheshier et al., 
1999). Adult HSCs cycle very rarely, this is proposed to reduce the chances of acquiring 
deoxyribonucleic acid (DNA) replication errors promoting the longevity of the cell and reducing 
the production of cytotoxic metabolic side products (reviewed by (Mikkola and Orkin, 2006)). 
HSCs preside over a haematopoietic hierarchy which results in at least 8 distinct functional effector 
cell types (Weismann model Fig 1.3 adapted from (Bryder et al., 2006)). Differentiation of HSCs 
arises through either asymmetrical division of HSCs or asymmetrical environmental exposures 
(Wilson and Trumpp, 2006). The former occurring through unequal distribution of cell fate 
governing factors and the latter due to differential environmental exposures, i.e. a daughter cell 
leaves the self-renewal supportive niche. 
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Fig 1.3 Weismann model of haematopoietic differentiation adapted from (Bryder et al., 2006). 
Consecutive rounds of differentiation with resultant decrease in self-renewal potential from LT-
HSC to ST-HSC resulting in the generation of MPP, oligopotential CLP and CMP resulting in 8 
terminally differentiated mature effector cell types.  
HSCs can be subdivided into two distinct types based on their functionality, long term (LT) and 
short term (ST). LT-HSCs are relatively infrequent in the bone marrow and possess lifelong self-
renewal ability and multilineage potential (Christensen and Weissman, 2001). LT-HSCs give rise to 
ST-HSCs which retain multilineage potential but have decreased self-renewal abilities (Weissman 
et al., 2001). The progressive stages of differentiation from HSC to multipotential progenitor (MPP) 
generate a cell which retains multilineage potential with a decrease in self-renewal capacity. The 
next round of differentiation generates oligo-potential progenitors which form lineage restrictions 
toward the lymphoid (common lymphoid progenitor-CLP) or myeloerythroid progenitors (common 
myeloid progenitor-CMP and megakaryocyte erythroid progenitor-MEP). Commitment toward a 
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specific lineage is simultaneously associated with de-selection for other possible lineages. These 
cells have lost self-renewal capabilities but have a high proliferative index. Terminal differentiation 
of the lymphoid lineage gives rise to B-Cells, T-Cells, Natural killer (NK) cells and dendritic cells. 
Terminal differentiation of GMPs produces granulocytes and macrophages while terminal 
differentiation of MEP produces erythrocytes and platelets (Fig 1.3 adapted from (Bryder et al., 
2006)). It is widely thought under normal physiological conditions differentiation is an irreversible 
state. In vitro experimentation has shown that overexpression of transcription factors governing one 
form of lineage commitment can reprogramme a cell already committed to another lineage (Xie et 
al., 2004, Laiosa et al., 2006b). Several well-defined transcription factors have been identified to 
govern terminal differentiation. Expression of these transcription factors has also been detected 
within the HSC, whereby they are thought to prime a HSC for its eventual fate. It is hypothesised 
that the invested chromatin remains in an open configuration allowing transcription of these cell 
fate determinants with successive rounds of differentiation extinguishing other potential pathways 
as opposed to applying a cell fate transcriptional signature on a blank cell (Orkin and Zon, 2008). 
1.1.3 Disruption of haematopoiesis  
Haematopoietic homeostasis is governed by HSC intrinsic factors and micro-environmental 
extrinsic factors. Disruption of the cell processes which tightly regulate stem cell self-renewal, 
proliferation or differentiation result in haematopoietic malignancy and leukaemic disease. These 
aberrant processes result in the generation of a leukaemic stem cell (LSC) with accompanying 
unregulated self-renewal and differentiation capabilities. The different haematopoietic cell type 
which acquires these malignant transformations governs the phenotypic manifestation of the 
haematopoietic disease. Intrinsic factors which may be disrupted include cell signalling cascades, 
cell cycle regulation and transcription factor functionality often due to chromosomal translocations 
and genetic aberrations. Extrinsically, developmental pathways have been found dysregulated and 
components of the extracellular HSC niche resulting in disruption of haematopoiesis. 
1.2. Leukaemia  
Leukaemia is the 11
th
 most common cancer in the United States, the 12
th
 most common cancer in 
Europe and 6
th
 leading cause of cancer related deaths (Ferlay et al., 2012). Five year survival rates 
have dramatically increased from 14 % in the 1960s however they have stalled at 56 % in the last 
decade (statistics from SEER cancer statistics review (Howlader et al., 2012). There is no staging 
associated with leukaemia presentation, patients are classified as untreated, in remission or 
relapsed. While socially leukaemia is largely associated with paediatric patients, leukaemia is more 
common in adults with median age of diagnosis 66 years. Leukaemia is categorised as acute or 
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chronic and further subdivided based on whether the blood lineage affected is myeloid or lymphoid. 
Chronic leukaemia (CL) progresses slowly over a course of months and years, resulting in the 
excessive accumulation of mature yet abnormal haematopoietic cells. Acute leukaemia (AL) 
progresses rapidly over weeks and months effecting haematopoietic progenitor cells resulting in 
accumulation of immature blast like cells and bone marrow failure. 
1.2.1 Chronic Leukaemias 
CL encompasses two disease entities; chronic myeloid leukaemia (CML) and chronic lymphoid 
leukaemia (CLL), determined by the identity of the originating LSC. Patients with CL do not 
usually develop bone marrow failure unlike AL patients. CL evolves slowly over 4-5 years; patients 
present with abnormal white blood cell counts, lymphadenopathy and splenomegaly with CL 
disease often entering an acute phase. CLL is currently incurable, all patients are anticipated to 
relapse with CLL disease (Gibson et al., 2013). CLL is characterised by the expansion of CD5
+
 
CD23
+
 B lymphocytes in blood, bone marrow and lymphoid tissues. No single recurrent genetic 
mutation is associated with CLL but deletions in chromosomes 11q22-23, 13q14 and 17p13 and 
trisomy of chromosome 12 have been identified (reviewed by (Zhang and Kipps, 2013)). 17p13 
(TP53 gene) and 13q14 (ATM gene) deletions are associated with a poor prognosis as functional 
p53 is required for cellular response to most current chemotherapies (Döhner et al., 2000). CLL was 
initially regarded as a disease manifesting through inhibition of apoptosis resulting in the 
accumulation of leukaemic cells. Circulating CLL cells were identified to be in G0 or G1 phase of 
cell cycle and to overexpress anti-apoptotic BCL2 (Dighiero et al., 1991, Kitada et al., 1998). 
However a distinct subset of patients have been identified with CLL cells with rapid cell cycle 
kinetics and increase their CLL cell population by 1 % in 1 day but yet have stable disease owing to 
simultaneous apoptosis (Messmer et al., 2005). Variability in CLL disease progression is reflective 
of huge heterogeneity in genetic lesions identified in patients. Studies of the CLL subclone 
populations prior to, during and post treatment identified huge heterogeneity in subclone 
populations complicating identification of initiating, maintenance and relapse associated genetic 
lesions (Schuh et al., 2012). Mutations in NOTCH1, SF3B1, BIRC3, MyD88, dysregulated Wnt 
signalling and NF-κB activation have all been identified in CLL patients reviewed by (Zhang and 
Kipps, 2013). Additionally the CLL microenvironment supports the CLL cell viability releasing 
prosurvival signals (Burger et al., 2009). The current standard treatment regime for CLL patients is 
combination of fludarabine, monoclonal CD20 antibody rituximab and cyclophosphamide (Hallek 
et al., 2010). Allogeneic stem cell transplants offer specific patients with a potential cure.  
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CML was the first malignancy identified to be associated with a recurrent cytogenetic abnormality, 
the Philadelphia chromosome (Nowell and Hungerford, 1960). The Philadelphia chromosome 
arises as a result of reciprocal translocation between chromosome 9 and 22 (t(9;22)(q34;q11)) 
producing breakpoint cluster region-Abelson leukaemia-virus (BCR)-(ABL) fusion protein which 
has constitutive receptor tyrosine kinase activity (de Klein et al., 1982, Lugo et al., 1990). CML is a 
clonal bone marrow stem cell disease resulting in the excessive expansion of granulocytes and is 
treated with a targeted therapy imatinib, a potent selective tyrosine kinase inhibitor (TKI). Imatinib 
competes for the adenosine triphosphate (ATP) binding site on BCR-ABL fusion oncoprotein, 
quenching tyrosine kinase activity resulting in cell death for pathway addicted leukaemic cells. 
Unfortunately 30 % of patients are required to discontinue imatinib treatment due to drug related 
toxicities and emergence of imatinib resistant disease. Imatinib resistance has been attributed to 
generation of mutations within the BCR-ABL kinase domain and the imatinib binding site T315I. 
Second generation TKIs nilotinib, dastainib, bosutinib and ponatinib offer reduced cytotoxicities 
with varying improvements to overall survival. Ponatinib has demonstrated efficacy against BCR-
ABL T315I imatinib resistant disease. 
1.2.2 Acute Leukaemias 
AL progresses more rapidly that CL and requires immediate treatment upon diagnosis. ALs are 
classified as lymphoid or myeloid depending on the cell lineage affected. ALL is a malignant 
haematopoietic disorder of pre B (80-85 %) and T (15-20 %) lymphocytes. The exact mechanisms 
resulting in transformation are unknown however many chromosomal translocations, regions of 
hyper/hypodiploidy and genetic lesions have been associated with ALL. The most common 
chromosomal translocation identified in B-cell precursor ALL (B-ALL) is the Philadelphia 
chromosome t(9;22)(q34;q11) (Moorman et al., 2010). Mixed lineage leukaemia (MLL) gene 
rearrangements and subsequent oncogenic fusions with various gene partners (t(v;11q23)) are 
frequent and indicative of an aggressive disease with a young age of onset. Further translocations 
identified include t(12;21) ETV6-RUNX1 which is associated with a favourable outcome, t(5;14), 
t(1;19) TCF3-PBX1 and rearrangement of MYC antigen (Inaba et al., 2013). Additional genetic 
lesions often accompany chromosomal translocation events and these include mutations in 
lymphoid gene regulators, cell cycle regulators and lymphoid signalling pathways TAL1, TLXA, 
TLX3, LYL1, PAX5, AK1, JAK2, CDK2NA, CDKN2B and NOTCH1 (Inaba et al., 2013). 
Treatment of ALL involves induction chemotherapeutics or the use of TKIs for t(9;22) positive 
disease and allogeneic stem cell transplant upon relapse. 
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AML is a vastly heterogeneous leukaemic subtype which is categorised by two classification 
systems; the world health organisation (WHO) and French American British (FAB) systems. AML 
is ultimately a generic term for a group of myeloid diseases resultant from rapid accumulation of 
immature myeloid cells through acquisition of self-renewal and hyper-proliferative properties. 
These abnormal immature myeloid cells then inhibit normal blood cell production. AML related 
mortality is predominately due to bone marrow failure and organ infiltration. AML to be discussed 
in extensive detail in 1.3. 
1.3 AML 
1.3.1 AML incidence, survival rates and standard treatment  
AML is the most common adult leukaemia with the lowest survival rate of all leukaemias 
(Howlader et al., 2012). The five year survival rates for patients >45 years, >65 years and <65 years 
are 41 %, 30 % and 4 % respectively (Redaelli et al., 2004). The incidence of AML is predicted to 
increase with an aging global population. Paediatric AML accounts for 20 % of childhood 
leukaemias and is the leading cause of paediatric leukaemia related mortality, 50 % of paediatric 
leukaemia related deaths are due to relapsed AML disease (Pui et al., 2011, Moore et al., 2013). 
AML may arise as de novo or secondary disease. Secondary AML arises as a result of treatment 
with cytotoxic agents (therapy related AML) or disease progression. 10-15 % of AMLs are therapy 
related and have poor prognosis (Kumar, 2011). Secondary AML may occur due to progression of 
CML, myeloproliferative/myelodyplastic disorders (MPN and MDS), polycynthemia and 
paroxysmal nocturnal haemoglobinuria. A number of factors will determine patient prognosis and 
the treatment regime implemented. Age is a factor associated with poor prognosis and older 
patients are less likely to receive chemotherapeutics due to high cytotoxicity and overall poorer 
quality of life. For such patients palliative care is available. The standard treatment for AML 
patients, with no adverse karyotypic features and low risk of relapse is induction therapy, the “3 +7 
induction regime”. This involves 3 days of intravenous daunorubicin (45-60 mg/m2/d) along with 7 
days of a continuous infusion of standard-dose cytarabine (SDAraC) (100-200 mg/m
2
) (Burnett et 
al., 2011).  
1.3.2 AML classification 
AML is classified into subtypes by two distinct classification schemes FAB and WHO (Bennett et 
al., 1976, Vardiman et al., 2009). The older FAB system classifies AML into 8 subtypes M0-M7 
based on cytogenetics, morphology and the extent of white blood cell differentiation (Bennett et al., 
1976) (Table 1.3.2 A). The newer WHO classification system aims to provide a globally applicable 
classification system based on cytogenetics, morphology, immunological markers and molecular 
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genetics and divides AML into four disease subgroups (Vardiman et al., 2009) (Table 1.3.2 B). The 
greatest difference between the two systems is FAB requires 30 % blasts in blood or bone marrow 
while WHO diagnosis AML at 20 %.   
FAB 
subtype 
Description Comments 
M0 Undifferentiated acute 
myeloblastic leukaemia 
Myeloperoxidase negative,myeloid markers positive 
M1 Acute myeloblastic 
leukaemia with minimal 
maturation 
Some evidence of granulocytic differentiation 
M2 Acute myeloblastic 
leukaemia with maturation 
Maturation at or beyond the promyelocytic stage of 
differentiation; can be divided into those with t(8;21) 
AML1-ETO fusion and those without 
M3 Acute promyelocytic 
leukaemia 
APL;most cases have t(15;17) PML-RARα or another 
translocation involving  RARα 
M4 Acute myelomonocytic 
leukaemia 
 
M4 eos Acute myelomonocytic 
leukaemia with 
eosinophilia 
Characterised by inversion of chromosome 16 involving 
CBFβ , which normally forms a heterodimer with AML1 
M5 Acute monocytic 
leukaemia 
 
M6 Acute erythroid leukaemia  
M7 Acute Megakaryoblastic 
leukaemia 
GATA1 mutations in those associated with Down’s 
syndrome 
 
Table 1.3.2 A FAB classification of AML. AML is divided into 8 categorises M0-M7. 
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Subgroup of  
Acute Myeloid Leukaemia 
Genetic and molecular details of disease 
1. Acute myeloid leukaemia (AML) and 
related precursor neoplasms 
 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22), RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;p22); 
CBFB-MYH11 
Acute promyelocytic leukaemia with 
t(15;17)(q22;q12);PML-RARA 
AML with t(9;11)(p22;q23)MLLT3-MLL 
AML with t(6:9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3.3)(q21;q26.2); RPN1-
EVl1 
AML (megakaryoblastic) with t(1:22)(p13;q13); RBM15-
MKL1 
AML with mutated NPM1 
AML with mutated CEBPA 
2. AML with myelodysplasia-related 
changes. 
       Therapy-related myeloid 
        Neoplasms. 
          
       Acute myeloid leukaemia, NOS 
 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic and monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
3. Myeloid sarcoma Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
 
4. Acute leukaemias of ambiguous lineage 
 
Acute undifferentiated leukaemia 
Mixed phenotype acute leukaemia with 
t(9;22)(q34;q11.2); BCR-ABL1 
Mixed phenotype acute leukaemia with t(v;11q23); MLL 
rearranged 
Mixed phenotype acute leukaemia, B/myeloid, NOS 
Mixed phenotype acute leukaemia, T/myeloid, NOS 
Natural killer (NK) cell lymphoblastic 
leukaemia/lymphoma 
 
Table 1.3.2 B The 4
th
 edition of WHO classification of AML. AML is classified into four 
categories. 
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1.3.3 Chromosomal translocations and aberrations in AML 
AML is a vastly heterogeneous disease in terms of both underlying genetic abnormalities and 
associated disease phenotypes. Cytogenetics is the most important determinant when predicting 
AML remission rates, relapse rates and overall survival. 50-60 % of newly diagnosed AML patients 
have chromosomal abnormalities. In 2011 over 749 different chromosome aberrations had been 
detected in AML (Mitelman et al., 2011). The most common chromosomal translocations result in 
the generation of a fusion gene/protein which acquires aberrant activity altering expression of target 
genes which govern myeloid differentiation (summarised in Table 1.3.3). A brief discussion of the 
5 most frequent translocations is outlined below. 
 
 
Table 1.3.3 The 12 most common chromosomal translocations in AML, the resultant oncofusion 
protein products, their frequency of occurrence in AML and FAB subtype adapted from (Martens 
and Stunnenberg, 2010). 
t(8;21) AML1-ETO 
t(8;21) is the most common chromosomal translocation event detected in AML, resulting in the 
production of the oncoprotein AML1-ETO (Muller et al., 2008). AML1 also known as RUNX1 is a 
transcription factor encoded on chromosome 21 which regulates expression of myeloid and 
lymphoid gene targets. AML1 knockout mice are embryonical lethal and display no evidence of 
definitive haematopoiesis in the foetal liver (Okuda et al., 1996). ETO encoded on chromosome 8, 
Translocations Oncofusion Proteins Frequency in AML FAB subtype 
t(8;21) AML1-ETO 10% M2 
t(15;17) PML-RARα 10% M3 
inv(16) CBFβ-MYH11 5% M4eos 
der(11q23) MLL-fusions 4% M4/M5 
t(9;22) BCR-ABL1 2% M1/M2 
t(6;9) DEK-CAN <1% M2/M4 
t(1;22) OTT-MAL <1% M7 
t(8;16) MOZ-CBP <1% M4/M5 
t(7;11) NUP98-HOXA9 <1% M2/M4 
t(12;22) MN1-TEL <1% M4/M7 
inv(3) RPN1-EVI1 <1% M1/M2/M4/M6/M7 
t(16;21) FUS-ERG <1% M1/M2/M4/M5/M7 
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acts as a transcriptional silencer through binding co-repressors. AML1-ETO has been identified to 
induce AML in murine models in the presence of additional cooperating mutations reviewed by 
(Hatlen et al., 2012). AML1-ETO leukaemias display a limited degree of maturation and are 
classified as FAB subtype M2 (Yamasaki et al., 1995).  
t(15;17) PML-RARα 
A translocation involving chromosome 15 and 17 results in the generation of promyelocytic 
leukaemia (PML) - retinoic acid receptor α (RARα) gene fusion. This oncogenic fusion protein is 
present in 95 % of acute promyelocytic leukaemias (APLs) (Grimwade et al., 2000). APL is a 
distinct subtype of AML FAB subtype M3 (Vardiman et al., 2009). RARα is a ligand inducible 
transcription factor which binds DNA response elements upon heterodimerisation with retinoid X 
receptors (RXRs). PML-RARα acts as an oncogenic transcriptional repressor through oligomeric 
complexing with RXR disrupting myeloid differentiation, apoptosis and self-renewal (Perez et al., 
1993, Zeisig et al., 2007). APL has the best survival rates of all leukaemia subtypes, as 90 % of 
patients achieve complete remission following treatment with all-trans retinoic acid (ATRA) and 
arsenic trioxide (Degos and Wang, 2001, Lengfelder et al., 2003). 
inv(16) CBFβ-MYH11 
Inversion 16 or translocation events involving 16q22 and 16p13 are associated with AML subtype 
M4eos. Patients possess monocytic and granulocytic differentiation but have abnormal eosinophils at 
various stages of differentiation arrest within the bone marrow (Larson et al., 1986). Aberration of 
chromosome 16 involves the introns of core binding factor β (CBFβ) and smooth muscle myosin 
heavy chain 11 gene (MYH11) producing the CBFβ-MYH11 chimeric protein, disrupting the 
transcription factor activity of CBFβ (Liu et al., 1993, Liu et al., 1995). CBFβ is essential for 
haematopoiesis, as evidenced in knock out murine models that result in mid-gestational fatalities 
due to a failure of haematopoiesis within the foetal liver, similar to AML1 knockout animals (Niki 
et al., 1997). CBFβ regulates transcription of a variety of genes involved in haematopoiesis 
including macrophage colony stimulating factor receptor (M-CSFR), IL-3 and myeloperoxidase 
(Nuchprayoon et al., 1994, Cameron et al., 1994, Rhoades et al., 1996). CBFβ binds and stabilises 
AML1 and also increases its affinity for DNA in a wildtype cellular environment (Huang et al., 
2001). However CBFβ-MYH11 stabilises AML1 to a greater extent and adapts AML1 into a 
constitutive transcriptional repressor resulting in leukaemogenesis. 
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der(11q23) MLL fusions 
Perturbations of MLL through aberrations to chromosome 11 results in oncogenic fusion of MLL 
with over 50 identified gene partners in approximately 10 % of ALs (Huret et al., 2001, Krivtsov 
and Armstrong, 2007). MLL is a large multidomain protein which possesses the ability to bind 
DNA through AT hooks and acts as both a transcriptional repressor and activator. MLL proteins 
contain plant homology domains, DNA methyltransferase homology domain and CREB binding 
site. MLL also forms large nuclear multiprotein complexes with various interacting protein partners 
including Menin and members of the HDAC family of proteins (Martens and Stunnenberg, 2010). 
MLL is expressed in HSCs and MPPs (Kawagoe et al., 1999). Patients which harbour MLL 
translocations often have leukaemias which display monocytic features and have a poor prognosis 
(Byrd et al., 2002). Despite extensive analysis of MLL fusion gene products in primary patients no 
direct targets have been identified (Martens and Stunnenberg, 2010). In ALL it is thought MLL 
fusion proteins elicit defects in chromatin modelling however it is not yet known if this also bears 
true in AML.  
t(9;21) BCR-ABL 
A reciprocal translocation between chromosome 9 and 22, produces the Philadelphia chromosome, 
the hallmark of CML results in aberrant tyrosine kinase activity. The Philadelphia chromosome was 
the first genetic aberration to be determined causative of the pathophysiology of a malignancy. 
CML is classified into three phases based on clinical and laboratory defined characteristics. In the 
absence of treatment CML will progress from chronic phase into accelerated phase resulting 
terminally in blast crisis. Chronic phase which is asymptomatic, the duration of which is variable 
and largely dependent on drug response and the leukaemogenic chromosomal driver. Progression 
into the accelerated phase is determined based on several characteristics e.g. 10-19 % circulating 
myeloblasts and elevated platelet counts. Accelerated phase indicates the disease is progressing. 
The final stage in the evolution of CML is blast crisis which behaves similar to AML with rapid 
progression and short survival blast crisis phase is determined by >20 % myeloblasts circulating in 
blood or in the bone marrow. 
1.3.4 Gene mutations in AML 
Maturation and differentiation of myeloid cells is coupled to a decreased in self-renewal and 
proliferation. These processes are tightly regulated by a small number of transcription factors which 
mediate appropriate target gene expression. Myeloid differentiation is regulated by a relatively 
small number of transcription factors e.g.; PU.1, CCAAAT/enhancer binding proteins (C/EBPα, 
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C/EBPβ, C/EBPε), growth-factor independent 1 (GFI1), interferon-regulatory factor 8 (IRF8), 
AML1, stem cell leukaemic factor (SCL), JUNB, IKAROS and myelocytomatosis (MYC). 
Mutation of these myeloid governing transcription factors results in severe myeloid defects in 
murine models and have been identified in AML patients.  
AML is proposed to occur through a two hit mechanism involving class I and class II mutations in a 
myeloid precursor cell (Gilliland and Griffin, 2002). Class I mutations result in an increase in 
proliferation through alteration to receptor tyrosine kinase activity and cell signalling cascades, and 
class I mutations typically affect classic oncogenes (Kelly and Gilliland, 2003). Class II mutations 
result in a differentiation block mediated by dysregulation of transcription factors (Kelly and 
Gilliland, 2003). Leukaemogenesis results when class I and class II mutations co-operate. This 
hypothesis is supported as a model of AML disease in murine models. Single mutations are 
insufficient for transformation while co-operation of class I and class II mutations results in AML, 
for example C/EBPα and Fms like tyrosine (FLT3)-ITD (McCormack et al., 2005, Reckzeh et al., 
2012b). However class I and class II mutational hits are not always readily identifiable in AML 
patients. Therefore it is proposed the two hit model may be an oversimplification of 
leukaemogenesis, as with any vastly heterogeneous disease it is not possible to entirely categorise 
biological entities (Dombret, 2011, Murati et al., 2012, Conway O'Brien et al., 2014). Through the 
advent of AML genome sequencing, lesions were identified in genes which are not associated with 
haematopoiesis e.g. isocitrate dehydrogenase 1/2 (IDH1/2) and DNA methyltransferase 3a 
(DNMT3a) (Mardis et al., 2009, Ley et al., 2010, Sanders and Valk, 2013). Thus modifications to 
the two hit model have been proposed to include a third class of mutations, class III, and these 
include mutations to epigenetic gene regulators (Dombret, 2011, Conway O'Brien et al., 
2014)(Table 1.3.4 A).  
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 Class I Class II Class III 
Pathways Signal Transduction Differentiation Epigenetic 
regulation 
Genes FLT3 AML1 TET2 
 KIT CBFβ 1DH1 
 NRAS, KRAS CEBPα 1DH2 
 JAK2 NPM1 ASXL1 
 PTPN11 PU.1 EZH2 
  MLL DNMT3A 
  RARα  
  EVI 1  
 
Table 1.3.4 A Classification of gene mutations identified in AML adapted from (Dombret, 2011, 
Conway O'Brien et al., 2014). 
A further modified and complex model of genetic mutation classification in leukaemogenesis has 
been proposed, termed “the slot machine model” extending the model to 5 classes of mutations 
(Table 1.3.5) (Murati et al., 2012). Class IV mutations affect tumour suppressor genes resulting in 
loss of their protective function. Class V mutations are those which affect the spliceosome during 
pre-messenger RNA (mRNA) processing, and these are mutually exclusive (Yoshida et al., 2011, 
Murati et al., 2012). Disruption of the spliceomsone results in intron retention, exon skipping, use 
of incorrect splice sites, resulting in the accumulation of many incorrectly spliced transcripts 
affecting mRNAs (Yoshida et al., 2011, Makishima et al., 2012). Murati et al propose that 
ultimately the hits required must affect proliferation and differentiation but that the number of 
oncogenic hits required to achieve these two phenomena may be greater than previously thought. In 
the slot machine model they propose the late steps are constrained by the initial steps and it is 
important to determine the number of “reels” (hits) and “symbols” (genes) and all possible 
combinations (Murati et al., 2012). Alternatively, a more contemporary model classifies the “hits” 
as pathways as opposed to specific genetic entities. The pathway model proposes that it is a 
combination of different “pathway hits“, be they genetic or epigenetic targeting the apoptotic, self-
renewal, differentiation, cellular metabolism and cell signalling pathways that will govern the 
initiation of disease (Hatlen et al., 2012). 
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 Class IV Class V 
Pathways Tumour suppressor 
 Genes 
RNA 
 maturation 
Genes CDK2NA SF3B1 
 CDKN2B SRSF2 
 TP53 U2AF1 
 WT1 ZRSR2 
  PRPF40B 
  SF1 
  SF3A1 
  U2AF65 
 
Table 1.3.4 B Further classification of leukaemogenic genes according to (Murati et al., 2012). 
1.4 C/EBPα  
C/EBPα is expressed in several tissues including adipose, lung epithelium, keratinocytes, 
hepatocytes and haematopoietic cells including the HSC, CMP and GMP (Zhang et al., 2004). High 
levels of C/EBPα expression characterises terminal differentiation of the cell type in which it is 
expressed. C/EBPα is a member of the C/EBP family of basic region leucine zipper transcription 
factor family. There are 6 family members identified by Greek symbols signifying chronological 
order of discovery (C/EBP α, β, δ, ε, γ, δ) (Cao et al., 1991). The C/EBP N-Terminal regions are 
highly divergent sharing only ~20 % sequence homology (reviewed by (Ramji and Foka, 2002)). 
However some N-Terminal short sequence motifs are retained, that are involved in interactions 
with basal transcriptional machinery (TBP/TFIIB), transcriptional co-activators (CBP/p300), and 
chromatin remodelling complexes (SWI/SNF) (Nerlov and Ziff, 1995, Erickson et al., 2001, 
Pedersen et al., 2001). C/EBP C-Terminal regions share regions of highly conserved sequence 
identity ~90 % (reviewed by (Ramji and Foka, 2002)). The C-Terminal region contains the basic 
DNA binding region and the leucine rich zipper region which facilitates protein dimerisation 
(Landschulz et al., 1988). C/EBP dimerisation is a requisite for DNA binding mediated by the basic 
region, and once C/EBP proteins bind DNA they activate transcription via their N-Terminal 
transactivation domain 1 (TAD1) (Landschulz et al., 1988, Vinson et al., 1989). C/EBP proteins 
recognise the consensus DNA binding sequence 5’ TKNNGYAAK 3’ (Y=C/T, K=T/G) within the 
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regulatory regions of their target genes. The high degree of C-Terminal homology permits 
intrafamilial C/EBP dimerisation. C/EBPα has been jokingly termed “Mcbindall” through its ability 
to bind multiple DNA sequences and vast number of protein partners (McKnight, 2001). 
1.4.1 Structure of C/EBPα 
C/EBPα exists as two isoforms, a full length p42 isoform and N-Terminally truncated p30 isoform, 
both generated from shared mRNA. C/EBPαp30 lacks the first 117 amino acids and TAD1 which 
mediates protein-protein interactions (Cleaves et al., 2004). C/EBPα is an intronless gene encoded 
on human chromosome 19q13, whose mRNA contains 3 translational AUG start sites. To date the 
crystal structure is only available for the C-Terminus bound to DNA, as the highly flexible N-
Terminus hinders X-ray crystallography (Fig 1.4.1) (Miller et al., 2003). The rigid structure of the 
C-Terminus facilitates structural analysis.  
 
Fig 1.4.1 C/EBPα-DNA complex adapted from www.rcsb.org protein data base published by 
(Miller et al., 2003) viewed using Jmol viewer. NBD ID: PD0395, PBD ID:1NWQ. Individual 
C/EBPα monomers highlighted in red and green and DNA double helix highlighted in purple. 
Full length C/EBPαp42 is translated from AUG1 and AUG2 (Fig 1.4.2). However C/EBPα also 
contains an additional weak upstream AUG site, and translation from this site is out of frame and 
results in premature protein truncation, causing the ribosome to scan over AUG1 and AUG2 and 
initiate translation from the alternative internal AUG3 start site generating C/EBPαp30. Ribosomal 
scanning is controlled by the activity of eukaryotic translation initiation factor 2 (eIF-2α). High eIF-
2α activity promotes translation for the weak upstream AUG and C/EBPαp30 translation 
(Calkhoven et al., 2000b). Alternatively it has also been proposed that generation of C/EBPαp30 
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occurs through partial proteolysis of C/EBPαp42 as occurs for nuclear factor kappa (NFκB) p105 
generating p50 (Lin and Ghosh, 1996). C/EBPαp30 is described to exert a dominant negative effect 
on C/EBPαp42. C/EBPαp30 isoform negatively affects C/EBPαp42 through heterodimer formation. 
C/EBPαp30:C/EBPαp42 heterodimers have impaired DNA binding ability and transactivation 
capacity in comparison to C/EBPαp42 homodimers (Cleaves et al., 2004). C/EBPαp30 only binds 
DNA with 14 % of the affinity as C/EBPαp42 hence negatively affecting C/EBPα dimers (Pabst et 
al., 2001b). Additionally C/EBPαp30 mediates sumoylation of C/EBPαp42 through enhanced 
ubiquitin conjugating enzyme 9 (Ubc9) expression resulting in a decrease in C/EBPαp42 
transactivation capacity (Geletu et al., 2007). Reference to C/EBPα within this text refers to both 
isoforms as a gene or protein entity as often in the literature there is no specification of isoforms. 
Where information is provided C/EBPα is referred to as either C/EBPαp42 or C/EBPαp30 
delineating the isoforms. 
 
Fig 1.4.2 Functionally distinct isoforms of C/EBPα generated from alternative translational start 
sites, adapted from (Reckzeh and Cammenga, 2010). C/EBPα is translated from alternative 
translational start sites. AUG1 and AUG2 results in translation of full length C/EBPαp42 isoform 
while translation from internal start site AUG3 results in generation of C/EBPαp30 isoform due to 
initial faulty translation from upstream AUG . 
1.5 C/EBPα is a master regulator of haematopoiesis 
 
1.5.1 C/EBPα in the HSC 
C/EBPα is a crucial regulator of haematopoiesis, controlling the proliferative capacity of the adult 
and foetal HSC and mediating myeloid differentiation through governing the transition from CMP 
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to GMP (Zhang et al., 2004, Mancini et al., 2012, Ye et al., 2013, Hasemann et al., 2014). Foetal 
liver HSCs cycle rapidly in order to produce a stockpile to maintain adult life (Morrison et al., 
1995). Four weeks post partum HSCs stop cycling and acquire a quiescent metabolic signature 
(Bowie et al., 2006). C/EBPα was identified to mediate this proliferative change in HSC behaviour, 
with increased C/EBPα expression associated with a decrease in HSC proliferation (Zhang et al., 
2004, Ye et al., 2013). Additionally loss of C/EBPα in the adult HSC resulted in a transcriptome 
signature similar to the foetal liver HSCs through downregulation of N-MYC (Ye et al., 2013). Loss 
of C/EBPα in adult HSC results in an increase in LT-HSC population defined as Lin-/Sca1+/Ckit+ 
(LSK)/CD150
+
/CD48
-
 (SLAM
+
) and an increase in cells in G1-G2-S/M phase (Ye et al., 2013). 
Overexpression of C/EBPα in the foetal liver HSC induced cell quiescence determining an inverse 
relationship between C/EBPα expression and HSC proliferation (Ye et al., 2013). Contrastingly, 
Hasemann et al report that excision of C/EBPα in the adult HSC does not increase HSC cell 
numbers and rather it mediates an exit from the quiescent state with a concomitant increase in cell 
death due to HSC exhaustion (Hasemann et al., 2014).  It was observed that C/EBPα expression 
represses lymphoid and erythroid gene expression while upregulating myeloid gene targets, 
supporting the idea of HSC lineage priming based on HSC gene expression (Hasemann et al., 
2014). While both studies agree on C/EBPα exerting control over adult HSC quiescence, Ye et al 
did not observe any change to apoptotic gene expression in C/EBPα knockout versus wildtype 
(WT) LSK SLAM
+
 murine cell population while Hasemann et al reported an increase in cell death 
and an increase in apoptotic and DNA damage repair pathways in C/EBPα knockout versus WT 
LSK SLAM
+
 murine cell population. The difference between the studies is proposed to be due to 
methodological differences namely the time difference between poly (I-C) (pIpC) injections used to 
excise C/EBPα in floxed mice and experimentation (Hasemann et al., 2014). PIpC induces 
interferon response which influences the HSC parameters investigated. However Ye et al analysed 
apoptotic gene expression 7 and 21 days post pIpC injection which is approximate to Hasemann et 
al which performed analysis 14-17 days post injection (Hasemann et al., 2014). Taken together 
C/EBPα is crucial for regulating HSC biology through regulating self-renewal, quiescence and 
lineage priming (Zhang et al., 2004, Bereshchenko et al., 2009, Ye et al., 2013, Hasemann et al., 
2014). 
1.5.2 C/EBPα promotes myeloid differentiation  
Expression of C/EBPα increases with myeloid commitment, as cells differentiate from CMPs to 
GMPs, at which stage C/EBPα expression is no longer required for terminal GMP differentiation 
(Zhang et al., 2004) (Fig 1.5.1 and 1.5.2). C/EBPα promotes the expression of myeloid terminal 
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differentiation effector genes G-CSFR, M-CSFR, GM-CSFR, myeloperoxidase and C/EBPε. 
C/EBPα is not expressed in the lymphoid or MEP cell lineages (Akashi et al., 2000, Miyamoto et 
al., 2002)(Fig 1.5.1).  
 
Fig 1.5.1 C/EBPα mRNA expression throughout human haematopoiesis analysis from 
HemaExplorer, each dot corresponds to the expression of C/EBPα in a microarray, while horizontal 
lines represent the median expression for each class of cell (Bagger et al., 2013). C/EBPα expressed 
highly in CMP, GMP and CD14+ monocytes, cells of the myeloid lineage. 
Non conditional knockout C/EBPα neonates die due to hypoglycaemia and have no granulocytes 
within the foetal liver (Wang et al., 1995, Zhang et al., 1997). The obligate haematopoietic 
requirement for C/EBPα expression was revealed as conditional knockout of C/EBPα in adult mice 
blocked CMP transition with a decrease in myelomonocytes, eosinophils, granulocytes and 
monocytes, with no changes observed to erythroid or lymphoid lineages (Zhang et al., 2004). 
Further refinement identified a pre-granulocyte-monocyte (preGM) CD41
-
/CD150
-
/CD105
- 
population which is unable to differentiate to GMPs in the absence of C/EBPα (Mancini et al., 
2012). In C/EBPα knockout preGMs, elevated levels of Globin transcription factor1/2 
(Gata1,Gata2), Fli1 and friends of GATA1 (Fog-1) erythroid lineage mediating genes were 
identified along with an increase in megakaryocytic and erythroid progenitor cells, indicating loss 
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of C/EBPα may result in lineage reprogramming (Mancini et al., 2012). Differing levels of C/EBPα 
expression were proposed to differentially steer terminal GMP differentiation (Paz-Priel and 
Friedman, 2011). Lower levels of C/EBPα expression in the GMP promote monopoiesis through 
formation of a heterodimer with activator protein 1 (AP-1), while higher expression levels promote 
homodimerisation and granulopoiesis (Wang et al., 2006a, Paz-Priel and Friedman, 2011).  
Committed lymphoid precursor cells may be reprogrammed to myeloid lineage cells via 
overexpression of C/EBPα (Fig 1.5.2). C/EBPα elicits reprogramming through its ability to both 
extinguish other lineage determining pathways and to elicit its myeloid inducing effects. 
Overexpression of C/EBPα in pre-T-cells can reprogramme cells to become macrophages (Laiosa 
et al., 2006b) (Fig 1.5.2). Forced expression of C/EBPα in CD19+ murine B-cells was able to 
reprogramme cell fate resulting in a macrophage phenotype (Xie et al., 2004) (Fig 1.5.2). C/EBPα 
mediates transdifferentiation through upregulation of miR-34a and miR-223 which decrease B-cell 
lineage gene expression (Rodriguez-Ubreva et al., 2014). C/EBPα downregulated B-cell 
commitment factor PAX5 in collaboration with PU.1 (Xie et al., 2004).  
There is an element of redundancy amongst C/EBPα and its family member C/EBPβ in governing 
haematopoiesis. Replacement of C/EBPα gene locus with C/EBPβ did not affect terminal myeloid 
differentiation, and cytokine-stimulated or infection-meditated upregulation of C/EBPβ rescued the 
C/EBPα deficient granulocytic differentiation block (Jones et al., 2002, Hirai et al., 2006). 
 
Fig 1.5.2 Cell fate governed by C/EBPα expression during haematopoiesis. Low levels of 
expression in the HSC promote quiescence and self-renewal capacity. C/EBPα expression levels 
increase from HSC to CMP and to the GMP. C/EBPα promotes granulopoiesis while 
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simultaneously inhibiting lymphoid and  2 is described as a myeloid tumour suppressor and its 
ability to promote myeloid differentiation is coupled to its ability to promote exit from the cell 
cycle, both functions governed independently by C/EBPα (Porse et al., 2001, Pabst et al., 2001b). 
C/EBPαp42 inhibits cell cycle progression from G1 to S phase and has been identified to do so 
independently of its DNA binding transcriptional activation activities, instead involving its 
association with multiple cell cycle proteins. C/EBPα was identified to inhibit cellular proliferation 
through repression of E2F dependent transcription and through repression of transcription from C-
MYC promoter via an E2F binding site (Slomiany et al., 2000, Johansen et al., 2001). E2F controls 
the expression of genes required for S phase of the cell cycle and DNA replication. C/EBPα 
represses E2F dependent transcription via its N-Terminal TAD1 and via protein-protein interactions 
mediated by basic region amino acids I294 and R297 (Porse et al., 2001). C/EBPαp30 which lacks 
this N-Terminal TAD1 region is unable to mediate terminal myeloid differentiation and to induce 
cell cycle exit (Keeshan et al., 2003, D'Alo et al., 2003). C/EBPα-BRM2 (C/EBPα mutant BRM2 
I294A/ R297A) is also unable to mediate myeloid differentiation in cell based assays and in vivo 
knockin murine studies identified an absence of neutrophils and expansion of early myeloid 
progenitor population (Porse et al., 2001, Keeshan et al., 2003, D'Alo et al., 2003, Porse et al., 
2005). Long term BRM2 mice developed myeloproliferative disorders which progressed to AML 
and had a transplantable disease (Porse et al., 2005). C/EBPα mediated repression of E2F is crucial 
for terminal granulopoiesis; loss of E2F mediated cell cycle control is proposed to promote 
malignant myeloid transformation. 
C/EBPα was also identified to complex with cell cycle regulators cyclin dependent kinase 2 and 4 
(CDK2 and CDK4) via their homologous T loop region (Wang et al., 2001). The central C/EBPα 
proline rich region 177-191 was identified to mediate CDK2 and CKD4 interaction (Wang et al., 
2001). C/EBPα and CDK2 interaction inhibited cyclin activation and E2F release, while C/EBPα 
and CDK4 interaction mediated proteasomal degradation of CDK4 by disrupting its association 
with protective chaperone proteins (Wang et al., 2001, Wang et al., 2002). Deletion of amino acids 
177-191 abrogated C/EBPα ability to inhibit the cell cycle at G1 phase in vitro cell line experiments 
(Wang et al., 2001). Functional assays however revealed C/EBPα mediated repression of 
CDK2/CDK4 was not required for granulopoiesis and knockin C/EBPα Δ177-191 mutant mice 
displayed no haematopoietic disturbances (Keeshan et al., 2003, Porse et al., 2006). It is currently 
thought C/EBPα mediated repression of CDK2/CKD4 is dispensable for terminal granulocytic 
differentiation (Johnson, 2005). Additionally C/EBPα expression was identified to increase p21 
expression, a cyclin dependent kinase inhibitor, through an increase in p21 transcriptional and post 
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transcriptional stabilisation (Timchenko et al., 1996, Timchenko et al., 1997). The role of p21 in 
C/EBPα mediated cell cycle exit has also been reported to be dispensable, as it can still do so in 
p21-deficient murine embryos (Johnson, 2005). The function of such interactions has varying 
degrees of responsibility and consequence in leukaemic transformation. 
1.6 C/EBPα dysregulation in AML 
Loss of C/EBPα function may occur directly through genetic mutations, promoter 
hypermethylation, post-translational modifications or indirectly through perturbations to upstream 
signalling cascades often mediated by chromosomal translocations in AML. Regardless of the 
cause of C/EBPα dysregulation patients are reported to display a characteristic haematopoietic cell 
marker expression profile CD7, HLA-DR, CD34, CD15, CD33, CD34 and CD65 (Fasan et al., 
2014). 
1.6.1 C/EBPα mutations in AML 
C/EBPα is the most frequently mutated transcription factor in AML. C/EBPα mutations are 
frequently reported to be present in 10-15 % of karyotypically normal AMLs, however a recent 
report has identified mutated C/EBPα in 31.8 % of elderly karyotypically normal AML patients, 
suggesting perhaps current figures of 10-15 % maybe an underrepresentation (Pabst et al., 2001b, 
Pabst and Mueller, 2007, Fasan et al., 2014, Su et al., 2014). These C/EBPα mutant (mutC/EBPα) 
AMLs are typically classified (77 % of mutC/EBPα AMLs) as M1 and M2 by the FAB 
classification scheme (Renneville et al., 2008b, Fasan et al., 2014). C/EBPα mutations can occur 
throughout the single exon gene however they are predominately identified clustered either in the 
N-Terminus resulting in generation of the truncated C/EBPαp30 isoform, or are found in the C-
Terminus between the basic region and the leucine zipper (Pabst et al., 2001b, Leroy et al., 2005). 
Under normal physiological cell conditions the ratio of C/EBPαp42 to C/EBPαp30 is greater than 1, 
when this ratio falls below 1 this is considered the leukaemic C/EBPαp42/p30 ratio and is observed 
in leukaemic cell lines and AML patients (Calkhoven et al., 2000a, Leroy et al., 2005, Keeshan et 
al., 2006, Koschmieder et al., 2007). N-Terminal mutations result in a disturbance of the wildtype 
C/EBPαp42:C/EBPp30 ratio, through decreasing C/EBPαp42 levels and increasing C/EBPαp30 
levels (Pabst et al., 2001b).  The haematopoietic importance of C/EBPαp42:C/EBPp30 ratio has 
been highlighted by a study identifying pharmacological induced differentiation of leukaemic cells 
and primary patient AML blasts (Koschmieder et al., 2007). 2-Cyano-3,12-dioxooleana-1,9-dien-
28-oic acid (CDDO) treatment increases C/EBPαp42 or decreases C/EBPαp30 via 
dephosphorylation of eIF2α and phosphorylation of eIF4E (Koschmieder et al., 2007). The resultant 
change to C/EBPαp42:C/EBPp30 ratio mediates differentiation of leukaemic cell lines via 
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upregulation of C/EBPα functionality through the reduction of C/EBPαp30 repressive effects 
(Koschmieder et al., 2007). The C/EBPαp42:C/EBPp30 ratio has also been proposed as a 
mechanism by which a cell can control its proliferation and state of differentiation in response to 
extracellular states e.g. nutrient/growth factor/cytokine conditions (reviewed by (Nerlov, 2004)). 
Thus in a situation of optimum growth, increased activity of eIF2α and eIF4E would permit 
increased translation of C/EBPαp30 from C/EBPαp42 shared mRNA, which lacks the inhibitory 
cell cycle control of C/EBPαp42 resulting in increased proliferation and delay to terminal 
differentiation (D'Alo et al., 2003). However an argument exists against the importance of 
leukaemic C/EBPαp42:C/EBPp30 ratio presented in a murine model whereby mice with one WT-
C/EBPαp42 allele and one C/EBPαp30 allele (L allele) do not develop AML or display any 
haematopoietic disturbances, despite a 2.5 fold decrease in C/EBPαp42:C/EBPαp30 ratio (Kirstetter 
et al., 2008). As discussed below L/L mice all developed fully penetrant AML indicating the 
leukaemogenic potential of C/EBPαp30 or/and the tumour suppressive function of C/EBPαp42. 
Further studies are required to fully decipher the leukaemogenic significance of alterations to this 
C/EBPαp42:C/EBPαp30 ratio. 
Several in vitro and in vivo studies have been aimed at deciphering the biological effect of N-
Terminal and C-Terminal mutations on WT-C/EBPαp42 function in an attempt to elucidate the 
biological mechanism of mutC/EBPα leukaemogenesis. In vitro studies reveal expression of 
C/EBPαp30 was insufficient to promote neutrophil differentiation of murine 32Dcl3 cells and 
granulocytic differentiation of primary murine bone marrow cells unlike C/EBPαp42 (Keeshan et 
al., 2003, Cleaves et al., 2004, Kato et al., 2011). However C/EBPαp30 retained the ability to stall 
the cell cycle at G1-S phase (Cleaves et al., 2004). Investigation by Schwieger et al reported 
C/EBPαp30 delayed but did not block myeloid differentiation in murine CD34+/lineage- bone 
marrow cells but blocked both myeloid and erythroid differentiation in human CD34
+
/lineage
-
 cord 
blood cells, highlighting differences between murine and human haematopoiesis and other 
published studies (Schwieger et al., 2004). Murine knockin studies investigating C/EBPαp30 
(termed L allele) oncogenicity in the absence of C/EBPαp42 showed that C/EBPαp30 induced fully 
penetrant transplantable AML (Kirstetter et al., 2008). C/EBPαp30 is sufficient for haematopoietic 
commitment to the myeloid lineage, it enables transition from the CMP to the GMP stage, however 
it does not retain the ability to control proliferation and myeloid progenitors have greatly increased 
self-renewal capacities (Kirstetter et al., 2008). Further investigation of a C-Terminal mutation (K 
allele K313dup mutation) combined with L allele (C/EBPαp30 expression only) revealed co-
operation and possible explanation for the  high prevalence of one N-terminal mutation and one C-
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terminal mutation in 90 % of biallelic C/EBPα mutAMLs (Bereshchenko et al., 2009). Fetal liver 
transplanted chimera mice harbouring K/L genotype developed AML with a shorter latency than 
K/K and L/L mice (Bereshchenko et al., 2009). K/L and L/L shared the similar phenotypic features 
of AML disease with a distinct myeloid dysregulated signature similar to subtype M2, however 
only 25 % of K/K mice developed an AML like disease (Bereshchenko et al., 2009). K/K murine 
induced leukaemia was identified to involve accumulation of erythroid progenitors and display a 
phenotype similar to C/EBPα null mice (Bereshchenko et al., 2009). The different K/K leukaemic 
phenotype was reported to be due to the absence of the leukaemia initiating cell (LIC). Both K/L 
and L/L LICs were identified to be committed myeloid progenitor cells however in K/K mice there 
was a distinct lack of this cell type (Kirstetter et al., 2008, Bereshchenko et al., 2009). K/K murine 
leukaemic transformation occurred in erythroid progenitor population with slower kinetics due to 
absence of GMP population explaining the longer latency observed in K/K disease. K/L and K/K 
and to a lesser extent L/L HSCs evaded homeostatic control with an increase in cell number 
(Bereshchenko et al., 2009). LSK subpopulations were identified to have decreased expression of 
quiescence associated genes and an increase in measurable proliferation (Bereshchenko et al., 
2009). Expansion of the HSC population was reported to accelerate leukaemogenesis by providing 
a pool of premalignant transformable cells. Gene set enrichment analysis identified that myeloid 
lineage gene expression was decreased in HSCs of K/K, K/L and to lesser extent in L/L mice. K/K 
HSCs had elevated erythroid gene expression thus it suggests presence of L allele is required for 
priming to commitment to the myeloid lineage. While the K allele is responsible for expansion of 
the HSC population (Bereshchenko et al., 2009). Kato et al confirmed the co-operative effect 
observed by Bereshchenko et al between N and C-Terminal C/EBPα mutations. Their study 
involved C/EBPα mutant T60fx159 termed the NM allele, generating the C/EBPαp30 isoform, 
similar to Bereshchenko and Kirstetter “L allele” and the C-Terminal mutation K304-323dup CM 
allele spanned K313dup “K allele” used by Bereshchenko (Kirstetter et al., 2008, Bereshchenko et 
al., 2009, Kato et al., 2011). Using bone marrow transplantation model (BMT) C
M
 transduced mice 
all developed AML with a latency 4-12 months. N
M
 mice did not develop AML but 37 % 
developed B-ALL. C
M
/N
M
 transduced mice developed AML with a shorter latency than C
M
. Kato et 
al explained their results in terms of the “the two hit mechanism of leukaemogenesis”. They 
identified C
M
 as the differentiation inhibiting hit (class II) and N
M
 to confer a proliferative 
advantage to the cells (class I) (Kato et al., 2011). Validation of this hypothesis was performed by 
combining C
M
 with a FLT3 mutation, a confirmed class I AML mutation, resulting in AML with a 
very short latency (Kato et al., 2011). An additional study combining biallelic C/EBPα and FLT3-
ITD mutations in a knockin murine model which facilitates expression of mutants from their 
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endogenous promoters at appropriate stages of development verified the co-operation observed by 
Kato et al (Reckzeh et al., 2012a). C/EBPα and FLT3-ITD mutations reduced the latency of 
induced AML (Reckzeh et al., 2012a). Differences in the Bereschchenko and Kato et al studies in 
terms of N and C-Terminal mutation leukaemogenecity were attributed to differences in murine 
models (knockin versus BMT) and different C/EBPα mutations. However both studies identify 
distinct roles for the N and C-Terminal C/EBPα mutations and their oncogenic co-operation during 
leukaemogenesis. 
To date there have been three different patterns of C/EBPα mutations observed in AML patients 1) 
a single mutation on one allele (monoallelic), 2) mutations on both alleles (biallelic) usually a N-
Terminal mutation on one allele and a C-Terminal mutation on the second allele or 3) a 
homozygous mutation due to loss of heterozygosity or uniparental disomy (Fasan et al., 2014). 
C/EBPα mutations are largely somatically acquired however there have been several reports of 
germline inheritance of C/EBPα mutations with a resulting familial predisposition to AML (Smith 
et al., 2004, Sellick et al., 2005, Pabst et al., 2008, Renneville et al., 2008a, Nanri et al., 2010, 
Gutman and Hoffner, 2012, Debeljak et al., 2013). Upon inheritance of a C/EBPα mutation a 
second second somatically acquired C/EBPα mutation is required for transformation (Pabst et al., 
2008). There is evidence of anticipation upon inheritance of a highly penetrant C/EBPα mutation 
with age of onset decreasing with successive generations (Pabst et al., 2008). A study by Pabst et al 
identified 11.1 % of C/EBPα mutations were inherited in germline DNA accounting for 1.1 % of all 
AMLs. To date reports of inheritance of C/EBPα mutations identified have been predominately N-
Terminally localised. Clinically C/EBPα mutAMLs are associated with favourable patient 
outcomes in response to a chemotherapy regime with a high dose ARA-C component; however the 
molecular biology surrounding this favourable response remains largely undetermined (Renneville 
et al., 2008b). The favourable response was later reported to be specific to patients who possessed 
biallelic versus monoallelic mutations (Wouters et al., 2009, Fasan et al., 2014). This differential 
treatment response is probably unsurprising as monoallelic and biallelic patients display different 
gene signature expression patterns (Wouters et al., 2009). Additionally patients who harboured a 
monoallelic N-Terminal single mutations have a poorer overall survival than monoallelic C-
Terminal mutations, indicating the localisation of the mutation may also provide prognostic 
information (Fasan et al., 2014). C/EBPα mutations remain constant pre and post relapse and are 
thus thought to be crucial in the initiation of leukaemogenesis. It is now a strongly held view that 
C/EBPα mutation analyses be included in standard diagnostic cytogenetic tests upon presentation.  
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1.6.2 AML chromosomal translocations which disrupt C/EBPα expression 
While C/EBPα mutations are predominately associated with cytogenetically normal AML patients, 
dysregulation of C/EBPα also occurs in AML patients with oncogenic fusion proteins created by 
chromosomal translocations summarised in Fig 1.6.2 (most common AML translocations outlined 
in Table 1.3.3). Translocation (8;21) which gives rise to AML1-ETO oncofusion protein 
downregulates C/EBPα expression and its DNA binding activity (Pabst et al., 2001a). AML1-ETO 
binds the C/EBPα promoter and inhibits its auto regulation repressing C/EBPα at the transcriptional 
level (Pabst et al., 2001a). Knockdown of AML1-ETO restores C/EBPα expression in leukaemic 
cells resulting in myeloid differentiation (Heidenreich et al., 2003). t(3;21) and inv(16) increase the 
expression levels of Calreticulin, an mRNA binding protein which strongly binds the GC rich 
C/EBPα mRNA (Helbling et al., 2004, Helbling et al., 2005). Calreticulin binding inhibits C/EBPα 
translation and decreases protein expression (Helbling et al., 2004, Helbling et al., 2005). BCR-
ABL the hallmark translocation of CML increases levels of hnRNP-E2 protein in a mitogen-
activated protein kinase (MAPK) signalling dependent manner (Perrotti et al., 2002). hnRNP-E2 
binds the 5’ untranslated region (UTR) of C/EBPα mRNA and also represses translation (Chang et 
al., 2007). Imatinib treatment was identified to restore C/EBPα protein expression and relieving the 
myeloid differentiation block (Chang et al., 2007). Translocation t(14;19) identified in  B-Cell 
precursor (BCP)-ALL patients results in overexpression of C/EBPα through the fusion of the 
immunoglobulin heavy chain (IGH) transcript on chromosome 14 to C/EBPα (Chapiro et al., 2006). 
Chromosomal translocations involving IGH result in deregulated expression of partner fusion genes 
due to the proximity of the transcription enhancers within IGH (Willis and Dyer, 2000). The 
breakpoint on chromosome 19 occurs in the 3’UTR of C/EBPα permitting full apparent normal 
isoform expression (Chapiro et al., 2006). The IGH-C/EBPα fusion results in aberrant ectopic 
C/EBPα expression in response to B-Cell signalling cascades perpetuated by IGH fusion, skewing 
the path of normal B-Cell differentiation. Indeed other C/EBP family members (C/EBPδ and 
C/EBPγ t(14;19) C/EBPβ t(14;20) C/EBPε t(14;14)) have also been identified to be up regulated in 
translocation events involving IGH in ~1 % of all BCP-ALLs (Akasaka et al., 2007). Under normal 
physiological conditions B-Cell differentiation is thought to be concomitant with decreasing C/EBP 
expression (Laiosa et al., 2006a). The mechanism by which all C/EBP family members (except 
C/EBPδ) confer oncogenic pathogenicity in BCP-ALL is as of yet unknown, but is proposed to be 
perpetuated via the C-Terminal highly conserved leucine zipper and DNA binding regions 
(Akasaka et al., 2007). Interestingly Akasaka et al is reported as the first evidence of multiple 
members of the same family being involved in translocations with the same gene locus within the 
same disease phenotype. 
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While examples of chromosomal translocations cited up- or down-regulated C/EBPα expression, 
expression of C/EBPα was identified as a pre-requisite for leukaemic initiation for some 
chromosomal translocations. In AML, chromosomal translocations involving MLL and 50 other 
interacting protein partners have been described (Krivtsov and Armstrong, 2007). Leukaemic 
transformation with MLL-ENL required the expression of C/EBPα for transformation; however 
C/EBPα expression was not required for disease maintenance (Ohlsson et al., 2014). Hoxa9/Meis1 
also requires C/EBPα expression for transformation, while E2A-HLF does not, indicating that 
C/EBPα is only required for leukaemia initiation in specific genetic backgrounds (Ohlsson et al., 
2014). It has been proposed that C/EBPα binds DNA maintaining it in an open configuration for 
resulting gene-fusion binding (Roe and Vakoc, 2014). 
 
Fig 1.6.2 Schematic of chromosomal and post-translation modifications identified to repress 
C/EBPα adapted from (Pabst and Mueller, 2009). 
1.6.3 Post-translational modifications disrupting C/EBPα in AML 
 
Sumoylation 
Sumoylation involves the reversible covalent conjugation of Small Ubiquitin like MOdifier proteins 
(SUMO) to target proteins thereby modifying their functionality and cell fate. Sumoylation is an 
evolutionary conserved process, involving a three step mechanism similar to ubiquitination (to be 
discussed). In general, sumoylation of transcription factors leads to repression of their 
transactivation activity, through conferring new protein-protein interactions which alter promoter 
binding (Khanna-Gupta, 2008). Both C/EBPαp42 and C/EBPαp30 isoforms have been identified to 
be sumoylated by SUMO-1 at K159 within the conserved negative subdomain “the synergy control 
motif” (Subramanian et al., 2003). Sumoylation was identified to negatively affect C/EBPαp42 
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functionality during neutrophil maturation (Hankey et al., 2011). Additionally C/EBPαp30 was 
identified to mediate sumoylation of C/EBPαp42 via upregulation of ubiquitin conjugation enzyme 
Ubc9 (Geletu et al., 2007). Knockdown of Ubc9 in C/EBPαp30 transduced human CD34+ cells was 
able to restore a C/EBPαp30 induced differentiation block (Geletu et al., 2007). Therefore it has 
been proposed that C/EBPαp30 mediated sumoylation of C/EBPαp42 is another mechanism by 
which C/EBPαp30 exerts a dominant negative effect on C/EBPαp42 in AML as the ratio of 
C/EBPαp42/C/EBPαp30 is often perturbed (Geletu et al., 2007). 
Phosphorylation of C/EBPα  
Phosphorylation describes the covalent transfer of a phosphate group from ATP to specific amino 
acids on a target protein subsequently affecting its functionality. Phosphorylation is the most 
common post-translation modification. C/EBPα to date has several identified phosphorylation sites 
(summarised in Table 1.6.3); however there is not a consensus behavioural response in terms of 
phosphorylated or dephosphorylated C/EBPα and the ability to differentiate cells in various tissues. 
This underlines the molecular complexity of these phosphorylation events and the multiple 
upstream kinases which mediate the phosphorylation events.  
Serine 21 (Ser21) was identified to be an extracellular kinase 1/2 (ERK1/2) phosphorylation site on 
C/EBPα, recognised via a proximal C-Terminal MAP Kinase docking site FXFP (Ross et al., 
2004). ERK1/2 mediated phosphorylation of C/EBPα was identified to alter the conformation of the 
C/EBPα dimer whilst not affecting dimer stability (Ross et al., 2004). Ser21 phosphorylation 
resulted in the N-Terminal TAD moving apart from the C-Terminal domain (Ross et al., 2004). It 
was speculated that phosphorylation at Ser21 does not affect the bZIP DNA binding functions 
rather the phosphorylation event affects N-Terminal interactions with protein partners (Ross et al., 
2004). High levels of phosphorylated Ser21 (P-Ser21) are present in the bone marrow and further 
investigation revealed P-Ser21 inhibited granulopoiesis in K562 cells and inhibited granulocytic 
differentiation of bipotental U937 cells (Ross et al., 2004). U937 leukaemic cells possess the ability 
to become either monocytes or granulocytes, phorbol 12-myristate 13-acetate (TPA) stimulation 
promotes the former, while retinoic acid (RA) stimulation promotes the latter. Expression of 
C/EBPα phosphorylation mimetic construct, S21D, permits monocytic differentiation while 
inhibiting granulocytic differentiation (Ross et al., 2004). FLT3 is a receptor tyrosine kinase 
mutated in ~30 % of AMLs, and classified as a class I mutation (Gilliland and Griffin, 2002). The 
most common mutation results from an internal tandem duplication (ITD) within the 
juxatamembrane domain resulting in constitutive signalling and aberrant activation of downstream 
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kinases including ERK1/2 (Nakao et al., 1996). Analysis of human FLT3-ITD mutant AML cell 
lines revealed hyperphosphorylation of Ser21 (Radomska et al., 2006). Treatment with both a FLT3 
inhibitor MLN518 and a mitogen/extracellular signal-regulated kinase (MEK) inhibitor PD98059 
relieved the differentiation block in mutant FLT3 (mutFLT3) AML cell lines and activated 
differentiation through detectible decreases to P-Ser21 (Radomska et al., 2006). Indeed 
overexpression of an unphosphorylated Ser21 mimetic (S21A) in mutFLT3 cell line was sufficient 
to induce differentiation while S21D expression had no effect (Radomska et al., 2006). The 
induction of differentiation observed upon inhibitor treatment and S21A expression was 
accompanied by a rapid decrease in C-MYC mRNA expression, reiterating the necessity for 
inhibition of the cell cycle upon initiation of differentiation (Radomska et al., 2006). Further 
investigation of S21D and S21A effects on cell cycle regulation revealed both phosphorylated and 
unphosphorylated mimetics displayed reduced inhibition of the cell cycle, reduced E2F repression 
and differential E2F protein binding to WT-C/EBPα (Ferrari-Amorotti et al., 2010). WT-C/EBPα 
was identified to associate with E2F2 and E2F3 while S21D and S21A displayed reduced binding 
to E2F2 and S21A displayed increased binding to E2F3 (Ferrari-Amorotti et al., 2010). Frangalisso 
et al investigated differentiation mediating properties of S21D and S21A and reported S21D ectopic 
expression in K562 cells marginally inhibited granulocytic differentiation and in fact S21A 
displayed a great inhibitory effect contradicting the previous studies by Ross et al, Radomska et al, 
and Twu et al all of which showed that S21D expression inhibited differentiation and that S21A and 
WT-C/EBPα expression mediated granulopoiesis in K562. Interestingly P-Ser21 was also identified 
to inhibit key processes in erythropoiesis (Twu et al., 2010). Unphosphorylated Ser21-C/EBPα 
upregulates IGnTC expression, which is essential for antigen i maturation during erythropoiesis  
(Twu et al., 2010). Phenotypic transition from antigen i to antigen I is a key process during 
erythroid development. P-Ser21 has reduced affinity for the IGnTC promoter, does not drive IGnTC 
expression and antigen i maturation (Twu et al., 2010). Thus phosphorylation of Ser21 appears to 
inhibit differentiation of both erythroid and myeloid cells. 
The first and only study to date identifying P-Ser21 specific C/EBPα protein partners using a mass 
spectrometry large scale approach, reports DEK as a specific binding partner for unphosphorylated 
C/EBPα at Ser21 (Koleva et al., 2012). The assembly of this DEK/C/EBPα complex occurs on the 
G-CSFR promoter, driving its transcription and myeloid differentiation. Thus DEK acts as a 
phosphospecific C/EBPα co-activator (Koleva et al., 2012). S21D was reported to retain the ability 
to bind the G-CSFR promoter in K562 cells but it was unable to drive its expression (Koleva et al., 
2012). Knockdown of DEK in cells expressing WT and S21A-C/EBPα resulted in a 2 fold decrease 
47 
 
in G-CSFR mRNA levels and a block in granulocytic differentiation (Koleva et al., 2012). These 
data corroborates the reported roles of S21D in inhibiting differentiation (Ross et al., 2004, Twu et 
al., 2010) and the effect of S21A in overcoming a differentiation block (Radomska et al., 2006). 
While unphosphorylated C/EBPα was identified to act as co-activator in the context of DEK 
mediated transcriptional activation, P-Ser21 was reported to relieve C/EBPα mediated repression of 
interleukin-10 (IL-10) production (Kang et al., 2013). IL-10 is an anti-inflammatory cytokine 
whose production is upregulated in myeloid cells by IL-32β expression (Kang et al., 2013). IL-32β 
induces Protein Kinase C delta (PKCδ) mediated phosphorylation of C/EBPα at Ser21 and this 
phosphorylation event relieves C/EBPα inhibitory effect on IL-10 promoter (Kang et al., 2013). IL-
32β binds both C/EBPα and PKCδ while IL-32β binding of C/EBPα is P-Ser21 independent. IL-
32β binding site was localised to the DNA binding domain of C/EBPα. It has yet to be elucidated if 
P-Ser21 recruits other potential co-activators or if C/EBPα promoter binding alone results in 
repression. 
The majority of reports on phosphorylated C/EBPα in haematopoietic cells document a 
differentiation block of cells committed to the granulocytic lineage however phosphorylation of 
C/EBPα has also been identified in two reports to skew lineage commitment of cells. p38MAPK 
was identified as a kinase capable of phosphorylating Ser21 (Geest et al., 2009). Pharmacological 
inhibition of p38MAPK in human cord blood derived CD34
+ 
(hCD34
+
) cells resulted in an increase 
in granulocytes with a concomitant decrease in eosinophil numbers (in granulocyte and eosinophil 
permissive culture conditions) (Geest et al., 2009). Inhibition of p38 was shown to decrease levels 
of P-Ser21 in neutrophil progenitors (Geest et al., 2009). Mice transplanted with hCD34
+
 cells 
transduced with CA-MKK3 (constitutively active- Mitogen-activated protein kinase 3, upstream 
p38 activator) had decreased numbers of neutrophils accompanied with an increase in eosinophil 
development, indicating that P-Ser21 regulates haematopoietic lineage fate (Geest et al., 2009). Co-
expression of CA-MKK3 and S21A abrogated activated p38 inhibition of neutrophil differentiation, 
permitting neutrophil development in colony forming assays. Thus in this context P-Ser21 skews 
granulocytic differentiation toward eosinophil lineage ultimately still exerting a negative effect on 
mature granulocyte cell numbers. When the Ser21 phosphorylation site was first identified by Ross 
et al., pharmacological inhibition of p38MAPK did not decrease ectopically expressed C/EBPα P-
Ser21 levels in 3T3-L1 cells, whereas inhibition of ERK1/2 activity alone elicited a decrease in P-
Ser21 levels (Ross et al., 2004). Additionally Radomska et al., also observed no increase in 
endogenous P-Ser21 upon p38 activation (Radomska et al., 2006). Thus to date there appears to be 
no consensus in the literature regarding activation and subsequent functionality of P-Ser21 with 
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regard to inhibition of granulopoiesis. There also appears to be a lack of studies investigating the 
differential effects of P-Ser21 within the HSC and as a regulator of quiescence. 
Protein Kinase B (PKB) is a downstream effector of PI3K pathway identified to mediate lineage 
commitment decisions during myelopoiesis through modulation of glycogen synthase kinase-3 
(GSK3) mediated phosphorylation of C/EBPα (Buitenhuis et al., 2008). GSK3 was identified as a 
kinase responsible for phosphorylation of C/EBPα at threonine 222/226 (Thr222/226) (Ross et al., 
1999). P-Thr222/226 also results in a conformational change to the C/EBPα protein as was 
observed by ERK1/2 mediated P-Ser21, suggesting phosphorylation of C/EBPα may be a 
mechanism by which it can alter its interactions with protein partners (Ross et al., 1999, Ross et al., 
2004). P-Thr222/226 has been suggested to be essential for controlling the autoregulatory function 
of C/EBPα (Zhang and Ma, 2010). Loss of this phosphorylation site through alanine substitution 
(T222A/T226A) abrogated the ability of C/EBPα to activate its own promoter, while loss of other 
phosphorylation sites S21A, S248A, S193A behaved similarly to wildtype C/EBPα (Zhang and Ma, 
2010). Expression of a constitutively active isoform of PKB (CA-PKB) inhibited neutrophil 
differentiation and enhanced eosinophil development in both ex vivo differentiation assays and in 
murine models while alternatively, the expression of dominant negative isoform of PKB (myr-
PKB) enhanced neutrophil expansion and blocked eosinophil development (Buitenhuis et al., 
2008). CA-PKB expression was identified to increase P-Thr222/2226 C/EBPα and GSK3 has 
already been described as a direct substrate for PKB. Thus in this study it was proposed that PKB 
activation results in GSK3 activation, an increase P-Thr222/226 C/EBPα, resulting in an increase in 
eosinophil production at the cost of neutrophils (Buitenhuis et al., 2008). Additionally P-
Thr222/226 also exerts a role in adipocytic differentiation but has no discernible effect on 
hepatocytes biology (Ross et al., 1999, Liu et al., 2006). Insulin was identified to decrease 
phosphorylation of C/EBPα affecting adipocyte biology (Hemati et al., 1997, Ross et al., 1999). 
Insulin mediates C/EBPα dephosphorylation through both inhibition of GSK3 which 
phosphorylates C/EBPα at Thr222/226 and through activation of the protein phosphatases 1 and 2A 
(PP1/ PP2A) which remove phosphate groups from C/EBPα (Ross et al., 1999). Inhibition of GSK3 
results in dephosphorylation of C/EBPα at Thr222/226 inhibiting preadipocytic differentiation 
suggesting in this cell context that unphosphorylated C/EBPα has an inhibitory effect on terminal 
cell differentiation (Ross et al., 1999). Further studies investigating the functional effects of GSK3 
mediated P-Thr222/226 revealed phosphorylation of these sites had no effect on hepatocyte biology 
and in fact reported C/EBPα was a poor substrate for GSK3 (Liu et al., 2006). However Liu et al 
did suggest P-Thr222/226 played a role in adipocytic biology as unphosphorylatible Thr222/Thr226 
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mutants (T222A/T226A) increased transactivation of C/EBPα targets compared to WT-C/EBPα in 
adipocytes. However no difference to C/EBPα transactivation functions of C/EBPα target 
promoters regardless of the phosphorylation status of Thr222/226 was observed in another study 
(Ross et al., 1999). In vivo knockin murine studies investigating the loss of GSK3 consensus 
phosphorylation site Thr222A/226A/Ser230A (TTS-C/EBPα mutant) identified no apparent 
physiological abnormalities or specifically no changes to amount or morphology of cells  in lung, 
liver and granulopoiesis (Pedersen et al., 2007). Detailed analysis of TTS livers revealed increased 
expression of genes expressed upon transition from the fasting to fed metabolic states. Authors 
propose that Thr222/226 phosphorylation of C/EBPα may serve as a hepatic-specific sensor 
regulating hepatic gene expression dependent on the metabolic state (Pedersen et al., 2007). 
Ser248 is a phosphorylation site identified in C/EBPα which also perturbs myeloid differentiation 
(Behre et al., 2002, Singh et al., 2008, Hasemann et al., 2012). Enhanced Ras signalling was 
identified to increase the transactivation capacity of C/EBPα as measured by its ability to drive G-
CSFR expression, however this was not as a result of altered DNA binding (Behre et al., 2002). 
Ser248 was identified as a site of Ras signalling-mediated phosphorylation and upon mutation 
Ser248A lost the ability to induce differentiation of 32Dcl3 and K562 cells (Behre et al., 2002, 
Singh et al., 2008, Hasemann et al., 2012). In vivo murine knock-in studies showed Ser248A-
C/EBPα was dispensable for early haematopoiesis as there was no disruption to the haematopoietic 
compartment of 8 week old mice (Hasemann et al., 2012). However Ser248A-C/EBPα aged mice 
developed a low penetrant haematopoietic disorder characterised by increased megakaryocytic and 
erythroid progenitor cells at the expense of granulocytic-monocytic lineage, accompanied with LSK 
expansion (Hasemann et al., 2012). Thus both Ser21- and Ser248-C/EBPα are phosphorylated by 
different mechanism with antagonistic effects on the differentiation function of C/EBPα with Ser21 
phosphorylation being anti-differentiation and Ser248 being pro-differentiation (Ross et al., 2004, 
Radomska et al., 2006, Behre et al., 2002, Singh et al., 2008, Hasemann et al., 2012). 
Ectopically expressed Protein Kinase C delta- catalytic fragment  (PKCδ-CF) was observed to 
mediate phosphorylation of C/EBPα at Ser21, Ser 266 and Ser277, the two latter sites identified as 
novel C/EBPα phosphorylation sites (Wu et al., 2013). PKCδ is cleaved upon induction of 
apoptosis generating an active PKCδ–CF protein. However initial studies by this group contradict 
their later findings that reported the absence of both direct PKCδ/C/EBPα binding and any 
phosphate transfer mediated by PKCδ to C/EBPα (Zhao et al., 2009). Induction of apoptosis, 
generation of PKCδ-CF, was identified to increase ubiquitination of C/EBPα in leukaemic cells 
(Zhao et al., 2009). Pharmacological inhibition of PKCδ using rotterlin abrogated the enhanced 
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C/EBPα ubiquitination observed upon induction of apoptosis (Zhao et al., 2009). PKCδ activation 
alters the localisation of C/EBPα, by promoting its cytoplasmic sequestration, resulting in enhanced 
ubiquitination of C/EBPα upon induction of apoptosis. It remains to be clarified whether the 
phosphorylation events themselves serve to trigger ubiquitination, or if the cytoplasmic localisation 
of C/EBPα is responsible for the subsequent ubiquitination upon PKCδ activation. Several C/EBPα 
phosphorylation events have been linked to ubiquitin-dependent proteasomal degradation of 
C/EBPα. Cellular stresses activate c-Jun N-Terminal kinase 1 (JNK1) which binds the DNA 
binding region of C/EBPα mediating phosphorylation of C/EBPα at unknown residues within this 
region (AA 278-352) (Trivedi et al., 2006). Activation of JNK1 and the subsequent C/EBPα 
phosphorylation stabilizes C/EBPα protein by inhibiting ubiquitination (Trivedi et al., 2006). 
Alternatively inactive JNK1 is permissive of C/EBPα ubiquitination (Trivedi et al., 2006). Another 
example of phosphorylation affecting C/EBPα protein stability revealed hyper-phosphorylation of 
C/EBPα occurs in the livers of aging mice and also induce liver tumourigenesis (Wang et al., 
2006b, Wang et al., 2010). Ser193 was identified to be phosphorylated by CDC2 and CDK4 (Wang 
et al., 2010). Under normal physiological conditions this phosphorylation event results in C/EBPα 
mediated inhibition of liver proliferation however during carcinogenesis, P-Ser193 is targeted by 
gankyrin mediated ubiquitin-dependent proteasome degradation. Gankyrin is a proteasomal subunit 
and only binds C/EBPα when phosphorylated at Ser193 (Wang et al., 2010). Therefore it appears 
different phosphorylation events mediated by different kinases in different cell types serve to either 
enhance or inhibit ubiquitination of C/EBPα increasing or decreasing protein stability (summarised 
in Table 1.6.3).  
 
Kinase Site Effecter Reference 
ERK1/2 
 
FLT3-ITD 
via ERK1/2 
 
ERK1/2 
 
 
Ser21 
 
 
 
-Phosphorylation inhibits granulocytic 
differentiation 
-Phosphorylation inhibits myeloid 
differentiation 
 
-Phosphorylation does not inhibit 
differentiation 
 
-Differential binding to E2F family 
members  
(Ross et al., 2004) 
 
(Radomska et al., 2006) 
 
(Ferrari-Amorotti et al., 
2010) 
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p38MAPK Ser21 -Inhibits granulocytic differentiation 
increases eosinophil development  
(Geest et al., 2009) 
Cdc2 Ser21 -Ubiquitin-dependent C/EBPα degradation 
in  hepatocytes 
(Wang et al., 2010) 
PKCδ 
Via IL-32β 
Ser21 -Suppress C/EBPα inhibition of IL-10 
production 
(Kang et al., 2013) 
PKCδ 
 
Ser21 
Ser266 
Ser277 
-Cytoplasmic sequestering of C/EBPα and 
enhanced ubiquitination upon induction of 
apoptosis  
(Zhao et al., 2009) 
(Wu et al., 2013) 
Not 
investigated 
 
Ser21 -Phosphorylation inhibits granulopoesies 
and antigen i/I transition and erythroid 
development 
(Twu et al., 2010) 
Not 
investigated 
Ser243 -Phosphorylation has no affect on 
granulopoiesis or erythroid development  
 
(Twu et al., 2010) 
Ras 
signalling 
Ser248 -Phosphorylation required for normal 
haematopoiesis 
-Loss of phosphorylation results in 
haematopoietic malignant disease 
(Behre et al., 2002) 
(Singh et al., 2008) 
(Hasemann et al., 2012) 
GSK3 
 
 
 
GSK3 via 
PKB 
Thr222/226 -Phosphorylation inhibits adipocytic 
differentiation 
-Dephosphorylation increases G6Pc hepatic 
gene expression, no physiological 
abnormalites 
 
-Skews toward eosinophil  differentiation 
(Ross et al., 1999) 
 
(Pedersen et al., 2007) 
 
(Buitenhuis et al., 2008) 
Unidentified  Ser230 -Not a GSK3 target kinase (Ross et al., 1999) 
 
JNK1 DBD 
unidentifie
d site 
-Phosphorylation stabilises C/EBPα protein 
decreasing ubiquitination 
(Trivedi et al., 2006) 
CDC2/CDK4 Ser193 -Promotes liver aging and tumourigenesis (Wang et al., 2010) 
ERK1/2 
GSK3 
Ser21 
Thr222/226 
-Phosphorylation promotes inhibitory effect 
mediated by C/EBPα on IL-12/p40 
expression in response to Triptolide 
(Zhang and Ma, 2010) 
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treatment in macrophages 
Table 1.6.3 Phosphorylation events and their effects on C/EBPα function.  
Ubiquitination  
Ubiquitination describes the signalled conjugation of an ubiquitin moiety to a target protein 
subsequent to three steps of an enzyme controlled pathway. The enzymes involved are E1 
ubiquitin-activating enzymes, E2 ubiquitin-conjugation enzymes and E3 ubiquitin ligases which 
conjugate ubiquitin to the target protein. Conjugation of ubiquitin results in alterations to the 
function of a protein, predominately resulting in proteasomal mediated degradation of its target 
protein however ubiquitination is now increasingly being attributed with non-degradative functions. 
Ubiquitination of C/EBPα discussed herein refers to ubiquitin-dependent proteasomal degradation. 
C/EBPα was first identified to be ubiquitinated resulting in its proteasomal degradation in 
keratinocytes (Shim and Smart, 2003). Lithium chloride treatment (LiCl) resulted in an increase in 
C/EBPα protein levels with no change to C/EBPα mRNA levels indicating a post transcriptional 
effect on C/EBPα (Shim and Smart, 2003). LiCl inhibits the chymotryptic activities of the 
proteasome thus inhibiting the degradation of ubiquitinated proteins. LiCl also inhibits GSK3, 
however the LiCl induced increase in C/EBPα protein levels was independent of any inhibitory 
effect on GSK3 and subsequent phosphorylation of C/EBPα (Shim and Smart, 2003). Analysis of 
TTS-C/EBPα protein expression in murine hepatocytes identified no difference in comparison to 
WT-C/EBPα mice suggesting loss of this phosphorylation site does not affect protein stability 
supporting the reports from Shim et al of increased stability of C/EBPα to be GSK3 independent 
(Pedersen et al., 2007). 
As introduced above C/EBPα phosphorylation events have been inextricably linked to protein 
ubiquitination, P-Ser193, P-Ser266 and P-Ser277 in response to CDC2, CDK4 and PKCδ mediated 
phosphorylation respectively have been associated with enhanced C/EBPα ubiquitination in 
leukaemic cells and in liver tumour cells. F-box/WD repeat-containing protein 7 (FBXW7), an E3 
ligase was identified to mediate ubiquitination of C/EBPα only upon P-Thr222/226 (Bengoechea-
Alonso and Ericsson, 2010). P-Thr222/226 acts as a phosphodegron motif for FBXW7 recognition 
of C/EBPα, thus FBXW7 only binds P-Thr222/226 and mediates ubiquitination inhibiting 
adipogenesis (Bengoechea-Alonso and Ericsson, 2010). Thus it appears phosphorylation triggered 
ubiquitination and subsequent elimination of C/EBPα protein is a common event in dysregulated 
differentiation of various cell types and in cancer cells.  
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Other E3 ligases have been identified to associate with C/EBPα mediating enhanced ubiquitination 
and proteasomal degradation in different cellular contexts (summarised in Table 1.6.4). In some 
instances an increase in ubiquitination has not been directly investigated, however proteasomal 
degradation has been identified to be dependent on E3 ligase binding which is predominately 
indicative of ubiquitin mediated proteasomal degradation however requiring further experimental 
investigation. E6 associated protein (E6AP) is an E3 ligase with a C terminal homologous to the 
E6-AP Carboxyl Terminus (HECT) domain. E6AP is one of only two E3 ligase identified to date 
which directly binds to C/EBPα in both myeloid cells and adipocytes (Pal et al., 2013a, Pal et al., 
2013b). E6AP binding results in ubiquitin-dependent proteasomal degradation of C/EBPα, resulting 
in inhibition of both myeloid and adipocytic differentiation, two processes governed by C/EBPα 
expression (Pal et al., 2013a, Pal et al., 2013b). Knockdown of E6AP or expression of dominant 
negative catalytically inactive form E6AP-C843A induced myeloid differentiation of K562, U937 
and 32Dcl3 cells through increased C/EBPα protein expression (Pal et al., 2013b). While to date 
E6AP has not been linked to carcinogenesis these studies underline the therapeutic potential of 
inhibition of C/EBPα ubiquitination in AML. 
Proteasomal degradation of C/EBPα has also been associated with the E3 ligase constitutively 
photomorphogenic 1 (COP1), however COP1 mediated ubiquitination or proteasomal degradation 
of C/EBPα is dependent on expression of a family of adaptor proteins “Tribbles” (Keeshan et al., 
2006, Keeshan et al., 2010, Yokoyama et al., 2010, Yoshida et al., 2013). These adaptor proteins of 
which there are three family members, Tribbles 1 (TRIB1), Tribbles 2 (TRIB2) and Tribbles 3 
(TRIB3), contain a highly conserved C-Terminal COP1 binding motif. TRIB1 and TRIB2 through 
their ability to bind both COP1 and C/EBPα mediate subsequent C/EBPα proteasomal degradation 
(Keeshan et al., 2006, Dedhia et al., 2010). TRIB1 and TRIB2 were identified to induce AML in 
murine models and this leukaemogenecity is dependent on their ability to bind COP1 (Keeshan et 
al., 2010, Yokoyama et al., 2010, Yoshida et al., 2013). Loss of COP1 binding, or COP1 activity 
through mutation of its active site, abrogated TRIB1 and TRIB2 ability to mediate ubiquitination 
and proteasomal degradation of C/EBPα (Yokoyama et al., 2010, Keeshan et al., 2010, Yoshida et 
al., 2013). TRIB1 and TRIB2 exert a differentiation block on myeloid cells inhibiting terminal 
differentiation through loss of C/EBPα protein expression (Keeshan et al., 2006, Yokoyama et al., 
2010). TRIB3 does not induce AML nor does it induce proteasomal degradation of C/EBPα. 
Proteasomal degradation of C/EBPα in lung cancer cells has also been identified through TRIB2 
adaptor binding however in this context TRIB2 was identified to bind TRIM21, another E3 ligase 
(Grandinetti et al., 2011). This report did not demonstrate bonafide ubiquitination of C/EBPα in this 
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context, however based on data identifying proteasomal inhibition rescued C/EBPα protein levels 
and E3 ligase requirement, it is highly likely TRIB2 mediates ubiquitin-dependent proteasomal 
degradation of C/EBPα in lung cancer cells via TRIM21 binding (Grandinetti et al., 2011). Thus 
direct association of C/EBPα with E3 ligases is not always a necessity for its mediated 
ubiquitination. Adaptor protein binding to C/EBPα also results in ubiquitination through the adaptor 
protein binding with an E3 ligase resulting in the formation of a multiprotein complex co-localising 
C/EBPα with an E3 ligase.  
 
 
 
Ligase Cell type Effect Reference 
FBXW7 
 
 
Adipocytes 
 
 
 
-Recognise phosphodegron. P-
Thr222/226 mediates ubiquitination 
and inhibits adipogenesis 
  
(Bengoechea-Alonso and 
Ericsson, 2010) 
E6AP Adipocytes 
Leukaemic 
cells 
-Directly binds C/EBPα mediating 
ubiquitin-dependent proteasomal 
degradation, inhibiting terminal 
differentiation of cells. 
(Pal et al., 2013a) 
(Pal et al., 2013b) 
TRIM21 
Via 
TRIB2 
Lung 
cancer cells 
-Proteasomal degradation of C/EBPα. (Grandinetti et al., 2011) 
COP1 
Via 
TRIB1 
Leukaemic 
cells 
-Ubiquitin-dependent proteasomal 
degradation of C/EBPα resulting in 
AML in murine models. 
(Yokoyama et al., 2010) 
(Yoshida et al., 2013) 
COP1 
via 
TRIB2 
Leukaemic 
cells 
-Proteasomal degradation of C/EBPα 
resulting in AML in murine models. 
(Keeshan et al., 2010) 
    
Table 1.6.4 Ligases identified to date which mediate ubiquitination and/or proteasomal degradation 
of C/EBPα. 
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1.7 Tribbles as regulators of haematopoiesis and potent leukaemogenes 
As mentioned previously there are three members of the tribbles family of proteins. TRIB1 and 
TRIB2 both induce proteolytic degradation of C/EBPα and induce AML in murine models and also 
have been identified to co-operate with Hoxa9 and Hoxa9/Meis1 leukaeamogenes (Keeshan et al., 
2006, Jin et al., 2007, Keeshan et al., 2008, Yokoyama et al., 2010). Data mining using leukaemic 
genome atlas (LGA) has identified elevated TRIB3 expression in AML harbouring t(15;17) and 
t(8;21) and in AML subtypes M2 and M3 but as of yet no leukaemogenecity has been attributed to 
TRIB3 (Dedhia et al., 2010, Liang et al., 2013). Thus this discussion will focus on TRIB1 and 
TRIB2 not TRIB3 as to date no reports suggest it elicits degradation of C/EBPα or AML in the 
murine models studied. 
1.7.1 Tribbles functional classification and protein structure  
TRIB proteins are classified as pseudokinase; while initial discoveries of TRIB1 and TRIB2 
described them as phosphoproteins, to date no in vitro kinase assay has identified TRIB-mediated 
phosphate transfer (Boylan et al., 2003, Hegedus et al., 2007). Lack of detectable kinase activity is 
either attributable to the kinase having unique untested substrates or that it is a true pseudokinase 
(Wilkin et al., 1997, Großhans and Wieschaus, 2000, Manning et al., 2002). A pseudokinase is 
defined as a protein which has a kinase-like domain, but lacks conserved motifs that are necessary 
for catalytic activity. Pseudokinases are now classified as a family of proteins which are predicted 
to comprise 10 % of the human kinome, these proteins are present on multiple branches of the 
human kinase tree, suggesting that they evolved independently of active kinases with distinct 
cellular roles (Manning et al., 2002). TRIB proteins are structurally comprised of three regions: an 
N-Terminal region, a C-Terminal region and a central pseudokinase domain (Fig 1.7.1). The N-
Terminal region is a short 60–80 amino-acid region which is proline- and serine-rich (PEST). 
Proteins containing PEST regions are indicative of proteins with short half-lives. TRIB1 and TRIB3 
are proposed to possess N-Terminal nuclear localisation sequence motifs [K/R]2×2[D/E]X[D/E] as 
determined by PSORT a protein domain prediction software (Hegedus et al., 2007). In silico 
analysis of TRIB1 and TRIB2 using PredictNLSonline revealed TRIB2 does not possess a NLS 
however it does contain a nuclear exportation sequence (NES) within the kinase domain 
(Unpublished work, Ciaran Forde, Dr. Karen Keeshan). TRIB1 also contains a NES. However 
experimental validation of these predicted NLS and NES domains is required. The central 
pseudokinase domain of the tribbles family resembles that of a canonical kinase as they retain some 
hallmark characteristics of a functional kinase while lacking other critical motifs and residues 
(Hanks and Hunter, 1995). To date there is no published 3D structure for TRIB proteins. Tribbles 
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has the predicted three-dimensional structure of a kinase (SWISS-MODEL homology modelling) 
and retains a critical lysine for ATP binding however it lacks motifs required for ATP catalysis and 
ATP orientation (Hegedus et al., 2007). The C-Terminal region contains two motifs: a COP1 RING 
E3 ubiquitin ligase binding motif [D/E]QXVP[D/E] and a MEK1-binding motif IL(L/D)HPWF. 
Both the COP1 and MEK1 binding motifs are highly conserved in mammalian tribbles homologues 
(Qi et al., 2006, Yokoyama et al., 2010, Dedhia et al., 2010). The presence of these two distinct 
protein-binding sites hints at functionally diverse roles of tribbles despite their lack of apparent 
kinase activity. Control of cell signalling pathways provides a cell with ability to respond to its 
extracellular environment and to control, proliferation, differentiation, cell survival and apoptosis. 
TRIB1 was reported to bind MKK4 and TRIB3 was reported to bind MKK7 while both TRIB1 and 
TRIB3 were identified to bind MEK1 (Kiss-Toth et al., 2004). MAPK binding was suggested to 
stabilise TRIB proteins and subsequent modulation of MAPK signalling cascades (Kiss-Toth et al., 
2004).  Further studies identified all TRIB proteins 1, 2 and 3 were able to bind MEK1 and only 
TRIB1 interacted with MKK4 (Yokoyama et al., 2010). TRIB proteins have been reported to act as 
adaptor/scaffold proteins, either facilitating the assembly of multiprotein complexes which result in 
a phosphorylation change, or in the degradation of their target proteins, or alternatively as 
signalling modulators. A conundrum to date has existed in the definition of tribbles functionality; 
they have been both proposed to act as degradation-mediation proteins and signal mediators. 
Additionally TRIB proteins have also been classified as decoy kinases; they do not exert kinase-like 
activity but have been shown to impede the function of other kinases through obstructive binding. It 
appears TRIB functionality is largely dependent on the cell context studied and the specific 
interacting protein partner (Lohan and Keeshan, 2013). 
 
Fig 1.7.1 Schematic of TRIB1/2 highlighting the amino acid sequence of; TRIB1 unique NLS 
sequence highlighted in orange, the catalytic domain highlighted in red, NES highlighted in yellow, 
MEK1 binding domain highlighted in purple, COP1 binding domain highlighted in green. Amino 
acid length of N-terminus, kinase-like domain and C-Terminus is indicated above and the amino 
acid identify of the domains identified of TRIB1 and TRIB2 indicated below. 
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1.7.2 Tribbles in haematopoiesis and their association with leukaemic disease  
Trib1 
To date elevated TRIB1 expression in leukaemic disease has only been reported in patients 
harbouring double minute (dmin) acentric chromatin bodies (Röthlisberger et al., 2007, Storlazzi et 
al., 2006). Dmin are frequent in AML, observed in ~1 % of cases and nearly always involve 
amplification of chromosome band 8q24 (Röthlisberger et al., 2007). Analyses of the amplicon 
produced showed that it contained the MYC locus however increased MYC transcription was not 
always identified in AML patients who harbour dmins indicating it was not the target gene of the 
amplification (Storlazzi et al., 2006, Röthlisberger et al., 2007). TRIB1 is also encompassed in this 
amplicon and was identified to be elevated in a subset of AMLs and MDS patients presenting with 
dmins (Storlazzi et al., 2006, Röthlisberger et al., 2007).  
TRIB1 was first discovered as a co-operating leukaemogene in BMT models investigating 
retroviral insertion sites of oncogenic fusion gene Hoxa9-Meis1 (Jin et al., 2007). Hoxa9-Meis1 
insertion increased Trib1 expression levels and combining Hoxa9-Meis1 and Trib1 in BMT models 
showed a reduced latency of Hoxa9-Meis1-induced AML (Jin et al., 2007). Additionally Trib1 
expression was identified to mediate an increase in levels of P-ERK1/2 in bone marrow and 
leukaemic cells, providing an example of TRIB functionality as signalling modulators (Jin et al., 
2007). TRIB1 expression was also identified to protect against apoptosis upon IL-3 withdrawal (Jin 
et al., 2007). Further BMT models revealed Trib1 expression alone was sufficient to induce murine 
AML and Trib1 was indeed a potent leukaemogene (Yokoyama et al., 2010). Trib1 
leukaemogenecity was intrinsically linked to its ability to bind MEK1, as MEK1 binding mutants 
lost the ability to induce AML (Yokoyama et al., 2010). Additionally Trib1-mediated increase in P-
ERK1/2 previously observed was also identified to be dependent on MEK1 binding (Jin et al., 
2007, Yokoyama et al., 2010). Trib1 was identified to bind C/EBPα and mediate proteasomal 
degradation of C/EBPαp42 (Yokoyama et al., 2010). However investigation by Dedhia et al did not 
observe any increase in P-ERK1/2 in response to Trib1 expression in 32Dcl3 cell (Dedhia et al., 
2010). Trib1 did mediate degradation of C/EBPα and inhibited C/EBPα driven differentiation in 
response to G-CSF (Dedhia et al., 2010). This study undermines the MAPK involvement in Trib1 
induced AML however it further supports the crucial role of C/EBPα mediated degradation.  
In an attempt to identify the C/EBPα binding site on TRIB1 a series of deletion constructs were 
made and their ability to bind C/EBPα was assessed, deletion of the N-Terminal region and part of 
the kinase-like domain of TRIB1 abrogated its ability to interact with C/EBPα (Yokoyama et al., 
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2010). However this N-Terminal deletion construct investigated was 180 amino acids shorter than 
WT-TRIB1 and may not retain the crucial tertiary structure of a protein required for the sterically 
complex interaction between two proteins during binding and additionally may alter cellular 
localisation. MEK1 binding was also observed to be a requisite for TRIB1 mediated degradation of 
C/EBPαp42, however the increase in P-ERK1/2 levels mediated by MEK1/TRIB1 did not result in 
an increase in P-Ser21 C/EBPα levels (Yokoyama et al., 2010). Loss of COP1 binding site on 
TRIB1 inhibited TRIB1-mediated degradation of C/EBPα indicating COP1 E3 ligase involvement 
in C/EBPα degradation (Yokoyama et al., 2010). Analysis of Down syndrome AML patients 
identified the existence of a TRIB1-R107L mutation which was proposed to be an early event in 
leukaemogenesis as it was retained in bone marrow cells during remission and was not identified in 
non-haematopoietic cell DNA (Yokoyama et al., 2012). Molecular characterisation of this mutant 
revealed it decreased the latency of TRIB1 induced AML in BMT models and enhanced TRIB1-
mediated increase in P-ERK1/2 and enhanced C/EBPα degradation (Yokoyama et al., 2012).  
TRIB1 plays a crucial role in regulation of myeloid cell differentiation during normal 
haematopoiesis (Satoh et al., 2013). Trib1 knockout (Trib1
-
/
-
) mice had decreased levels of M2-
tissue resident macrophages, an absence of eosinophils and increased granulocytes and neutrophils 
within their spleenic tissue (Satoh et al., 2013). Reversal of differentiation effects observed in 
colony forming assays was achieved by ectopic WT-Trib1 expression in Trib1
-
/
-
 bone marrow cells 
which resulted in a decrease in C/EBPα expression (Satoh et al., 2013). Ectopic expression of 
TRIB1ΔCOP1 did not rescue the haematopoietic deficient phenotypes or decrease C/EBPα 
expression (Satoh et al., 2013). Knockdown of C/EBPα expression in Trib1-/- cells abrogated Trib1-
/
-
 effects validating that the haematopoietic defects resulting from loss of Trib1 expression are 
attributable to increased C/EBPα levels (Satoh et al., 2013). Interestingly the authors noted a 
decrease in IL-10 production in adipose tissue of Trib1
-
/
- 
mice, and as mentioned previously 
C/EBPα represses IL-10 production via promoter binding and this inhibitory effect was relieved by 
P-Ser21 (Kang et al., 2013, Satoh et al., 2013). Investigations by Liu et al showed that knockdown 
of Trib1 expression in macrophage cells altered their morphology and their migratory behaviour 
(Liu et al., 2013). Liang et al investigated TRIB1 expression using LGA platform in different AML 
FAB subtypes and showed a significant increase in TRIB1 expression levels in FAB subtypes M4 
and M5 and also in patients with karyotypic abnormalities involving chromosome 16 (Liang et al., 
2013). Liang et al also investigated TRIB1 expression in normal physiological conditions and 
identified TRIB1 expression was significantly increase in granulocyte/monocyte and B-Cell 
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lineages supporting the observed effects of Trib1 knockout animal models discussed above (Liang 
et al., 2013).  
Trib2 
TRIB2 was initially discovered as a transcript down-regulated upon inhibition of NOTCH1 
signalling in a T-ALL cell line, and it was further validated as a direct transcription target of 
NOTCH1 upon identification of NOTCH1 binding to the TRIB2 promoter (Wouters et al., 2007). 
NOTCH1 is found mutated in 50% of T-ALLs resulting in aberrant signalling and activation of 
downstream signalling cascades (Weng et al., 2004). TRIB2 was also identified as a PITX1 gene 
target. PITX1 is recurrently activated in T-ALL via chromosome 5 deletion (Nagel et al., 2011). 
TRIB2 was reported to be essential for T-ALL cell survival; leukaemic transformation resulting in 
upregulation of TAL1 protects TRIB2 from Ebox proteins which are proposed to have a repressive 
effect on TRIB2 (Sanda et al., 2012). Additionally elevated TRIB2 expression is correlated with 
NOTCH1 activation, resulting from either gain of function NOTCH1 mutations or loss of function 
FBXW7 mutations, in a cohort of T-ALL paediatric patients (Hannon et al., 2012). Analysis of 
TRIB2 mRNA expression in AML FAB subtypes revealed TRIB2 expression is generally low albeit 
increased expression was observed in FAB subtypes M0 and M3 (Liang et al., 2013). Analyses of 
TRIB2 mRNA expression across 16 acute and chronic leukaemic subtypes from the MILE study 
identified a statistically significant increase in TRIB2 expression in T-ALLs specifically in patients 
with normal karyotypes and t(1;19) (Hannon et al., 2012). Further expression analysis identified 
genes associated with high TRIB2 expression in ALL were involved in T-cell and NOTCH1 
signalling (Hannon et al., 2012). Analysis of TRIB2 mRNA expression during normal 
haematopoiesis (Fig 1.7.3) revealed TRIB2 expression is highest in T-cells, specifically CD4
+
 T-
cells supporting the associations observed between TRIB2, T-cell leukaemogenes and T-cell 
leukaemias and suggesting TRIB2 is involved in T-cell biology (Hannon et al., 2012, Liang et al., 
2013). B-Cells and MEPS were also identified to express high levels of TRIB2 mRNA (Hannon et 
al., 2012) (Fig 1.7.3). Studies on knockout Trib2 mice showed that loss of Trib2 expression resulted 
in diminished levels of red blood cells indicating TRIB2 may also be crucial for normal 
erythropoiesis (ASH conference 2013 poster (Li et al., 2013). Indeed Fog1 and Gata1, 
megakaryocyte and erythroid governing transcription factors, have been identified to bind the Trib2 
promoter (Mancini et al., 2012). Knockout of Fog1 in preMegEs (bi-potential cells capable of 
forming megakaryocyte or erythroid lineages but not myeloid) resulted in a myeloid cell fate 
through upregulation of myeloid cell regulators (Mancini et al., 2012). Knockout of Fog1 decreased 
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Trib2 expression implicating a crucial role for TRIB2 in megakaryocyte and erythroid cell lineage 
commitment (Mancini et al., 2012). 
TRIB2 was the first member of the TRIB family to be classified as a leukaemogene. Its 
overexpression drives fully penetrant transplantable AML in BMT models (Keeshan et al., 2006). 
In these murine models Trib2 overexpression induces a myeloid leukaemic disease exclusively, 
phenotypically presenting as CD11b
intermediate
/ Gr-1
low
 which is a profile characteristic of immature 
myeloid cells and indicative of murine myeloid leukaemias (Keeshan et al., 2006). TRIB2 mRNA 
expression was shown to steadily increases as cells commit to the myeloid lineage; an increase in 
expression is detectible from HSC to CMP to GMP to granulocytes (Hannon et al., 2012) (Fig 
1.7.3). While as mentioned above TRIB2 expression has been reported to associate with human T-
ALL disease and also implicated in MEP differentiation, analysis of TRIB2 expression in 285 
human AML patients (VALK dataset) revealed elevated TRIB2 expression clustered with a cohort 
of patients who displayed a mixed myeloid/lymphoid phenotype (cluster 4) (Valk et al., 2004, 
Keeshan et al., 2006, Wouters et al., 2007) These patients identified in cluster 4 had elevated levels 
of T-cell signature genes including CD7 while also expressing CD34
+
 an immature cell marker 
(Wouters et al., 2007). Gene expression profiling of patients in cluster 4 identified a dysregulated 
C/EBPα gene expression signature, despite a subgroup of patients possessing no C/EBPα 
mutations. Patients harbouring C/EBPα mutations displayed high levels of C/EBPα expression 
while WT-C/EBPα patients had very low or no C/EBPα expression (Wouters et al., 2007). Elevated 
TRIB2 levels were identified in patients with no C/EBPα mutations (Keeshan et al., 2006).  
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Fig 1.7.3 Profiling TRIB2 mRNA expression during normal human haematopoiesis from dataset 
published by (Novershtern et al., 2011). A) TRIB2 expression across multiple haematopoietic 
lineages adapted from (Hannon et al., 2012) the intersecting line in boxplot represents mean 
expression while maximum and minimum whiskers represent range in expression. B) TRIB2 
expression analysed by LGA in CD8
+
 and CD4
+
 T-cells adapted from (Liang et al., 2013). C) 
TRIB2 expression analysed by LGA in monocytes, granulocytes, GMP and eosinophils adapted 
from (Liang et al., 2013). 
The dysregulated C/EBPα signature and low expression levels of WT-C/EBPα patients may be 
explained by the TRIB2-mediated proteasomal degradation of C/EBPα, (Keeshan et al., 2006). 
Additionally the T-lymphoid phenotype of these leukaemic cells may also be attributed to elevated 
TRIB2 expression due to its association with T-cell gene expression. TRIB1 levels were decreased 
with elevated TRIB2 in this cohort of patients indicating distinct modalities for TRIB1 and TRIB2 
induced AML (Keeshan et al., 2006). TRIB2 also co-operates with Hoxa9 and Nup98-Hoxd13-
Meis1 fusion gene reducing the latency of AML in BMT models (Argiropoulos et al., 2008, 
Keeshan et al., 2008). Hox genes are common retroviral integration sites in murine myeloid and are 
crucial mediators of haematopoiesis reviewed by (Alharbi et al., 2012). Trib2 was identified as an 
insertion site in the Hoxa9 gene locus, mediating increased Hoxa9 expression. Indeed Hoxa9 was 
identified to co-operate with Trib2 to rapidly accelerate the onset of Trib2 induced AML in BMT 
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models by ~100 days (Keeshan et al., 2008). Meis 1 was identified to directly increase Trib2 
expression via occupancy on the Trib2 promoter facilitating Trib2 and Nup98-Hoxd13-Meis1 co-
operation during leukaemogenesis (Argiropoulos et al., 2008). 
Structural analysis of the Trib2 protein revealed its leukaemogenecity is dependent on an intact 
kinase-like domain and its C-Terminal COP1 binding site (Keeshan et al., 2010). Deletion of 
TRIB2 N-Terminal domain does not abrogate the ability of Trib2 to mediate proteasomal 
degradation of C/EBPα or to inhibit myeloid cell differentiation. Mutation of the Trib2 kinase-like 
domain to resemble a canonical kinase (TRIB2-KDM) inhibited the proteolytic effect of Trib2 on 
C/EBPα and also abrogated its ability to induce AML in BMT models (Karen Keeshan unpublished 
data and (Keeshan et al., 2010). Mutation of a lysine which is a hallmark of a serine/threonine 
(ser/thr) kinases within the kinase-like domain of Trib2 to resemble a tyrosine kinase (K177R), was 
performed to assess if Trib2 possessed any ser/thr kinase activity. Trib2-K177R also abrogated the 
ability of TRIB2 to degrade C/EBPα and to induce AML (Karen Keeshan unpublished data and 
(Keeshan et al., 2010). Therefore, while no kinase activity has yet been attributed to TRIB2 perhaps 
modulation of these amino acids within the kinase-like domain may have major ramifications on its 
protein structure hence altering its protein-protein interactions. TRIB2 modulation of signalling has 
been implicated in the immune response through mediation of Toll like receptor (TLR) signalling. 
TRIB2 was shown to negatively regulate TLR5-mediated activation of NFκB (Wei et al., 2012). 
This inhibition was attributed to TRIB2 binding directly to NFκB2 decreasing the activity of 
NFκB2 (p100) (Wei et al., 2012). Indeed, TRIB2 knockdown results in a decrease in TLR mediated 
phosphorylation of JNK and p38, but not ERK1/2 and knockdown of TRIB2 in macrophages 
resulted in increased levels of p65 and inhibitor of NFκBα and β (iKKα) and (iKKβ) 
phosphorylation (Wei et al., 2012). TRIB2 is also induced by TLR5 and this feedback loop 
contributes to TRIB2-mediated control of the immune response (Wei et al., 2012). 
A prominent role for TRIB2 is now emerging as a modulator of cell cycle and proliferation, 
providing leukaemic cells with increased proliferative advantage (Rishi et al., 2014). Indeed 
knockdown of TRIB2 expression in leukaemic cells results in a decrease in cell proliferation, an 
increase in cells paused in G1 with a concomitant increase in apoptosis and cell death indicating a 
requirement for TRIB2 expression (Rishi et al., 2014). Additionally in Drosophila dTrbl  mediates 
proteasomal degradation of dString/CD25C pausing the cell cycle at the G2/M transition during 
morphogenesis and gastrulation (Mata et al., 2000). Mammalian conservation of this relationship is 
currently under investigation in our group. TRIB2 expression was identified to be directly regulated 
by E2F1, the master cell cycle regulator (Rishi et al., 2014). E2F1 along with transcriptional 
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activator family members E2F2, E2F3 were identified to bind the TRIB2 promoter increasing 
TRIB2 expression (Rishi et al., 2014). C/EBPαp42 as mentioned previously elicits a pause in the 
cell cycle through repression of E2F1 and C-MYC transcription. C/EBPαp30 lacks the N-Terminal 
domain required for this interaction (Johansen et al., 2001, D'Alo et al., 2003). Under normal 
haematopoietic conditions C/EBPαp42 was identified bound to the TRIB2 promoter via a C/EBP 
binding site, repressing TRIB2 expression in GMPs (Rishi et al., 2014). Upon TRIB2-mediated 
disruption of the C/EBPα42/p30 ratio elevated levels of C/EBPαp30 resulted in an increase in 
C/EBPαp30 binding to the TRIB2 promoter, which was identified to co-operate with E2F1 and 
enhance TRIB2 expression (Keeshan et al., 2006, Rishi et al., 2014). Indeed pharmacological 
inhibition of the cell cycle in leukaemic cells resulted in a decrease in E2F1 levels and an 
associating decrease in TRIB2 levels (Rishi et al., 2014). Pharmacological inhibition of the cell 
cycle in normal WT and Trib2 knockout bone marrow cells revealed very little cytotoxicity, 
providing evidence to suggest that targeting this pathway may be a viable option to inhibit the 
acquired proliferative advantage of leukaemic cells (Rishi et al., 2014).  
To date several microRNAs have been identified to modulate TRIB2 expression. miR-99 decreases 
TRIB2 expression and inhibits cervical carcinoma cell proliferation (Xin et al., 2013). miR-511 and 
miR-1297 also downregulate TRIB2 expression with an increase in C/EBPα protein expression 
observed (Zhang et al., 2012a). Overexpression of miR-511 and miR-1297 inhibits adenocarcinoma 
cell proliferation and increases apoptosis (Zhang et al., 2012b). Thus far two miRNAs have been 
identified to modulate TRIB2 expression in haematopoietic cells miR-155 and miR-100 (Zheng et 
al., 2012, Palma et al., 2014). MiRNAs are multifunctional short stretches of noncoding RNA; miR-
155 is upregulated in HSCs, GMPs, granulocytes and macrophages and is required for normal 
haematopoietic cell maturation (Rodriguez et al., 2007). MiR-155 has been reported to be elevated 
in AML associated with FLT3-ITD and downregulated in AML with inv(16) thus its functional 
effects remain largely speculative (Jongen-Lavrencic et al., 2008, Faraoni et al., 2012). 
Overexpression of miR-155 was identified to upregulate TRIB2 expression and was also identified 
to promote differentiation of AML with an associating increasing in Caspase-3 dependent apoptosis 
(Palma et al., 2014). Induction of myeloid differentiation was reported to be independent of 
C/EBPα as no increase in mRNA levels was observed (Palma et al., 2014). It was proposed that 
induction of differentiation is occurring through an alternate pathway to that mediated by C/EBPα 
expression as there was no change in expression observed and the increase in TRIB2 levels is 
contradictory to induction of myeloid maturation (Palma et al., 2014). 
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To date TRIB2 and to a large extent TRIB1 leukaemogenecity is inextricable linked to inactivation 
of C/EBPα. Perhaps overexpression of TRIB proteins may be classified as a type I mutation (as loss 
of TRIB2 expression inhibits cellular proliferation) and subsequent inactivation of C/EBPα 
resulting in inhibition of differentiation acts as a class II mutation fitting the Gilliland two hit model 
of leukaemogenesis (Kelly and Gilliland, 2003).  
1.8.1 Ubiquitin proteasome system 
The ubiquitin proteasome system (UPS) is the main protein proteolysis pathway in eukaryotic cells 
(Hershko et al., 2000). Ubiquitination involves the hierarchical sequential action of three ubiquitin 
enzymes; E1, E2 and E3 resulting in degradation performed by the proteasome, a nonspecific 
protease. Specificity is applied by the action of the three ubiquitin enzymes. 
The actions of E1 at the beginning of the cascade are required for activation of the 76 amino acid 
ubiquitin moiety and its transfer to the E2 enzyme. To date the functions of the E1 enzyme are the 
most characterised of the whole UPS system (Kleiger and Mayor, 2014). E1 activation of ubiquitin 
and transfer to E2 is a multistep ATP-dependent process involving; the adenylation of the ubiquitin 
C-terminus, the formation of a thioester bond between the C-Terminus of ubiquitin and the E1 
catalytic cysteine residue in its active site and the subsequent transfer of ubiquitin from E1 to E2’s 
catalytic cysteine residue (Kleiger and Mayor, 2014). The absolute requirement for E1 activity was 
identified upon chemical inhibition of E1 resulting in almost immediate shutdown of the UPS 
(Yang et al., 2007). In order for E1 to bind both ubiquitin and deliver it to E2 a high degree of rapid 
protein flexibility is required (Huang et al., 2007). Additionally E1 enzymes must recognise 40 
human E2 ligases. Structural analysis revealed E1 is capable of multiple domain rearrangements 
and shows no apparent selectivity for E2 binding as the rate of ubiquitin transfer is similar for 
different E2 proteins (Tokgoz et al., 2012).  
The next step of UPS involves E3 ubiquitin ligases. E3 ligases function like adaptor or protein 
scaffolds mediating co-localisation of the substrate protein and the E2-ubiquitin adduct and the 
subsequent ubiquitin transfer to the lysine side chain of the amino terminus of the substrate protein. 
E3 ligases may accelerate the rate of ubiquitin transfer however catalysis of the reaction is 
dependent on the E2 enzyme (Ohta et al., 1999). Upon formation of the E2-ubiquitin thioester 
linkage the conformational location of this linkage against particular E2 interphases optimises 
ubiquitin transfer (Pruneda et al., 2011). E3 ligases may accelerate the transfer by acting to stabilise 
the E2-ubiqutin-E3 complex. Indeed E3 ligases possessing a really interesting new gene (RING) 
domain recruit E2-ubiqutin adducts (Plechanovova et al., 2012). In such circumstances, ubiquitin 
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contacts E3 RING ligase resulting in stabilisation of the interaction. Alternatively phosphorylation 
of residues neighbouring the RING domain have been identified to further aid ubiquitin binding 
(Dou et al., 2013). Not all E3 ligases possess RING domain, some possess HECT domains, the 
molecular mechanism for ubiquitination with such ligases varies greatly from that of RING E3 
ligases. HECT E3 ligase require an additional trans-thioesterification step, ubiquitin is first 
transferred from E2 to E3 before its conjugation to the substrate protein. HECT domains are 
comprised of two lobes an N-Terminal lobe and a C-Terminal lobe separated by a linker region. 
The E3 ligase’s N-lobe binds E2~ubiquitin adduct and ubiquitin is then transferred from the E2 to 
the catalytic cysteine of the C-lobe of the E3 ligase. The C-lobe then undergoes a 130 degree 
rotation about a linker region to juxtapose E2~Ubiquitin and the ubiquitination target site (usually a 
lysine residue) on the substrate protein to facilitate ubiquitin transfer (reviewed by (Kamadurai et 
al., 2013)).  
 
 
 
Fig 1.8.1 Mechanism of ubiquitination A) Schematic representation of the chain of E1, E2 and E3 
mediated events during ubiquitination. ATP-dependent activation of ubiquitin following 
adenylation of C-Terminus of ubiquitin producing an E1-ubiqutin adducts. E2 ubiquitin conjugating 
enzyme receives ubiquitin from E1 and forms a thioester bond with a cysteine residue in its active 
site. E3 ligase is responsible for conjugation of ubiquitin to target protein.  B) Model of RING E3 
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ligase mediated conjugation of ubiquitin to substrate protein adapted from (Kleiger and Mayor, 
2014). 
E2 enzymes have been identified to function maximally only when in the presence of E3 ligases. 
This is proposed to occur to prevent the high cellular concentrations of E2-ubiqutin from 
ubiquitinating non target substrate proteins (Kleiger and Mayor, 2014). In order for a protein to be 
targeted for proteasomal degradation by its ubiquitin linkers it requires the attachment of at least 4 
ubiquitin moieties. Upon transfer of the first ubiquitin to substrate protein the rate of substrate 
dissociation is sufficiently slow to allow ubiquitin chain formation. Ubiquitination and subsequent 
proteasomal degradation of regulatory proteins is a rapid process providing abrupt termination to 
effects propagated, however ubiquitination also serves to degrade misfolded proteins for protein 
quality control purposes (Pierce et al., 2009, Comyn et al., 2014). In some instances a protein may 
acquire the correct fold when provided with time, the lack of consensus E3 ligase motifs is 
proposed to slow polyubiquitination providing time for correct conformational folding. Once the 
ubiquitinated protein dissociates from the E3 ligase it is exposed to, deubiquitination enzymes 
(DUBs) that remove and edit ubiquitin polychains. Some DUBs associate with the proteasome (the 
final resting place of degradation ubiquitin linked proteins), and are proposed to enable efficient 
proteolysis by removing the ubiquitin motifs facilitating their proteasomal processing (Kleiger and 
Mayor, 2014). Several types of ubiquitination chains may be produced through the identity of the 
lysine in ubiquitin which forms the linkage e.g. K6, K11, K27, K29, K33, K48 and K63. K48 
polyubiquitination targets the substrate protein for degradation while alternative ubiquitination 
chains are increasingly being identified with distinct molecular roles (discussed in greater detail in 
Chapter 4).  
1.8.2 The 26S proteasome 
The 26S proteasome a highly dynamic holocomplex, of 2.5mDA size, comprised of two 
multisubunit components, the 20S subunit and its regulatory subunit the 19S (Fig 1.8.2). Only 
recently has the structure of the 26S proteasome been described in detail using electron microscopy 
based approaches reviewed by (Förster et al., 2013). The 20S subunit is arranged in a hollow 
cylindrical structure with the proteolytic active subunits facing in (Peters et al., 1993). Within this, 
protein proteolysis occurs. The ends of the 20S barrel are gated by the 19S regulatory subunits. 
Ubiquitinated proteins dock on the 19S subunit through binding proteasome receptors Rpn13, 
Rpn10 (Zhou et al., 2013). The Rpn11 subunit then cleaves the ubiquitin polychain from the 
substrate protein enabling recycling of the ubiquitin proteins and reducing the size of the substrate 
protein, which now enters the 20S core (Fig 1.8.2). 
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Fig 1.8.2 Schematic of ubiquitinated protein proteolysis at the 26S proteasome. The grey 
chambers represent the 20S core, the blue chambers represent the 19S regulatory subunit. Rpn10/13 
are represented in green and Rpn11 is pink. Upon ubiquitinated-protein binding to Rpn10/13, 
alterations to the 19S conformation permit entry of unfolded and deubiquitinated protein after the 
actions of Rpn11. The protein is then passed into 20S core in an ATP dependent manner adapted 
from (Kleiger and Mayor, 2014). 
1.8.3 Proteasome inhibitors as chemotherapeutic agents 
Loss of apoptosis (cellular suicide), is one of the major causes of tumourigenesis. The UPS is a 
crucial modulator of cell cycle, proliferation and apoptosis. Indeed disruption of the UPS is 
increasingly being associated with neoplastic disease. Aberrant activation of NOTCH1 signalling 
observed in T-ALL is often due to loss of function mutations in FBXW7 an E3 ligase. The first 
food and drug administration (FDA) approved inhibitor of the UPS, Bortezomib, which targets the 
proteasome is used in the treatment of refractory multiple myeloma and currently in phase II and 
phase III trials as a potential treatment for B-cell lymphoma and follicular non-Hodgkin’s 
lymphoma (Richardson et al., 2006, Kane et al., 2007). Carfilzomib a mechanistically and 
structurally distinct proteasome inhibitor has been reported to induce cell cycle arrest, apoptosis and 
displays sensitivity against Bortezomib resistant disease (Kuhn et al., 2007, Rentsch et al., 2013). 
The promising results of these proteasome inhibitors has fuelled the search for other antagonists of 
the UPS (reviewed by (Zhang and Sidhu, 2014)). An allosteric E2 inhibitor has been identified 
which is able to inhibit ubiquitination of cell cycle regulators leading to inhibition of proliferation 
human cancer cells (Ceccarelli et al., 2011). Ubistatins have been described which bind to the K48 
ubiquitin polychain disrupting the conformation of ubiquitin polychains and affecting proteasome 
receptor binding of K48 ubiquitinated proteins (Verma et al., 2004). Ubistatins have a strong 
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negative charge and are not cell permeable however they represent another promising emerging 
therapeutic agent (Nalepa et al., 2006). 
Aims of this project 
TRIB2 possesses potent murine leukaemogenic potential and has also been shown to be elevated in 
cohorts of AML patients. Trib2 was previously identified to mediate murine AML via its 
proteolytic effect on C/EBPα, a crucial regulator of haematopoiesis frequently identified mutated in 
patient AML. The aims of this project were to determine the mode by which TRIB2-mediated the 
degradation of C/EBPα and to investigate the proteolytic requirement for direct TRIB2-C/EBPα 
interaction through elucidation of the direct regions of C/EBPα interaction on TRIB2. TRIB2 is 
classified as a pseudokinase as it lacks kinase function despite possessing some hallmark of kinase 
characteristics. The aims of this work were to investigate TRIB2 functionally required regions and 
their effect on C/EBPα. TRIB2 is classified as an adaptor protein facilitating the formation of 
multiprotein complexes which mediate proteasomal degradation and modulation of cell signalling 
cascades. Phosphorylation of C/EBPα exerts differing differentiation inhibiting effects on C/EBPα 
function, governed by the action of upstream kinases. This work investigates TRIB2 effects on 
C/EBPα phosphorylation and attempts to further define the role of TRIB2 as an adaptor protein. 
Improvement of AML survival rates has stalled during the last decade owing to limited knowledge 
of the vastly heterogeneous nature of the disease and a subsequent lack of targeted therapies. 
Through increased knowledge of TRIB2-mediated disease this study aims to identify a potential 
therapy to target TRIB2-mediated AML. This research was conducted using peptide array 
technology, in vivo binding, ubiquitination and drug cytotoxicity assays. The therapeutic effect of 
TRIB2 overexpression on the leukaemic cell and on AML patient cell biology was explored by 
measuring the in vitro response to proteasome inhibition. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 General Chemicals and Reagents 
All salts and reagents including protease and phosphatase inhibitors were purchased from Sigma-
Aldrich unless otherwise stated. Protein G-Sepharose Fast Flow 4 Beads and Nitrocellulose 
membrane were procured from GE Life Sciences, United Kingdom (UK). Prestained molecular 
weight protein markers and chemiluminescent Clarity 
TM
 Western ECL substrate detection kit for 
Chemidoc
TM 
XRS+ system were purchased from Biorad Laboratories, UK. Bradford protein 
quantification solution, Immunoblot stripping buffer, CL-XPosure Film, Ponceau S Solution, 
chemiluminescent detection kits ECL Pico and Femto were purchased from Thermo Scientific, UK. 
Restriction enzymes were purchased from New England Biolabs, UK. Purified C/EBPα protein was 
purchased from Genway, United States of America (USA). Bortezomib was purchased from LC 
Labs, USA. Peptide arrays and specific alanine scanning substitution arrays (SASSA) were 
generated by Dr. Patrick Kiely, University of Limerick. 
2.1.2 Molecular Biology Reagents 
2.1.2.1 Immunoblotting antibodies 
Antibody Clone Specie
s 
Incubation Blocking 
Soln. 
Dilution Company 
TRIB2 
sc-100878 
 
B-06 Mouse Overnight 5% milk 1:250 Santa Cruz 
C/EBPα 
sc-61 
14AA Rabbit 1 hr at RT 
(O/E) 
Overnight 
(E/N) 
5% milk 1:2000 (O/E)* 
1:114 (E/N)** 
Santa Cruz 
C/EBPαX 
sc-61X 
14AA Rabbit Overnight  
CO-Immuno 
precipitation 
- 5μg per  
Immuno-
precipitation 
 
Santa Cruz 
Myc-tag 9E10 Mouse Overnight 5% milk 1:250 Homemade 
P-Ser21 
C/EBPα 
2841 
 
No clone 
number 
Rabbit 
 
Overnight 5% BSA 1:500 (E/N) 
1:1000(O/E) 
Cell 
Signaling 
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P-Thr222/ 
226 
C/EBPα 
2844 
No clone  
number 
Rabbit Overnigh 5 % BSA 1:500 (E/N) 
1:1000 (O/E) 
Cell 
Signaling 
Actin 
A5441 
AC-15 Mouse Overnight/  
1 hr RT 
5% Milk 1:2500 Sigma 
HA 
H9658 
HA-7 Mouse Overnight 5% Milk 1:1000 Sigma 
K48- 
Ubiquitin 
05-1307 
APU-2 Rabbit Overnight 5% Milk 1:1000 Millipore 
K63- 
Ubiquitin 
05-1308 
APU-3 Rabbit Overnight 5% Milk 1:1000 Millipore 
P-ERK1/2 
4695s 
D13.1.4
E 
 
Rabbit Overnight 5% BSA 1:2000 Cell 
Signaling 
ERK1/2 
4370s 
137F5 
 
Rabbit Overnight 5% BSA 1:2000 Cell 
Signaling 
*O/E-overexpression, ** E/N-Endogenous, RT-room temperature 
 
2.1.2.2 FACS antibodies 
Antibody Clone Fluorophore Incubation Dilution Company 
Annexin V 
556422 
550475 
 
No clone 
number 
PE 
APC  
 
15 mins RT  1:100 BD 
Cd14 
557700 
 
M5E2 PE 30 mins  
4°C 
1:100 BD 
Cd15 
560827 
H198 PECY7 30 mins  
4°C 
1:100 BD 
Cd11b M1/70 PE 30 mins  1:100 BD 
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557397 
553312 
553310 
APC 
FITC 
4°C 
Cd34 
345803 
8G12 PE CY 30 mins  
4°C 
1:100 BD 
 
2.1.2.3 Cell lines 
Human embryonic kidney (HEK) 293t cells (ATCC) were maintained in Dulbecco Modified Eagle 
Medium (DMEM) (Invitrogen) supplemented with 10 % Fetal Bovine Serum (FBS) (Invitrogen), 
12 μM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen). U937 cells (a 
kind gift Dr. Martin Carroll) were maintained in rpmI 1640 medium supplemented with 10 % FBS, 
12 μM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. NIH-3T3 fibroblast cells 
were maintained in DMEM supplemented with 10 % Cosmic (Invitrogen), 12 μM L–glutamine, 
100 U/mL penicillin and 100 μg/mL streptomycin. Cells were maintained in culture for no longer 
than three months and were routinely tested for mycoplasma infection using MycoAlert 
Mycoplasma detection kit purchased from Lonza (Dublin, Ireland).  
2.1.2.4 Plasmid Sources 
Expression constructs murine (m) TRIB2-pcDNA3.1, mTRIB2-VPM-pcDNA3.1, mTRIB2-KDM-
pcDNA3.1, rat (r) C/EBPα-pcDNA3.1–Myc-His (PHMA), MigR1-eGFP, mTRIB2-MigR1-eGFP 
and mTRIB2-VPM-MigR1-eGFP were described previously (Keeshan et al., 2006, Keeshan et al., 
2010). See PHMA and MIGR1 backbone vector maps below (Fig 2.1.2.4 A, B and C). Retroviral 
packaging plasmids pCPg and envelope encoding VSVg were used in order to produce retrovirus 
using respective retroviral expression vectors (Fig 2.1.2.4 D and E). Ubiquitin (Ub) - haemagluttin 
(HA), Ubiquitin mutant K48R-HA and Ubiquitin mutant K63R-HA were kind gifts from Dr. R. J. 
Carmody, University of Glasgow. mC/EBPα-S21D-pcDNA3, mC/EBPα-S21A-pcDNA3, 
mC/EBPα-S21D-ER-IRES-MSCV-eGFP and mC/EBPα-S21A-ER-IRES-MSCV-eGFP were kind 
gifts from Dr. D. Tenen, Harvard Medical School and described previously (Ross et al., 2004). 
mTRIB2 mutants R77A, S227A/S229A/S231A/K233A and  K322A with a N-Terminus fused 
FLAG tag were created in PHMA expression vector by GenScript, USA. rC/EBPα mutant K313R 
noSTOP-myc in PHMA expression vector was generated by GenScript, USA. C/EBPα mutants 
R333A, R393A and R343A-HA-PHMA were previously generated in the laboratory by C. Forde 
using SDM primers (eurofins MWG operon) outlined below. Complete list of plasmids used see 
table below (Table 2.1.2.4 A). 
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R333A forward 5’GTG GAA CAG CTG AGC GCT 
GAA CTG GAC ACG CT 3’ 
R333A reverse 5’AGC GTG TCC AGT TCA GCG CTC 
AGC TGT TCC AC 3’ 
R339A forward 5’AAC TGG ACA CGC TGG CGG 
GTA 5’TCT TCC GCC 3’ 
R339A reverse 5’GGC GGA AGA TAC CCG CCA 
GCG TGT CCA GTT 3’ 
R343A forward 5’TGC GGG GTA TCT TCG CCC AGC 
TGC CTG AG 3’ 
R343A reverse 5’CTC AGG CAG CTG GGC GAA 
GAT ACC CCG CA 3’ 
Table 2.1.2.4 A Primer pairs used for construction of various C/EBPα mutants 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 
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Vector maps 
 
Fig 2.1.2.4 Backbone vector maps used. A) pcDNA3.1 B) pcDNA 3.1 myc-His A (PHMA) vector 
map. C) MigR1 retroviral expression vector. D) VSVg retroviral packaging vector. E) pCPg 
retroviral envelope producing vector. 
 
A B 
C D 
E 
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Gene Vector Tag 
C/EBPα PHMA HA/Myc 
C/EBPα-R339a PHMA HA 
C/EBPα-R333a PHMA HA 
C/EBPα-R343a PHMA HA 
C/EBPα-K313R PHMA  Myc 
C/EBPα-S21D pcDNA3.1 - 
C/EBPα-S21A pcDNA3.1 - 
C/EBPα-L12V PHMA HA 
Ubiquitin-WT PHMA HA 
Ubiquitin-K48R Unknown HA 
Ubiquitin-K63R Unknown HA 
WT-TRIB2 PHMA Myc 
TRIB2-KDM PHMA Myc 
TRIB2-VPM PHMA Myc 
TRIB2-R77A PHMA Flag 
TRIB2-
S227A/S229A/S231A/K233A 
PHMA Flag 
TRIB2-K322A PHMA Flag 
Expression vector control PHMA - 
pCPg Retrovirus production  
VSVg Retrovirus production  
WT-TRIB2 MigR1 GFP 
TRIB2-VPM MigR1 GFP 
C/EBPα-S21D IRES ER 
C/EBPα-S21A IRES ER 
Retrovirus control MigR1 GFP 
Table 2.1.2.4 B List of plasmids used 
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2.2 Methods  
2.2.1 Molecular Biology 
2.2.1.1 Competent cell preparation and transformation 
DH5α were streaked for single colonies and grown on an LB plate overnight at 37 °C. A single 
colony was picked and grown in 5 mL of LB medium overnight at 37 °C. 3 mL of overnight grown 
DH5α cells were inoculated into 100-200 mL of LB solution and grown for 2-3 hours (hrs). Once 
cell density reached OD595 0.6-1.0, cells were harvested by centrifugation of cells at 3000xg for 15 
mins at 4 °C. The supernatant was discarded and the pellet resuspended in pre-cooled 0.1 M 
Magesnium sulphate (MgS04) at one third the volume of the bacterial culture volume. Cells were 
then harvested as above and the pellet resuspended in 0.1 M Calcium chloride (CaCl2) containing 15 
% (v/v) of glycerol with 1/25 of bacterial culture volume. Aliquots were stored in pre-cooled 
eppendorfs, frozen on dry ice and then stored at -80 °C. 
2.2.1.2 Transformation of DH5α competent cells for plasmid production 
DH5α cells thawed on ice for 10 mins. DH5α were inoculated with 1 μL of plasmid DNA (10-50 
ng) and placed in water bath at 37 °C for 1 min. 100 μL of LB broth was added, the inoculate was 
smeared on sterile LB + Ampicillin (AMP)(100 µg/mL) plates and incubated at 37 °C overnight. 
Single colonies were selected and grown in 3 mL of sterile starter culture (LB broth + 37 °C AMP) 
for 8 hrs in shaker at 37 °C. Starter culture was added to 150 mL of LB broth + AMP and incubated 
overnight in shaker at 37 °C. Plasmid preparation was performed using PureYield 
TM
 Plasmid 
Midiprep kit. DNA was quantified using Nanodrop 2000 (Thermo).  
2.2.1.3 Restriction enzyme digests and verification of plasmid preparation. 
Plasmid preparations were checked by restriction enzyme digests. All C/EBPα constructs (1 μg) 
were digested with 0.5 μL Xho1 and 0.5 μL EcoR1 high fidelity in 10 μL NEB buffer 4, 
supplemented with 2 μL bovine serum albumin (BSA) in a final volume of 20 μL for 1 hr at 37 °C. 
WT-TRIB2, TRIB2-KDM and TRIB2-VPM constructs were digested similarity instead using Xho1 
and BamH1 NEB buffer 3. TRIB2 mutants R77A, S227A/S229A/S231A/K233A and K322A were 
digested with Xho1 and EcoR1. Digests were run on an agarose 1 % gel alongside DNA ladder and 
visualised using the Chemidoc. Plasmid preparation were screened for 1.5 kb (C/EBPα constructs) 
and 1.2 kb (TRIB2 constructs) insert drop outs and 5.4 kb PHMA vector back bone as restriction 
enzymes chosen each had only one recognition site. 
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2.2.2 Cell Biology 
2.2.2.1 X-tremeGENE transfection of HEK293t cells 
Transient overexpression of respective plasmid vectors was performed using X-tremeGENE HP 
DNA Transfection reagent (Roche) following manufactures guidelines in HEK293t cells. Cells 
were seeded on day 1 at a density of 4X10^6 cells per 10 cm dish, or 0.3X10^6 cells per well in 6 
well plate. Twenty four hrs post seeding, when cells were at optimum confluency (70-90 %), cells 
were transfected as required using a DNA to X-tremeGENE ratio of 3:1. The total amount of DNA 
transfected was 6 μg or 2 μg for 10 cm and 6-well plate respectively. Cells were lysed 24 hrs post 
transfection as outlined in 2.2.4. 
2.2.2.2 Retroviral production using calcium phosphate method and virus titration. 
Retrovirus was produced in HEK293t cells and titered by transduction of NIH-3T3 cells. On day 1 
5X10^6 HEK293t cells were seeded in 10 cm plate in a final volume of 10 mL. Day 2 cells were 
replenished with 3 mL fresh DMEM medium. For the transfection, 1 volume transfection buffer 
was added to 1 volume DNA cocktail drop by drop. The buffer/cocktail mixture was incubated with 
cells overnight. Each 10 cm plate used 500 μL of buffer and 500 μL of cocktail. The transfection 
buffer contained 0.05 M HEPES, 0.18 M sodium chloride (NaCl), 2 mM sodium phosphate 
(Na2HPO
4
) made up to a final volume 500 μL using ddH2O. The DNA cocktail contained 31 μg 
total DNA (15 μg of transfer plasmid, 10 μg pCPg and 6 μg VSVg), 0.25 M CaCL2, 10X NTE (0.01 
M ethylenediaminetetraaceteic acid (EDTA) pH8.0, 0.1 M Tris hydrochloric acid (HCl) pH7.4, 
0.15 M NaCl and ddH2O) made up to a final volume 500 μL using ddH2O. HEK293t cells were 
transfected no longer than 16 hrs at which time the medium was aspirated from the cells and 4.5 
mL of fresh warm medium was added. Viral harvests were collected 24 hrs, 48 hrs and 72 hrs post 
medium replenishment. Viral harvests were centrifuged at 1500rpm for 5 mins at 4 °C, the 
supernatant was snap frozen on dry ice and stored at -80 °C. NIH-3T3 cells were transduced in 
order to titer the virus. 2X10^5 NIH-3T3 cells were seeded in 3 cm dish in 3 mL of medium. 
Twenty four hrs later medium was aspirated and the cells were incubated with 100 μl of viral 
supernatant to be titered and 2 µg/mL polybrene in 1 mL of medium. 2 mL of medium were added 
24 hrs later. Twenty four hrs later cells were trypsinised and percentage transduction as measured 
by green fluorescent protein (GFP) expression was determined by comparing GFP expression to 
non-transduced control by fluorescent activated cell sorting (FACS) analysis.  
2.2.2.3 Retroviral transduction of U937 cells 
U937 cells were seeded at a density of 2X10^5 cells per mL 12 hrs prior to transduction. 1-5X10^6 
cells were resuspended in 3-5 mL fresh medium supplemented with 20 % FBS, 1-3 mL of virus 
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(dependent on titre and cell number required), 2 ug/mL polybrene in 6 well plate. Cells were 
centrifuged for 90 mins at 1500rpm at room temperature. Six hrs post transduction, transduced cells 
were replenished with fresh medium to reach a final volume of 10 mL. Percentage transduction was 
determined by GFP expression measured by flow cytometry at desired time points. 
2.2.2.4 Preparation of cellular protein extracts, protein quantification and SDS–polyacrylamide 
gel electrophoresis and western blotting 
Cellular protein extracts were prepared using lysis buffer optimized for extraction of respective 
proteins. For TRIB2 protein expression, cells were lysed in Tris Lysis buffer (50 mM Tris pH7.4, 
150 mM NaCl, 1 mM EDTA, 0.5 % NP-40, 5 % glycerol, supplemented with tyrosine phosphatase 
inhibitors;1 mM sodium orthovanadate (Na3VO4) and 1 mM Sodium Flouride (NaF) and protease 
inhibitors;1 mM phenylmethylsulfonyl fluoride (PMSF), 1 μM Pepstatin A, 2 ug/mL Aprotonin and 
2 ug/mL Leupeptin) for 30 mins on ice, vortexing every 5 mins, then centrifuged at 14,000rpm for 
10 mins at 4 °C. Lysates were stored at -80 °C. Direct lysis was performed in order to assess 
C/EBPα protein expression. 15X10^5 cells were suspended in 25 μL of 2x Laemmli buffer (120 
mM Tris-CL pH 6.8, 20 % Gylcerol, 4 % sodium dodecyl sulphate (SDS), 0.02 % bromophenol 
blue), vortexed, boiled at 95 °C for 5 mins and then stored at -80 °C. Protein quantification was 
performed using Bradford solution graphing the absorbance of BSA protein concentration standards 
versus the absorbance of protein lysates to be determined. Absorbance was measured at wavelength 
595 nm using a spectrophotometer. Protein concentration was determined using SoftMax Pro 
software ®. Typically, 50-100 μg of protein was resolved by 8-12 % SDS–polyacrylamide gel 
electrophoresis (PAGE). Proteins were transferred to nitrocellulose membrane. Post transfer 
membrane was washed with Ponceau S solution in order to visualise efficiency of protein transfer. 
Membranes were blocked for 1 hr at room temperature in 5 % milk/BSA in Tris-buffered saline-T 
(TBST) (20 mM Tris, 150 mM NaCl and 0.05 % Tween 20, pH 7.6). Primary antibodies were 
diluted and incubated with membrane at concentrations outlined previously Table 2.1.2. Horse 
radish peroxidise (HRP)-conjugated secondary antibodies were incubated with membranes at 
dilution of 1:2000 for 1 hr at room temperature. Membranes were washed 3 X 15 mins in TBST. 
Protein detection was visualised by two methods 1) using CL-XPosure Film on KODAK X-MAX 
developer post incubation with SuperSignal West Pico/Femto Chemiluminescent Substrate. 2) 
Using ChemiDoc TM XRS Biorad ® post incubation with Clarity TM Western ECL substrate. 
2.2.2.5 In vivo overexpression HA ubiquitination assay 
For in vivo overexpression HA ubiquitination assays, 4X10^6 HEK293t cells were seeded in a 10 
cm plate. Twenty four hrs later cells were transiently transfected with 2.5 μg of Ubiquitin vectors, 
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0.5 μg of C/EBPα vectors and 3 μg of TRIB2 vectors for 24 hrs. Five hrs prior to cell lysis, cells 
were treated with 10 μM Z-Leu-Leu-Leu-al (MG-132). Cells were incubated with 100 mM N-
Ethylmaleimide (NEM) for 30 seconds (sec) and then washed in ice cold phosphate-buffered saline 
(PBS), boiled at 95 °C for 5 mins in 1 % SDS, sonicated for 20 sec and centrifuged at 14,000rpm 
for 10 mins at 4 °C. Total inputs were collected by harvesting 10 μL of lysate and combining it with 
10 μL of 2X Laemlli buffer. Inputs were boiled at 95 °C for 5 mins and stored at -20 °C. Remaining 
lysates were diluted in 900 μL radio-immuno precipitation assay (RIPA) lysis buffer (50 mM Tris, 
pH 8.0, containing 0.5 % NP-40, 0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 
supplement with 20 mM NEM, protease and phosphatase inhibitors). Lysates were precleared with 
25 μL Protein G Sepharose 4 fast flow beads rotating for 30 mins at 4 °C. Precleared lysates were 
centrifuged at 1500rpm for 5 mins at 4 °C, supernatant was incubated with 5 μg of C/EBPα 
antibody and 25 μL of fresh Protein G beads rotating overnight. The following day lysates were 
washed three times in RIPA lysis buffer. Post final wash all RIPA buffer was eluted from the beads 
using a 1 mL insulin syringe with a 26G needle attached, 30 μL of 2X Laemmli buffer was added 
and beads were then boiled at 95 °C in for 5 mins. Lysates and beads were centrifuged at 1500rpm 
for 5 mins at 4 °C. Supernatant was eluted using 1 mL insulin syringe with a 26G needle and equal 
volumes were separated on an 8 % SDS-PAGE, whilst total inputs were separated on a 12 % SDS-
PAGE and immunoblotted as indicated.  
2.2.2.6 Co-immunoprecipitation of overexpression proteins in HEK293t cells. 
For co-Immunoprecipitation (co-IP) 4X10^6 HEK293t cells were transiently transfected with 4 μg 
of C/EBPα vectors and 4 μg of TRIB2 vectors as described for 24 hrs. Five hrs prior to cell lysis, 
cells were treated with 10 μM MG-132 cells were lysed in Tris lysis buffer. Immunoprecipitation 
reaction was performed as described for in vivo ubiquitination assay. Lysates were separated on 12 
% SDS-PAGE.  
2.2.2.7 Peptide array and specific alanine scanning substitution arrays (SASSA). 
Essentially, scanning libraries of overlapping 18-mer peptides (shifted to the right by 3 amino 
acids) covering the entire TRIB2 murine protein (NCBI reference NM_144551.5) were produced 
by automatic SPOT synthesis and attached on continuous cellulose membrane supports on 
Whatman 50 cellulose using 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry with the AutoSpot-
Rosbot ASS 222 (Intavis Bioanalytical Instruments), schematic representation of peptide array 
synthesis see blow (Fig 2.2.2.7 A and B). Arrays were produced in collaboration with Dr. Patrick 
Kiely, University of Limerick. The specific alanine scanning substitution arrays (SASSA) were 
generated for selected peptides on TRIB2 using the same synthesis procedure, see schematic 
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representation below (Fig 2.2.2.7 C). Peptide arrays were activated in 100 % ethanol for 5 mins 
then washed with TBS-T 0.1 % (v/v). Arrays were blocked for 1 hr with 5 % (w/v) Marvel 
milk/TBS-T 0.1 % (v/v). TRIB2 arrays were then incubated in purified protein buffer (20 mM Tris-
HCL pH7.5, 0.1 M NaCl, 5 mM β-Mercaptoethanol) or 2 μg/mL of purified CEBPα protein 
(Genway 10-002-38004). Arrays were washed with TBS-T 0.1 % (v/v) and incubated with 1/114 
anti-C/EBPα, washed, then incubated in 1/2000 anti-rabbit HRP conjugated secondary or with 
specific Alexa Fluor 800-coupled anti-rabbit secondary antibodies (LI-COR
 
Biosciences) (for 
SSASs). Bound protein was detected and visualised using ECL or the Odyssey® Infrared Imaging 
System (LI-COR Biosciences). True positive results were determined by comparison of the binding 
pattern with the controls (protein buffer) to the results from the protein incubations. 
 
 
Fig 2.2.2.7 Schematic Representation of SPOT synthesis technology. A) Production of amino 
acid library spanning TRIB2 protein shifted by 3 amino acids B) Graphical representation of amino 
acid peptides spotted on cellulose support. C) Depiction of production of alanine scanning 
substitution arrays. 
A 
B 
C 
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2.2.2.8 FACS analysis and cell sorting. 
Cell pellets were resuspended in chilled PBS supplemented with 10 % FBS and incubated with 
antibodies on ice for 30 mins. Samples were washed with PBS and 10 % FBS before fluorescence 
intensity was analysed by flow cytometry (FACS CantoTM II BD). Data analysis was performed 
using Flow Jo Version 10 software (Treestar). For apoptosis assays cell suspensions were prepared 
in Hanks buffered Saline Solution (HBSS) (Life technologies) and stained with Annexin V-PE (BD 
Biosciences 556422) or Annexin V-APC (BD Biosciences 550475) and 4',6-diamidino-2-
phenylindole (Dapi) (Sigma) for 15 mins at room temperature in the dark. Cells were washed with 
HBSS and analysed on FACS within 60 mins of cell staining. Annexin V is a member of the 
Annexin family of proteins which bind intracellular phosphatidylserine (PS). Upon induction of 
apoptosis cell membrane asymmetry is lost and PS translocates external to the cell membrane. Thus 
Annexin V staining can be exploited to detect apoptotic cells. Dapi is a fluorescent stain that 
strongly intercalates at AT rich regions of DNA. Dapi passes less efficiently through the 
membranes of live cells therefore strong Dapi staining serves as a marker of dead cells. Cell sorting 
was performed as requested by Ms. Jennifer Cassels using FACS Aria I (BD Biosciences, UK). 
2.2.2.9 Cryopreserved AML patient sample thawing and culturing 
AML peripheral blood samples were collected in accordance with the Declaration of Helsinki; all 
patients provided written consent. Samples were kindly provided by Dr. Mary Cahill, University 
College Cork and Dr. Ruud Delwel, Erasmus University. Mononuclear cells were isolated using 
Histopaque (Sigma) according to manufacturer’s instructions. Cryopreserved AML patient samples 
were defrosted by rapidly warming cyrovials in 37 °C water bath. Cells were added drop by drop 
over 20 mins to pre-warmed thawing medium (IMDM supplemented with 20 % ES Fetal Calf 
Serum (Biosera), 5000 U/mL Heparin, 200 mM L-Glutamine and 100 u/mL DNAse (Stem Cell 
Technologies)) using Pasteur pipette. AML patient samples were then centrifuged for 15 mins at 
1000rpm. The supernatant was discarded and cells were washed in thawing media and centrifuged 
for 10 mins at 1000rpm. The supernatant was removed and AML patient samples were cultured 
overnight at a density of ~ 1X10^6 cells/mL in StemSpan medium (Stem Cell Technologies) 
supplemented with 10 % Myelocult (Stem Cell Technologies), hIL-3, hIL-6, hSCF and hFLT3 
cytokines at final concentrations of 10 ng/mL (Peprotech).  
2.2.2.10 Pharmacological inhibition of the ubiquitin-proteasome degradation pathway in U937 
cells and AML patient samples 
Bortezomib a proteasome inhibitor was stored in 1M aliquots solubilised in dimethyl sulfoxide 
(DMSO) at -20 °C. U937 cells were seeded at density of 0.2X10^6/mL 24 hrs prior to treatment. 
AML patient sample seeding densities were dependent on cell number, where possible AML patient 
82 
 
cells were kept at density of 1X10^6/mL. U937 cells were plated at a density of 0.2X10^6 cells/mL 
in final volume of 200 µl in 96 well plate. Cells were treated with 10 nM Bortezomib diluted in 
PBS for indicated time points.  
2.2.2.12 Cycloheximide treatment 
For overexpression cycloheximide (CHX) treatment 2X10^5 HEK293t cells were seeded in 6 well 
plate. Twenty four hrs later cells were transfected as necessary. Twenty four hrs post transfection 
cells were treated with 100 ng/mL CHX for indicated time points. Cells were lysed, protein 
extracted and quantified followed by SDS-PAGE and western blotting as previously described. 
2.2.2.13 Bioinformatical Analysis 
SARPRED a real value prediction of surface accessibility software, generates a prediction of 
solvent-accessible surface area amino acids (ASA) (http://imtech.res.in/raghava/sarpred/). The ASA 
score is generated by performing PSI- Basic Local Alignment Search Tool  (BLAST) which 
compares distant relationships between proteins and then predicts the secondary structure of a 
protein from its amino acid sequence (Garg et al., 2005). UbPred online software, predictor of 
protein ubiquitination sites http://www.ubpred.org/help.htmL (USCD). UbPred predicts potential 
ubiquitination sites in a protein through analysis of the amino acids identity of a protein. It was 
trained on 266 known ubiquitination sites and is reported to have a class based of accuracy 72% 
(Radivojac et al., 2010). NCBI BLAST (http://blast.ncbi.nlm.nih.gov/BlastAlign.cgi) finds regions 
of similarity between two sequences (Altschul et al., 1997). Chou Fasman secondary structure 
prediction software (http://www.biogem.org/tool/chou-fasman/) was used to determine the 
predicted secondary structure of TRIB2. This is an empirical technique whereby the frequencies of 
amino acids in secondary structures of know protein structures is applied to the amino acids of 
unknown secondary structure to get a probable secondary structure prediction (Chou and Fasman, 
1974). Protein-protein interaction prediction engine was used to predict sites of protein interactions 
PIPE (Pitre et al., 2006).  Neural Network Prediction of Beta-turns (NetTurnP) 
(http://www.cbs.dtu.dk/services/NetTurnP/) uses information on evolutionary and predicted protein 
sequences to determine the presence of β-turns based on protein amino acid sequence (Peterson et 
al., 2010). 
2.2.2.14 Statistical Analysis 
Statistical analysis was performed using Microsoft Excel and Prism Graphpad software 
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Chapter 3: Results 
Investigating the TRIB2 and C/EBPα direct protein-protein 
interaction  
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3.1 Introduction 
The interaction between the TRIB family of proteins and C/EBP family of proteins is evolutionary 
highly conserved in a cell type specific manner. In Drosophila the tribbles ortholog dTrbl was 
identified to bind dSlbo the homolog of mammalian C/EBP proteins resulting in its ubiquitination 
and subsequent degradation (Rørth et al., 2000, Masoner et al., 2013). There are three mammalian 
isoforms of dTrbl (TRIB1, TRIB2 and TRIB3). The TRIB family of proteins are structurally 
comprised of three regions or domains. TRIB proteins contain a large central kinase-like domain 
flanked by two smaller N-Terminal and C-Terminal regions. Sequence analysis of the TRIB protein 
family in different species revealed the N-Terminal region is highly divergent amongst family 
members but the kinase-like domain retained regions of high sequence similarity as did pockets of 
the C-Terminus (Hegedus et al., 2007).  
The N-Terminal is rich in Serines and Prolines indicative of a Proline (Pro-P), Glutamic acid (Glu-
E), Serine (Ser-S) and Threonine (Thr-T) (PEST) region. Canine Trbl was identified to be a laible 
protein with a half life of approximately 1 hr (Wilkin et al., 1997). The half life of TRIB2 in human 
cells was reported to be 2 hrs increasing upon deletion of its first 5 amino acids (MNIHR) (Wang et 
al., 2013a). Within the C-Terminal all TRIB proteins retain MEK1 (IL(L/D)HPWF) and the E3 
ligase COP1 (DQXVPL) binding sites (Kiss-Toth et al., 2004, Qi et al., 2006, Yokoyama et al., 
2010). 
Canonical kinases have 12 distinct subdomains each comprised of 10-30 amino acids, and within 
these subdomains certain sequences are functionally highly conserved (Hanks and Hunter, 1995). 
Analysis of the TRIB2 kinase-like domain revealed it contained some characteristics of an active 
kinase but not all (Hegedus et al., 2007). The kinase domain of a protein is folded in 2 lobed 3D 
structures (Hanks and Hunter, 1995). Subdomains I-IV are located in the amino terminal lobe and 
subdomains VIA-XI are located in the carboxy terminal lobe. Subdomain V is located in the hinge 
region between the two lobes which acts to catalyse enzymatic reactions. The amino terminal lobe 
is largely structured in β-sheets and is responsible for anchoring the phosphate donor, ATP (Hanks 
and Hunter, 1995). The carboxy terminal lobe is largely α-helical and responsible for anchoring the 
phosphate acceptor. Conservation of subdomains I, II and VIB is considered to be the most 
important for kinase functionality (Hegedus et al., 2007). Within subdomain I is a highly conserved 
GXGXXG sequence which is necessary for ATP orientation, and is lacking in TRIB2. Subdomain 
II contains a highly invariant lysine (K) within the sequence VAIK which binds ATP, and all TRIB 
proteins retain this critical lysine. Subdomain VIB contains the catalytic loop LRDLKLRNF, the 
third residue of this sequence is a crucial aspartic acid (D) which is retained by all TRIB proteins. 
85 
 
The majority of canonical kinases retain an asparagine (N) residue, 5 residues downstream of the 
crucial asparagine whilst in TRIB2 it is replaced with a lysine (LRDLKLRKF). Within subdomain 
VII there is a conserved tripetpide sequence APE which is responsible for the stability for the C-
Terminal lobe through formation of a salt bridge between the gluatamic acid (E) of the tripeptide 
and an arginine (R) residue in subdomain IX. TRIB2 retains the second and third amino acids in 
this sequence but has a serine in the first position (SPE) (Hegedus et al., 2007). The DVWSXG 
heptapeptide in subdomain IX is also a signature of functional kinases retained by TRIB2. TRIB2 
lacks a DFG triplet motif in subdomain VII, which is the most striking difference between 
functional kinases and the TRIB family of proteins (Hegedus et al., 2007). The aspartic acid in the 
DFG motif chelates Mg+
2
 ions, necessary for catalysis of the phosphate transfer and is also 
essential for orientating ATP through binding of α and β phosphates in the ATP binding cleft. There 
are of course examples of functionally active kinases which lack some of these functionally 
conserved motifs (reviewed by (Boudeau et al., 2006)). 
TRIB proteins are currently defined as pseudokinases as they lack phosphate transfer activity 
despite having the predicted 3D structure of a kinase (Wilkin et al., 1997, Boudeau et al., 2006, 
Hegedus et al., 2007). When first identified in canine thyroid cf5W/Trbl was described as a 
phosphoprotein as it is phosphorylated upon stimulation however it was unable to 
autophosphorylate or phosphorylate substrates (Wilkin et al., 1997). Further in vitro kinases assays 
investigating the kinase-like domain of SKIP3/TRIB3 homolog of TRIB2 also stated that TRIB3 
was unable to autophosphorylate or phosphorylate substrates (Boylan et al., 2003). TRIB2 retains 
the ability to bind ATP through this critical lysine K90 in subdomain II and TRIB2 is able to 
turnover ATP but not sufficiently to result in kinase function (Unpublished result, personal 
communication Dr. P Eyers, University of Liverpool). Despite the apparent lack of kinase activity 
of TRIB2 its kinase-like domain still remains crucial for its biological functions (Keeshan et al., 
2010, Masoner et al., 2013).  
TRIB1 and TRIB2, unlike TRIB3, both possess the ability to perturb normal haematopoiesis 
resulting in malignant leukaemic disease (Keeshan et al., 2006, Dedhia et al., 2010, Yokoyama et 
al., 2010, Yoshida et al., 2013). TRIB1 and TRIB2 were identified to bind C/EBPα and induce its 
proteasomal degradation, whilst TRIB3 which retained a low binding affinity for C/EBPα was 
unable to induce degradation and AML (Dedhia et al., 2010). Overexpression of TRIB2 results in 
degradation of the C/EBPαp42 isoform with a concomitant increase in the levels of the N-
Terminally truncated C/EBPαp30 isoform, disrupting the normal C/EBPαp42:C/EBPαp30 ratio 
(Keeshan et al., 2006). TRIB2 expression resulting in altered C/EBPαp42:C/EBPαp30 ratio disrupts 
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haematopoiesis (Keeshan et al., 2006). BMT models identified TRIB2 mice had reduced numbers 
of BM granulocytes and increased BM and splenic monocytes with mice finally succumbing to an 
AML like disease (Keeshan et al., 2006). Reversal of low C/EBPαp42:C/EBPαp30 ratio has been 
identified to induce differentiation of leukaemic cell lines and patient derived primary AML blasts 
(Koschmieder et al., 2007). Pharmacological treatment with CDDO increases 
C/EBPαp42:C/EBPαp30 ratio resulting in overcoming of differentiation block, highlighting the 
importance of C/EBPαp42:C/EBPαp30 ratio in controlling haematopoietic cell differentiation 
(Koschmieder et al., 2007). TRIB2 degradation of C/EBPαp42 can be inhibited by treatment with 
the proteasomal inhibitor MG-132. C/EBPαp42 co-immunoprecipitates with TRIB2 only in the 
presence of MG-132 whilst C/EBPαp30 co-immunoprecipitates in the absence and in the presence 
of MG-132, indicating that the direct interaction of C/EBPαp42 and TRIB2 results in its subsequent 
proteasomal degradation (Keeshan et al., 2006).  
In order to assess the functional regions required for TRIB2 leukaemogenecity, the domains of 
TRIB2 were investigated. All TRIB proteins retain a COP1 binding site in their C-Terminus (Qi et 
al., 2006). COP1 is a RING-Finger E3 ubiquitin ligase responsible for conjugation of ubiquitin 
proteins to lysine residues on target substrates. It was determined loss of the COP1 binding to 
TRIB2 through deletion of the COP1 binding site (1-324 TRIB2-dCOP1) or mutation of COP1 
binding site (DQVPL to AQLAA TRIB2-VPM) abrogated its ability to degrade C/EBPαp42 and 
ultimately to induce AML in murine models (Keeshan et al., 2010). TRIB2-dCOP1 still retained the 
ability to bind C/EBPα indicating that abrogation of C/EBPα-TRIB2 interaction was not 
responsible for the loss of TRIB2 function. COP1 binding was necessary for TRIB2-mediated 
degradation of C/EBPαp42 and the resultant leukaemic disease (Keeshan et al., 2010).  
Further structural analysis into the essential functional domains of TRIB2 required for this 
proteolytic relationship revealed that the N-Terminus was not essential, whilst an intact central 
kinase-like domain was necessary for TRIB2 leukaemogenecity (Keeshan et al., 2010). Deletion of 
the N-Terminal dNTRIB2 (63-343) did not abrogate WT-TRIB2 function however extension of the 
deletion into the N-Terminus of the kinase-like-domain (121-343 ΔNS) did abrogate TRIB2 ability 
to degrade C/EBPα (Keeshan et al., 2010). As mentioned, within the kinase-like domain TRIB2 
does not retain the canonical kinase motif HRDLKPEN characteristic of a catalytic loop (Table 
3.1.1). Mutation of TRIB2 to resemble a canonical kinase (LRDLKLRK to LRDLKPEN TRIB2-
KDM) resulted in a loss in its ability to degrade C/EBPα and induce leukaemia (Unpublished data, 
Karen Keeshan and (Keeshan et al., 2010). TRIB2 does retain the lysine at position 5 LRDLKLRK 
which defines active Ser/Thr kinases. Mutation of TRIB2 to resemble a tyrosine kinase 
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LRDLRLRK (TRIB2-K177R) also abrogated TRIB2s ability to degrade C/EBPα and induce 
leukaemia (Unpublished data, Karen Keeshan and (Keeshan et al., 2010). The homologous 
mutation to K177R was investigated in Drosophila dTrbl K266R, and this mutant retained dTrbl 
functionality and the ability to degrade the C/EBPα homolog dSlbo (Großhans and Wieschaus, 
2000). However mutation of the essential aspartic acid retained by dTrbl (position 3) in Drosophila 
DLK to NLK reduced dTrbl ability to interact with dSlbo and mediate its degradation (Masoner et 
al., 2013). These data proved the TRIB protein sequence LRDLKRK is crucial for protein 
functionality. Mutation of these crucial amino acids may not affect kinase-like activity of TRIB but 
perhaps the amino acid changes are structurally crucial for protein folding. Investigation of other 
crucial kinase motifs VAIK in subdomain II and SLE in subdomain VII in Drosophila determined 
that neither mutation of the crucial ATP binding lysine in VAIK nor mutation of crucial Glu in SLE 
abrogate dTrbl function (Masoner et al., 2013). 
 
Table 3.1.1 TRIB protein kinase subdomain VIB mutants 
TRIB proteins were demonstrated to bind MEK1, MKK4 and MKK7 and share a conserved MEK1 
binding site in the C-Terminus (Kiss-Toth et al., 2004, Yokoyama et al., 2010). TRIB1 binding to 
MEK1 is reported to be essential for mediating degradation of C/EBPα and induction of murine 
AML in BMTs. TRIB1 and C/EBPα binding was localised to the N-Terminus of TRIB1. 
TRIB1ΔN1 (1-90) mutant retained the ability to bind C/EBPα whilst an extension of the deletion 
further into the kinase-like domain of TRIB1 to 160 amino acids (TRIB1ΔN2) resulted in loss of 
C/EBPα binding, loss in TRIB1 ability to degrade C/EBPα and a loss in TRIB1 induced AML. 
TRIB1 binds C/EBPα resulting in its degradation but this proteolytic association requires MEK1 
binding (Yokoyama et al., 2010). Thus, although both TRIB1 and TRIB2 bind C/EBPα resulting in 
its degradation and AML, there are mechanistic differences and similarities. Deletion of TRIB1 N-
Terminus and N-Terminal region of kinase-like domain (TRIB1ΔN2) resulting in a loss in C/EBPα 
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binding and degradation, and similarly deletion of N-Terminus and N-Terminal region of kinase-
like domain TRIB2 (TRIB2ΔNS) also abrogated TRIB2s ability to degrade C/EBPα. Despite low 
percentages of sequence similarities between the N-Termini of TRIB1 and TRIB2 loss of both N-
termini results in loss of C/EBPα binding, thus suggesting possible conservation of protein binding 
site on homologous proteins despite low sequence similarities between the proteins.  
Much literature exists attempting to identify protein binding sites and any conservation of protein 
binding sites amongst protein families (Nooren and Thornton, 2003, Korkin et al., 2005, Tyagi et 
al., 2009). Protein binding sites are generally sought through physiochemical investigation of 
protein size, binding surface areas, residue composition, polarity and hydrophobicity but there still 
remains no consensus for protein binding site identification, due in part to the transient nature of 
many interactions and lack of published 3D structures (Nooren and Thornton, 2003, Korkin et al., 
2005). There are several factors governing protein-protein interactions such as protein 
concentrations (Nooren and Thornton, 2003), cellular localisation and ultimately the proteins must 
be geometrically compatible (Lawrence and Colman, 1993). It is postulated that only a very small 
number of amino acids are involved in protein binding, in small proteins even just one amino acid 
(Bogan and Thorn, 1998) and there is also reports of selection bias regarding the identity of amino 
acids at protein interaction sites (Murakami, 1995, James and Tawfik, 2003, Ofran and Rost, 2007). 
Aim 
The COP1:TRIB2:C/EBPα multiprotein degradation complex is a key event in TRIB2 induced 
leukaemogenesis. Loss of COP1:TRIB2 binding through mutation or deletion abrogates the ability 
of TRIB2 to degrade C/EBPα and induce AML (Keeshan et al., 2010). TRIB2 directly binds 
C/EBPα. Previous work in the laboratory identified the TRIB2 binding site on C/EBPα as R339, 
through use of peptide array analyses, SASSA, SDM and confirmation by GST-IP. In order to 
understand this malignant interaction, detailing of the sites of C/EBPα interaction on TRIB2 was 
necessary. In our study through use of peptide array analyses, SASSA, SDM and verification by co-
IP I determine mutation of TRIB2-S227/S229/S231/K233 results in a loss in C/EBPα binding, 
while mutation of TRIB2 residues R77 and K322 does not abrogate C/EBPα binding. I also confirm 
using mammalian co-IP R339 as the TRIB2 binding site on C/EBPα. 
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Result 3.2.1 Peptide array analysis identified TRIB2 interacting sites on C/EBPα-
array 1 
It has previously been reported by our group that TRIB2 and C/EBPα interact as ascertained by co-
IP assay in HEK293t cells (Keeshan et al., 2006). However the identity of the TRIB2 protein 
domains and amino acids involved in C/EBPα binding had yet to be determined. TRIB1 the 
homolog of TRIB2 was identified to bind C/EBPα and the crucial TRIB1 region was mapped to an 
N-Terminal pseudokinase spanning region (Yokoyama et al., 2010, Dedhia et al., 2010). TRIB3 
was identified to associate very weakly with C/EBPα (Dedhia et al., 2010). In order to assess the 
TRIB2 amino acids responsible for mediating the interaction with C/EBPα, peptide arrays were 
produced which spanned the entire TRIB2 protein. The arrays were produced by Dr. Patrick Kiely 
as described in Materials and Methods 2.2.2.7. Two identical peptide arrays were produced, one 
was incubated with the stabilisation C/EBPα protein buffer (referred to from this point as control 
buffer) in order to control for any nonspecific binding and the second was incubated with 2 μg/mL 
C/EBPα purified protein in its stabilisation buffer (Genway, USA). Arrays were then incubated 
with anti C/EBPα antibody and anti rabbit HRP conjugated secondary antibody and visualised 
using ECL. True positive results were determined by comparison of the binding pattern of the 
control array to that of array incubated with the C/EBPα protein. Dark spots were indicative of 
C/EBPα protein binding to the respective 18mer peptides. Five binding spots unique to the C/EBPα 
incubated array were identified as is indicated by red numbering (Fig 3.2.1 A). Characterisation of 
these TRIB2 18mer peptides revealed that C/EBPα interaction sites spanned throughout the TRIB2 
protein from amino acids 25-318 indicating a strong pattern of C/EBPα binding (Fig 3.2.1 B). 
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Fig 3.2.1 Analysis of C/EBPα binding sites on TRIB2 peptide array A) Peptide array analysis of 
identical TRIB2 arrays incubated with Control buffer and Test (2 μg/mL of purified C/EBPα 
protein). Arrays were then incubated with anti C/EBPα primary antibody and secondary anti rabbit 
HRP. Binding was visualised using ECL. Dark spots are indicative of binding sites. Numbers 1-5 
indicate the binding sites unique to protein incubation versus control buffer. B) Table lists the 17 
amino acid residues in each of the binding spots. 
 
 
  
A 
B 
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Result 3.2.2 Peptide array analysis identified TRIB2 interacting sites on C/EBPα-
array 2 
Results from C/EBPα protein incubation with TRIB2 peptide array 1 identified the potential 
involvement of multiple TRIB2 amino acids in C/EBPα protein binding (Fig 3.2.1). In order to 
verify these results before generation of specific alanine scanning substitution arrays a third TRIB2 
peptide arrays (array 2) was produced. The array was first incubated with the control buffer and 
then purified C/EBPα protein (Fig 3.2.2). In order to confirm the previous results these arrays were 
visualised using a different secondary approach on an Odyssey® Infrared Imaging System (LI-
COR Biosciences) following incubation with specific Alexa Fluor 800-coupled anti rabbit 
secondary antibody (LI-COR
 
Biosciences). The binding pattern between control buffer incubation 
and protein incubation was compared. Ten unique binding spots were identified in the array 
incubated with purified C/EBPα protein in stabilisation buffer versus incubation with control buffer 
alone (Fig 3.2.2 A). The background signal detected using Odyssey® Infrared Imaging System was 
greater than that observed using ECL detection as has been previously reported for use of 
fluorescent antibodies (Frank, 2002). Binding sites throughout the TRIB2 protein were identified 
replicating the results from array 1 (Fig 3.2.1). An observable cluster of C/EBPα binding sites was 
observed for amino acids ranging from 199-249 spots C7, C8, C16, C17 and C18 highlighting a 
distinct C/EBPα potential binding region (Fig 3.2.2 B). 
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Fig 3.2.2 Identification of C/EBPα interacting sites on TRIB2. Peptide array analysis of TRIB2 
array first incubated with control buffer then C/EBPα protein. The peptide array was visualised on 
Odyssey® Infrared Imaging System (LI-COR Biosciences) following incubation with Alexa Fluor 
800-coupled anti rabbit secondary antibodies. A) Ten unique binding spots were identified on test 
incubation versus control buffer incubation. B) Table lists the amino acid identity of the 10 binding 
spots unique to the test array.  
 
 
 
A 
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Result 3.2.3 Identification of six TRIB2 regions as potential C/EBPα binding sites 
from array 1 and array 2 
Generation of two independent sets of TRIB2 peptide arrays yielded a list of 5 and 10 potential 
C/EBPα binding sites (Fig 3.2.1 and Fig 3.2.2). Comparison of the amino acid sequences identified 
in both peptide arrays yielded a list of 6 stretches of amino acid sequence, i.e. potential binding 
sites. The amino acid sequences identified were largely clustered within TRIB2 pseudokinase 
domain, (4 of the 6 common binding sites, DHVFRAVHLHSGEE, AYILRGDDD, AYV and 
SGSYSGKA). One binding site was located in the N-Terminus EELSSIRSA and one binding site 
was identified at the bridge of the kinase-like domain and the C-Terminus DHPWFSTDFSVSNSG 
(Fig 3.2.3 A). As previously mentioned TRIB1 has the ability to interact with C/EBPα and an N-
Terminal region was determined to be crucial for C/EBPα binding (Dedhia et al., 2010, Yokoyama 
et al., 2010). Therefore TRIB2 was blasted against TRIB1 to identify any conservation of amino 
acids within the N-Terminus of the protein, thus identifying any potential common C/EBPα binding 
sites. The EELSSIRSA sequence is located in N-Terminus of the TRIB2 protein, was a region 
identified not conserved with TRIB1. Investigation of this sequence does not support the previously 
outlined hypothesis of conservation of protein binding localisation sites amongst family members 
TRIB1 and TRIB2, however an equally compelling argument exists for non conservation of protein 
binding sites (Nooren and Thornton, 2003). TRIB1 and TRIB2 do not retain 100% sequence 
similarity therefore there are unquestionable differences in protein tertiary structure and protein 
interactions. As this sequence was strongly identified in both peptide arrays, further investigation as 
a C/EBPα binding site was warranted (Fig 3.2.3 C). The DHVFRAVHLHSGEE TRIB2 sequence 
from amino acids 74-86 in subdomain I of the kinase-like domain, retains 50% homology with 
TRIB1 (Fig 3.2.3 C). TRIB2-R77 is homologous to TRIB1-R107 which, which when mutated to 
R107L increased C/EBPα degradation with a resulting decrease in TRIB1 AML latency 
(Yokoyama et al., 2012). Thus, as the degradation of C/EBPα by TRIB1 was reported to be binding 
dependent and mutation of this arginine results in increased degradation perhaps R77 may act as 
C/EBPα binding site in TRIB2. The sequence AYILRGDDD is a stretch of TRIB2 sequence which 
is homologous to a region of TRIB1 sequence which when deleted loses the ability to bind C/EBPα. 
(Yokoyama et al., 2010) (Fig 3.2.3 C). Examination of this sequence will determine conservation 
of protein binding sites between homologous proteins. The sequence AYV is located within 
subdomain VII of the kinase-like domain of TRIB2 and located beside a region SPE which is 
highly conserved throughout evolution across tribbles family members and species. PE sequence is 
one of the vestiges of an active kinase which TRIB2 retains (Hegedus et al., 2007). Multiple 
sequences within the kinase-like domain of TRIB2 were identified as potential sites strongly 
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suggesting kinase-like domain involvement; this warranted further investigation of this site. The 
sequence SGSYSGKA resembles the consensus GSK3 phosphorylation site motif S/TXXXS/T. 
The N-Terminal S/T is the target and the second S/T serves as a phosphorylation priming site. 
Phosphorylation priming is reported to increase the efficiency of substrate transfer thought not 
always necessary (Doble and Woodgett, 2003). Potential phosphorylation at this site within the 
kinase-like domain of TRIB2 may be important for structure of TRIB2 and its resulting protein-
protein interactions. The DHPWFSTDFSVSNSG sequence is located at the junction between the 
kinase-like domain and the C-Terminus of TRIB2. It contains part of the MEK1 binding site 
ILDHPWF on TRIB2 (Yokoyama et al., 2010). Analysis of promiscuous protein binding has 
identified the existence of “multiple protein binding interfaces”, whereby the same “hotspot” is 
capable of binding multiple different protein partners involved in different cell pathways (Tyagi et 
al., 2009). Therefore pre-existing knowledge of a known protein binding site on a protein may 
suggest the presence of one such multiprotein binding hotspot. Thus this MEK1 binding site on 
TRIB2 warranted further investigation as it may potentially also be involved in C/EBPα binding. 
Each of these 6 TRIB2 sequences were further analysed for their involvement in C/EBPα binding 
by SASSA. 
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Fig 3.2.3 Identification and annotation of six potential C/EBPα binding sites on TRIB2. A) A 
schematic of TRIB2 protein domains with the localisation of the potential binding sites. B) A brief 
annotation of the binding sites identified on TRIB2. C) BLAST of TRIB2 versus TRIB1 identifying 
homologous sequences with regard to identified potential binding sites. 
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Result 3.2.4 SASSA identifying TRIB2 peptides D, G, H and J are important for 
C/EBPα binding 
In order to determine specific amino acids involved in C/EBPα and TRIB2 binding, SASSA was 
generated as described in Materials and Methods 2.2.2.7 and designed based on combined results 
from peptide arrays 1 and 2 and annotation of sequences identified (Fig 3.2.1, 3.2.2 and 3.2.3). 
Each identified sequence was mutated twice on the array in order to validate its importance in the 
interaction. Array A represents the results from the first incubation of the SASSA with purified 
C/EBPα protein (Fig 3.2.4A). The array was stripped, re-activated and re-blocked as detailed in 
Materials and Methods 2.2.2.7. The efficacy of stripping was tested by incubation with Alexa Fluor 
800-coupled anti rabbit secondary and visualised on Odyssey® Infrared Imaging System. The array 
was then reincubated with purified C/EBPα protein and data represented as Array B (Fig 3.2.4 B). 
Analysis of Spot 1 in Peptides A-J represents the unmutated peptide sequence, a dark spot is 
indicative of the importance of that particular peptide sequence in C/EBPα binding. Array B 
directly matched the binding pattern trends observed in Array A for Spot 1 in Peptides A, B. C .D. 
F. G. I and J. Figures 3.2.4 C and 3.2.4 D plot the intensities of the unmutated peptide sequence 
(i.e. the 18 amino acid peptide stretch anlaysed Spot 1) as total percentages. From these graphs the 
importance of the TRIB2 peptides in C/EBPα binding can be directly compared. High signal 
intensity for Spot 1 Peptides D, H and J confirmed the importance of these amino acid sequences in 
C/EBPα binding. Peptide D strongly binds C/EBPα indicating amino acids 73-90 are important for 
TRIB2 binding. Peptide H, residues 221- 238, displayed low signal intensity in Array A, however 
in Array B the observed signal intensity was much stronger confirming the importance of these 
residues. Peptide J had the highest intensity of C/EBPα binding on the alanine array. Low signal 
intensity for Spot 1-19 in Peptides A, B, C, E, F and I indicated these sequence are not important in 
C/EBPα binding. Low binding signal intensity for A, B and C suggest that the N-Terminus of 
TRIB2 does not bind C/EBPα. Peptides E and F, residues 193-230 and Peptide I, residues 301-318 
do not appear important for C/EBPα binding as is evident by the low intensity. Comparison of 
Array A to Array B confirmed the circumference of Spots E1, E4 and E7 were clarified to be 
artefacts. Peptide G, which overlaps with the sequence of Peptide H determined to be important for 
C/EBPα binding, displayed low signal intensity for the unmutated sequence Spot 1 but the signal 
intensity increased from Spot 3-Spot 17 suggesting Peptide G may be important for C/EBPα 
binding. Of note, lower overall signal intensity was observed in Array B owing probably to the 
stripping procedure. 
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Fig 3.2.4 SASSA identifying C/EBPα binding sites on TRIB2. SASSA was generated as 
described in Materials and Methods and designed based on results from both peptide arrays. Spot 1 
on each lane represents the wild type un-mutated 18 amino acid peptide. Each subsequent amino is 
sequentially mutated to an alanine. A) SASSA were incubated with 2 μg/mL purified C/EBPα 
protein, anti C/EBPα primary antibody and Alexa Fluor 800-coupled anti rabbit secondary antibody 
and visualised on Odyssey® Infrared Imaging System. B) Array was stripped and probed as in (A). 
C) and D) The binding intensity of C/EBPα protein to each un mutated Peptide Spot 1 (A-J), 
quantified by densitometry was plotted as the percentage binding intensity of both arrays A and B. 
E) The amino acid identity of the array.  
E 
D 
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Result 3.2.5 SASSA identifying amino acids in TRIB2 peptides D, G, H and J 
important for C/EBPα binding 
High binding signal intensities indicated Peptides D, G, H and J are potential C/EBPα binding sites 
on TRIB2 (Fig 3.2.4). Within Peptide D mutation of amino acids F76A, R77A, A78E, V79A, 
H80A, L81A, H82A and K90A resulted in a greater than 50 % reduction in intensity relative to the 
un-mutated wildtype peptide sequence Spot 1 (Fig 3.2.5 A). Previous analyses identified the amino 
acids phenylalanine, alanine, valine and leucine to be under-represented at protein binding sites 
(Ofran and Rost, 2007, Tyagi et al., 2009), whilst arginines have been identified to be over 
abundant at protein binding sites (Villar and Kauvar, 1994, Ofran and Rost, 2007, Tyagi et al., 
2009). Arginines have been implicated in being energetically important for protein binding. 
Mutation of K90 reduced binding signal intensity of C/EBPα to TRIB2. K90 is a critical lysine for 
ATP-binding located in subdomain II of the pseudokinase domain and one of the vestiges of an 
active kinase which TRIB proteins retain (Hegedus et al., 2007). Mutation of K90M ablates the 
ability of TRIB2 to turnover ATP as measured by autophosphorylation assays (Personal 
communication, unpublished data, Fiona Bailey and Dr. P. Eyers). It is hypothesised that TRIB 
proteins retain the ability to bind ATP like a kinase but do not posses sufficient kinase activity to 
engage in phosphate transfer. Thus K90 was not investigated as a C/EBPα binding site as it had a 
defined role in TRIB2 ATP-binding and subsequent mutation may perturb the highly conserved 
functional structure of the TRIB2 kinase-like domain. Thus as arginines have been identified to be 
strongly involved in protein binding and TRIB2-R77 is homologous to TRIB1-R107 with an 
already identified link to C/EBPα, TRIB2-R77 from Peptide D was chosen as an amino acid to be 
investigated for its role in binding C/EBPα. Peptide G Spot 1 (unmutated peptide sequence) 
displayed low binding intensity with an increase in binding from amino acid Y218A to G232A. 
This trend was observed in both arrays suggesting Peptide G is important for C/EBPα binding. 
Mutation of K233A and A234E resulted in a greater than 50 % reduction in binding signal intensity 
(Fig 3.2.5 B). Peptide G (residues 217-234) spanned some of the same amino acids as Peptide H 
(221-238). Amino acids K233A and A234E were also contained within Peptide H again showing a 
greater than 50 % reduction in binding intensity. Also within Peptide H mutation of A235E and 
W238A resulted in a 50 % drop in binding signal intensity (Fig 3.2.5 C). Alanines at protein 
binding sites are selected against as mentioned previously. Initial annotation of this sequence of 
TRIB2 from its identification on both peptide arrays 1 and 2 (Fig 3.2.1 and 3.2.2) identified a 
putative GSK3 phosphorylation site. SGSYSGKA resembles the consensus GSK3 phosphorylation 
site motif S/TXXXS/T. Analyses of amino acid identity at protein binding sites revealed an over 
abundance of serines and glycines at protein binding sites (Ofran and Rost, 2007, Tyagi et al., 
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2009). Glycines are common at protein binding sites as they provide flexibility to the region (James 
and Tawfik, 2003). Serines and glycines are common amino acids in β turns which are prominent 
2° structures at protein binding sites (Murakami, 1995, Ofran and Rost, 2007, Murakami and 
College, 2014). TRIB2 secondary structure analysis confirmed the presence of 2 predicted β turns 
within the sequence GSYSG (residues 228-232) using Chou and Fasman Secondary structure 
prediction server (Appendix 8.1.1)  (Chou and Fasman, 1974). Additional in silico analysis using β 
turns specific software NetTURN B, identified β turns structures encompassing S227-S231 
(Peterson et al., 2010) (Appendix 8.1.2). Protein-protein interaction prediction engine (PIPE) 
analysis predicted amino acids 227-258 in TRIB2 as C/EBPα interaction site (Appendix 8.2). PIPE 
predicts protein interaction sites based on primary protein sequence and comparison of sequences to 
known interaction sites (Pitre et al., 2006). Combining bioinformatic analyses performed, 
knowledge of amino acid identity at protein-protein binding sites, peptide array and SASSA results 
S227/S229/S231/K233 was investigated as a potential C/EBPα binding site. Peptide J displayed the 
strongest binding signal for C/EBPα on the array. Binding intensity remained high for all alanine 
substitution within Peptide J, except for substitution of K322A (Fig 3.2.5 D). Mutation of K322A 
resulted in a near complete ablation of binding signal. Thus with such a profound effect of binding 
this lysine warranted further investigation as a potential C/EBPα binding site on TRIB2.  
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Peptide G (Fig 3.2.5 B) 
Peptide D (Fig 3.2.5A)  
Peptide H (Fig 3.2.5 C) 
Peptide J (Fig 3.2.5 D) 
A 
B 
C 
D 
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Fig 3.2.5 SASSA of Peptide D, G, H and J. SASSAs were probed with purified C/EBPα protein. 
The binding of C/EBPα protein to each alanine substituted peptide was quantified by densitometry 
and presented as relative intensity of the control unmutated WT sequence, with an underlay 
identifying the amino acid which was substituted with an alanine.  
 
Result 3.2.6 TRIB2 binding mutant expression in HEK293t cells 
Based on the results from the SASSA and interpretation of these data three binding mutants were 
selected for further study, R77A, S227A/S229A/S231A/K233A and K322A (Fig 3.2.5). In the 
absence of 3D structures for interacting proteins the most conclusive method to identify the 
important residues in an interaction is to experimentally mutate them to alanine and determine any 
effect these mutations have on the protein interaction (Ofran and Rost, 2007). R77A is located in 
subdomain I, S227A/S229A/S231A/K233A is located in subdomain VIII and K322A is located in 
the C-terminus. Mutants were produced by GenScript (USA) in PHMA expression vector backbone 
(Fig 3.2.6 A). In order to determine expression levels and validate antibody recognition of TRIB2 
mutants, HEK293t cells were transiently transfected with 4 μg of WT-TRIB2, R77A, 
S227A/S229A/S231/K233A, K322A and an untransfected lane served as a control to confirm 
specificity of antibody binding. Both WT-TRIB2 and K322A expression were similar, running at 
approximately 38 kDa as a tight doublet. S227A/S229A/S231/K233A ran lower than both K322A 
and WT-TRIB2 as a singlet at 37 kDa. This could be due to mutation of a putative GSK3 
phosphorylation site, as it has been known for phosphorylation events to be detected on SDS–
PAGE as a doublet and to slightly increase the molecular weight that the protein runs at. R77A 
expression was the weakest expressing mutant and ran as a single band like 
S227A/S229A/S231/K233A but higher at approximately the same level of the bottom singlet of 
WT-TRIB2 and K322A. Actin showed that while there was equal protein loading, TRIB2 mutants 
were not expressed equivalent to WT-TRIB2 (Fig 3.2.6 B). Densitometry of mutant expression 
relative to Actin levels determined that S227A/S229A/S231/K233A expression was greater than 2 
fold R77A expression, whilst K322 and WT-TRIB2 expression was nearly 3 fold stronger than 
R77A and approximate to each other (Fig 3.2.6 C). 
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Fig 3.2.6 TRIB2 binding mutant expression in HEK293t cells A) A Schematic diagram of 
TRIB2 mutants R77A, S227A/S229A/S231A/K233A and K322A. B) HEK293t cells were 
transfected to express WT-TRIB2 and mutants R77A, S227A/S229A/S231A/K233A and K322A. 
Lysates were collected 24 hrs post transfection and were separated by 12 % SDS-PAGE and 
 1           2              3            4               5     
A 
C 
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immunoblotted with anti TRIB2 and Actin serving as a loading control. C) Densitometry on 
expression levels of the proteins relative to their respective Actin levels. 
 
Result 3.2.7 TRIB2-S227A/S229A/S231/K233A loses the ability to interact with 
C/EBPα in vitro.  
Having identified potential C/EBPα binding sites on TRIB2 following SASSA (Fig 3.2.5) an 
overexpression co-IP was performed in order assess their importance as C/EBPα binding sites. 
HEK293t cells were transiently transfected to overexpress 4 μg TRIB2-R77A, TRIB2-
S227A/S229A/S231/K233A, TRIB2-K322A, WT-TRIB2 and 4 μg C/EBPα. C/EBPα was 
immunoprecipitated overnight and the immunoprecipitates were immunoblotted with anti TRIB2 
and anti C/EBPα (Fig 3.2.7 A top panel). WT-TRIB2 as previously described (Fig 3.2.1, (Keeshan 
et al., 2006) strongly associates with C/EBPα (Fig 3.2.7 A lane 3, top panel). Surprisingly mutation 
of K322A retains TRIB2s ability to interact with C/EBPα (Fig 3.2.7 A lane 6); R77A also faintly 
retained the ability to bind C/EBPα (Fig 3.2.7 A lane 4). S227A/S229A/S231A/K233A loses the 
ability to interact with C/EBPα (Fig 3.2.7 A lane 5). Immunoblotting of input lysates with TRIB2 
and C/EBPα confirmed the expression of constructs (Fig 3.2.7 A bottom panel). Densitometry 
analysis of TRIB2 immunoprecipitate relative to input expression, determined approximate equal 
C/EBPα binding to WT-TRIB2 and K322A (Fig 3.2.7 B). R77A immunoprecipitated more strongly 
with C/EBPα than WT-TRIB2 and K322A, suggesting this mutant may in fact have increased 
affinity for C/EBPα, which is interesting as the equivalent mutation R107L in TRIB1 is a gain of 
function mutation associated with increased C/EBPα degradation (Yokoyama et al., 2012). These 
results show that mutation of TRIB2-S227A/S229A/S231/K233A affects its ability to interact with 
C/EBPα (Fig 3.2.7 A and B). 
 
 
 
 
 
 
 
 
 
104 
 
 
      
 
Fig 3.2.7 TRIB2-S227A/S229A/S231A/K233A loses ability to interact with C/EBPα in vivo. A) 
HEK293t cells were transiently transfected with C/EBPα alone and in combination with WT-
TRIB2, R77A, S227A/S229A/S231A/K233A and K322A for 24 hrs. Five hours prior to lysate 
harvest cells were treated with 10 μM MG-132. C/EBPα was immunoprecipitated overnight; lysates 
were separated by 12 % SDS-PAGE and immunoblotted with anti TRIB2 and anti C/EBPα (top 
panel). Immunoblot analysis of inputs confirmed expression of all constructs (bottom panel). Data 
presented is representative of three independent transfection experiments. B) Densitometric 
analysis quantified TRIB2 immunoprecipitation relative to TRIB2 input expression from three 
independent experiments. The mean of input expression relative to immunoprecipitation of the 
three experiments was plotted +/- SEM. 
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Results 3.2.8 C/EBPα R339A
 
loses its ability to interact with TRIB2. 
Previous work in the laboratory identified R339 as the TRIB2 binding site on C/EBPα using 
peptide array analysis, SASSA and subsequent verification by GST-IP using site direct mutant 
C/EBPα-R339A (Appendix 8.4). A schematic diagram indicates the location of R339 within the C-
Terminus which is common to both C/EBPαp30 and C/EBPαp42 isoforms of C/EBPα (both 
isoforms of capable of binding TRIB2 (Keeshan et al., 2006))(Fig 3.2.8 A). Therefore, a co-IP 
assay was performed in mammalian cells to verify the requirement of this amino acid for the 
interaction between TRIB2 and C/EBPα in mammalian whole cell lysates. HEK293t cells were 
transfected with 4 μg WT-TRIB2-MYC and 4 μg WT-C/EBPα or C/EBPα-R339A. MYC-TRIB2 
was immunoprecipitated and immunoprecipitates were immunoblotted with anti C/EBPα. C/EBPα-
R339A does not immunoprecipitate with MYC-TRIB2 (Fig 3.2.8 B top panel lane 3), whilst WT-
C/EBPα does immunoprecipitate with TRIB2. Immunoblot analysis of input lysates confirmed 
expression of all constructs (Fig 3.2.8 B bottom panel). These results verify previous identification 
of C/EBPα-R339A as the TRIB2 binding sites and also display evidence of WT-TRIB2 and 
C/EBPα binding through reciprocal IP. 
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Fig 3.2.8 C/EBPα-R339A loses the ability to interact with TRIB2 in vivo. A) Schematic of 
C/EBPα highlighting location of R339 and C/EBPαp30, C/EBPαp42 translational start sites. B) 
HEK293t cells were transfected with WT-C/EBPα-WT, C/EBPα-R339A and WT-TRIB2- MYC for 
24 hrs. Five hours prior to lysate harvest cells were treated with 10 μM MG-132. MYC was 
immunoprecipitated overnight, lysates were separated by 12 % SDS-PAGE and immunoblotted 
with anti MYC and anti C/EBPα.  
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3.3 Discussion 
TRIB2 binds C/EBPα and mediates proteasomal degradation of the C/EBPαp42 isoform increasing 
levels of the N-Terminally truncated C/EBPαp30 isoform (Keeshan et al., 2006). Disturbance of the 
C/EBPαp42/p30 ratio results in disruption of myeloid differentiation and AML disease (Keeshan et 
al., 2006). TRIB2-induced AML is dependent on its proteolytic effect on C/EBPα (Keeshan et al., 
2010). Structurally TRIB2 relies on 2 distinct domains for C/EBPα degradation 1) a COP1 binding 
site in its C-Terminus and 2) an intact kinase-like domain (Keeshan et al., 2010). The N-Terminus 
was identified not to be essential for TRIB2s functionality (Keeshan et al., 2010). Previous work in 
our laboratory identified the TRIB2 binding site on C/EBPα at R339. Herein I identify and confirm 
the amino acid features of the TRIB2:C/EBPα protein-protein interaction to consist of 
S227A/S229A/S231A/K233A in TRIB2 kinase-like subdomain VIII and  R339 in the bZIP domain 
of C/EBPα. 
Examinations of protein-protein interaction amongst family members identified that there is 
generally a conservation of protein binding localisation amongst protein homologs and the 
existence of multiprotein binding hotspots (Korkin et al., 2005, Tyagi et al., 2009). Evolution 
strives to conserve existing biological functions e.g. conservation of the dTrbl and dSlbo interaction 
identified in Drosophila, but it also strives to generate novel biological functions. dTrbl mediated 
degradation of dSlbo abrogates the ability of border cells within the ovarian epithelium to migrate 
during oogenesis resulting in generation of eggs which are unable to be fertilized (Montell et al., 
1992). Further investigations revealed conservation of the interaction between mammalian TRIB 
proteins and C/EBP protein families in different cellular contexts. It was reported that TRIB2 binds 
and degrades the LAP isoform of C/EBPβ disrupting adipogenesis (Naiki et al., 2007). The N-
Terminus of TRIB3 was reported to bind C/EBP homologs protein (CHOP) in response to 
Endoplasmic reticulum (ER) stresses caused by accumulation of unfolded or misfolded proteins in 
the ER (Ohoka et al., 2005). Preservation of the biological function of TRIB1 and TRIB2 in 
mediating leukaemic disease through binding and degradation of C/EBPα places constraints on 
amino acid sequence identity thus perhaps towards conservation of the C/EBPα binding site. TRIB1 
and TRIB2 are the most similar family members in terms of amino acid sequence (71.3 %). Both 
the N-Terminal regions of the kinase-like domains of TRIB1 and TRIB2 were identified to be 
essential for maintaining WT-TRIB leukaemic function (Yokoyama et al., 2010, Dedhia et al., 
2010).  
108 
 
In order to localise C/EBPα binding site(s) on TRIB2 we generated peptide arrays spanning the 
entire TRIB2 protein. Comparison of C/EBPα binding regions identified on two independent sets of 
peptide arrays identified sequences which mostly clustered to the pseudokinase region of TRIB2 
protein, a region known to be critical for TRIB2 function (Keeshan et al., 2010, Masoner et al., 
2013). Identification of protein binding on a peptide array is suggestive of the binding site being a 
linear sequence and not a conformational sequence formed by the folding of the protein (Beutling 
and Frank, 2010). Thus C/EBPα binding to the TRIB2 peptide array indicates that its binding site is 
a linear sequence and not formed during TRIB2 protein folding. In order to functionally annotate 
the 6 identified amino acid sequences common to both arrays, TRIB2 sequence was aligned to the 
TRIB1 sequence to determine if there was any conservation of residues in the regions of TRIB1 
identified to be functionally important for C/EBPα binding. Subsequently we generated a TRIB2 
SASSA which allowed identification of individual amino acid involvement in C/EBPα binding 
within the stretches of 6 amino acids identified from the peptide arrays. Peptides D, G, H and J 
were identified to be involved in C/EBPα binding. Sequential mutation of the amino acids within 
Peptide D to alanine identified a loss in C/EBPα binding upon mutation of amino acids F76-K90 to 
alanine. Comparisons of the reported prevalence of amino acids common in protein binding sites 
with TRIB2 functional data narrowed the selection for mutagenesis as a potential C/EBPα binding 
site. R77 was chosen as a candidate to be investigated from Peptide D. It possessed several qualities 
promoting its choice 1) arginines are heavily present at protein binding sites, 2) it is homologous to 
TRIB1-R107 which when mutated increases degradation of C/EBPα and 3) it is located in the N-
Terminus of the kinase-like domain supporting the hypothesis of conservation of binding sites 
within families of proteins (Villar and Kauvar, 1994, Korkin et al., 2005, Ofran and Rost, 2007, 
Tyagi et al., 2009, Yokoyama et al., 2010). Peptide G and H both spanned the same stretch of 
amino acids including a putative region of β-turn secondary structure and GSK3 phosphorylation 
site SGSYSGK. S227/S229/S231/K233 was chosen as a site warranting further investigation from 
Peptides G and H due to prevalence of serine in protein binding site (Ofran and Rost, 2007), 
presence of predicted β-turn secondary structures and near complete ablation in binding upon 
mutation of K233. Mutation of K322 on Peptide J resulted in a complete loss of C/EBPα binding, 
this was very striking as Peptide J had the strongest binding intensity of all peptides investigated on 
the array. Thus K322 was chosen as a candidate binding site. Verification of the TRIB2- R77, 
S227/S229/S231/K233 and K322 role in C/EBPα binding was assessed by co-IP. Surprisingly 
K322A retained the ability to strongly bind C/EBPα similarly to WT-TRIB2, concluding this lysine 
had no role in C/EBPα binding, perhaps suggesting that in the folded protein this site may not be 
accessible. Indeed, initial peptide array analysis identifying C/EBPα binding sites on the TRIB2 
109 
 
array did not include this amino acid suggesting why K322A is not required for C/EBPα binding. 
Despite lower expression levels of R77A this mutant still retained the ability to bind C/EBPα, and 
in fact densitometry normalising protein input expression to protein pulldown identified that R77A 
actually had stronger affinity for C/EBPα. TRIB1-R107L increased C/EBPα degradation a 
phenomenon suggestive of binding dependency from published data (Yokoyama et al., 2012), 
therefore TRIB2-R77A possessing increased affinity for C/EBPα may suggest mutation of this 
amino acid increases TRIB  protein affinity for C/EBPα. Mutation of S277A/S229A/S231A/K233A 
abrogated TRIB2:C/EBPα binding. This sequence is located in subdomain VIII of TRIB2 kinase-
like domain. It is not contained in either of the TRIB1 or TRIB2 N-Terminal/N-Terminus kinase-
like domain deletion mutants identified to lose their effect on C/EBPα; however both of these 
mutations involve deletion of a very large portion of the protein (Keeshan et al., 2010, Yokoyama 
et al., 2010). Their subsequent loss of effect on C/EBPα may be secondary to protein misfolding 
due to the large deletions and not due to actual loss of the C/EBPα binding site. 
 
With no crystal structure currently available for TRIB2 it is not possible to identify where these 
amino acids lie within the folded conformation of the protein or if these amino acids are exposed 
for direct interactions. Analysis using SARPRED: Real Value prediction of surface accessibility 
software generates a prediction of solvent-accessible surface area amino acids (ASA) and also the 
extent to which an amino acid is buried in and involved in protein folding (Durham et al., 2009). 
The ASA score is generated by performing PSI-BLAST which compares distant relationships 
between proteins and then predicts the secondary structure of a protein from its amino acid 
sequence (Garg et al., 2005). Provisional analysis of TRIB2 to identify the probability of the 
identified residues being on the surface of the protein generated ASA scores of S227=39, S229=23, 
S231=35 and K233=55 (Appendix 8.3). K233 generated the highest ASA score of 55. The high 
scores of S227=39, S231-35 and K233-55 indicate strong evidence for their presence on the 
exposed surface necessary for protein interactions. Also as previously mentioned serine and glycine 
residues are frequently identified in β-turn secondary structures (Ofran and Rost, 2007, Murakami, 
1995). β-turns are proposed to be favourable secondary structure of protein binding sites. β-turns 
structures were predicted within SGSYSGK sequence (Appendix 8.1 and 8.1.2). PIPE analysis 
identified TRIB2 amino acids 227-258 to be involved in the TRIB2 and C/EBPα interaction 
(Appendix 8.2). Together, the in silico and in vitro experimental data strongly support the 
importance of S227/S229/S231/K233 in the interaction between TRIB2 and C/EBPα. 
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Gene expression analysis of 285 AML patients identified a cohort of patients which had 
dysregulated C/EBPα signature (Keeshan et al., 2006). However within this cohort not all patients 
had mutated C/EBPα, and it was identified that patients with WT-C/EBPα had high TRIB2 
expression explaining the dysregulated C/EBPα signature in these AML patients (Keeshan et al., 
2006). With increasing demand for personalised target therapies, small molecule inhibitors of 
protein binding may provide a novel specific approach and offers huge therapeutic potential. 
Current antibody based therapies while highly specific to their molecular interaction are difficult 
and costly to manufacture and have problems permeablising the cell wall. Small molecule protein-
protein inhibitors overcome these problems but are currently an under-used option due to the lack 
of well defined binding pockets (reviewed by (Arkin and Wells, 2004)). Targeted inhibition of the 
TRIB2-C/EBPα interaction may provide a therapeutic opportunity for such elevated TRIB2 AMLs 
with a dysregulated C/EBPα signature. In summary, in this study I identify and confirm the TRIB2 
and C/EBPα reciprocal binding sites as R339 on C/EBPα and S227/S229/S231/K233 on TRIB2 
which may be an opportunity to develop such targeting therapies.  
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Chapter 4: Results 
TRIB2-mediates K48 ubiquitin-dependent degradation of C/EBPαp42 
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4.1 Introduction 
C/EBPα is a crucial regulator of haematopoiesis controlling the self-renewal capacity of HSCs and 
mediating  GMP differentiation of myeloid cells (Zhang et al., 1998, Zhang et al., 2004, Ye et al., 
2013, Hasemann et al., 2014). C/EBPα is often referred to as a gatekeeper gene in AML, as loss of 
functional C/EBPα results in uncontrolled proliferation of immature myeloid precursor cells 
(reviewed by (Reckzeh and Cammenga, 2010)). C/EBPα may be disrupted by several modalities: 
suppression of transcription, post-transcriptional modification, post-translational modification and 
DNA mutations affecting protein functionality (summarised in Fig 4.1.1 adapted from (Reckzeh 
and Cammenga, 2010)). C/EBPα is reported to be mutated in approximately 5-14 % of 
cytogenetically normal AMLs (Taskesen et al., 2011). Mutations predominately occur either in the 
N-terminus, resulting in an out-of-frame shift generating the C/EBPαp30 truncated protein. 
Mutations also occur in the C-Terminus affecting C/EBPα ability to bind DNA and to dimerise. 
C/EBPα mutations are predominately associated with AML FAB subtypes M1 and M2 (Fasan et 
al., 2014). To date post-translational modifications identified to functionally disrupt C/EBPα 
include phosphorylation (to be discussed in Chapter 5), sumoylation and ubiquitination. The focus 
of this chapter is post-translational modification of C/EBPαp42 through TRIB2-mediated 
ubiquitination.  
 
Fig 4.1.1 Schematic diagram of C/EBPα deregulation in AML adapted from (Reckzeh and 
Cammenga, 2010). 
Ubiquitination is a highly regulated ATP dependent process, involving the covalent attachment of 
76 amino acid ubiquitin polypeptide(s) to a substrate protein. Ubiquitination triggers a plethora of 
effects within the cell but predominately signals the target protein for proteasomal degradation. 
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Ubiquitin is conjugated through the formation of a thioester bond between C-Terminal of ubiquitin 
(G76) and ε amino side chain of a lysine on the target protein (Hershko et al., 1983). Lysine is the 
predominate amino acid identified to serve as the ubiquitin conjugation site on a protein. However 
the amino acids cysteine, threonine, serine and the free ε amino side chain at the N-Terminal of a 
protein have also been identified to bind ubiquitin in rare cases (Cadwell and Coscoy, 2005, 
Scaglione et al., 2013). Single ubiquitin polypeptides may be conjugated (mono or multi-
monoubiquitination) or polymers of ubiquitin may be conjugated termed polyubiquitination 
(Schematic Fig 4.1.2). There are several species of ubiquitination which are determined by the 
identity of the lysine in ubiquitin which forms the polychain linkage with the adjacent ubiquitin 
(K6, K11, K27, K29, K33, K48 and K63). K48 ubiquitination signals proteasomal degradation and 
four K48 linked ubiquitin polypeptides are the minimum length polychain recognised by the 
proteasome (Chau et al., 1989, Pickart, 1997, Thrower et al., 2000). K63 ubiquitination triggers 
endocytosis, protein trafficking and DNA repair responses but not proteasomal degradation 
(Schematic Fig 4.1.2) (reviewed by (Chen and Sun, 2009)). K48 and K63 to date are the most 
widely studied ubiquitin polychains.  
 
           Fig 4.1.2 Schematic of mono- and poly-ubiquitination. 
Conjugation of ubiquitin to a substrate protein involves the hierarchical action of three enzymes, 
E1, E2 and E3 ubiquitin ligases. A cell is estimated to contain only 2 E1, 37 E2 and >600 E3 
ligases, which can tightly control the UPS through stringent substrate identification (Deshaies and 
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Joazeiro, 2009). The 26S proteasome is the primary site of controlled protein proteolysis within the 
cell. The proteasome is comprised of 2 multisubunit components, the 20S and the 19S regulatory 
subunit. Upon proteasome binding the polyubiquitinated protein is degraded rapidly thus promptly 
and irreversibly terminating any signal transduction propagated by the protein. C/EBPα has been 
identified to be targeted by the UPS as a result of direct binding to a number of E3 ligases and also 
through associations with adaptor proteins which facilitate subsequent ubiquitination in a variety of 
mammalian tissues.  
Mammalian C/EBPα was first identified to be ubiquitinated in keratinocytes upon Lithium induced 
proteasomal inhibition (Shim and Smart, 2003). To date the E3 ligases E6AP and FBXW7 have 
been identified to directly bind C/EBPα mediating its ubiquitination (Bengoechea-Alonso and 
Ericsson, 2010, Pal et al., 2013a, Pal et al., 2013b). The E3 ligases COP1 and TRIM21 have also 
been identified to degrade C/EBPα however in an adaptor protein dependent manner (Yokoyama et 
al., 2010, Keeshan et al., 2010, Grandinetti et al., 2011, Yoshida et al., 2013). Additionally the 
phosphorylation status of C/EBPα has been linked to its ubiquitination in response to various 
proteins. PKCδ and JNK1 have been reported to mediate ubiquitination of C/EBPα upon 
phosphorylation and dephosphorylation in response to apoptosis induction and stress signal 
responses in AML cells (Trivedi et al., 2006, Zhao et al., 2009, Wu et al., 2013). 
E6AP was identified as an E3 ligase upregulated in Tamoxifen treated Henrietta Lacks (HeLa) cells 
with a resultant decrease in C/EBPα protein levels (Cheng et al., 2007). E6AP was identified to 
directly bind C/EBPα mediating its ubiquitination in myeloid cells and in adipocytes resulting in a 
block in cell differentiation (Pal et al., 2013a, Pal et al., 2013b). Mutation of E6AP catalytic site 
C834A abrogated C/EBPα ubiquitination (Pal et al., 2013a, Pal et al., 2013b). Knockdown of E6AP 
or overexpression of E6AP-C834A induced myeloid differentiation of U937 cells, K562 and 
32Dcl3 cells through increasing C/EBPα protein expression (Pal et al., 2013b). While similarly 
knockdown of E6AP or E6AP-C834A overexpression promotes adipocyte differentiation through 
increasing C/EBPα protein levels (Pal et al., 2013a).  
FBXW7 is a tumour suppressor controlling the expression of C-MYC, NOTCH1, Cyclin E and C-
jun (Koepp et al., 2001, Wei et al., 2005, Malyukova et al., 2007, Welcker and Clurman, 2008). 
Inactivating FBXW7 mutations are frequently associated with activated NOTCH1 T-ALL disease 
(Kraszewska et al., 2012). Interestingly elevated levels of TRIB2 have been identified in a cohort of 
paediatric T-ALL patients which harbour NOTCH1 or FBXW7 mutations (Hannon et al., 2012). 
Differential phosphorylation has been reported to both protect and promote UPS degradation of 
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C/EBPα (Trivedi et al., 2006, Bengoechea-Alonso and Ericsson, 2010, Wu et al., 2013). FBXW7 
has been identified to mediate ubiquitination through recognition of a phosphodegron motif. 
FBXW7 only binds and mediates ubiquitination of C/EBPα upon phosphorylation of residues 
Thr222/Thr226 resulting in the inhibition of adipocyte differentiation (Bengoechea-Alonso and 
Ericsson, 2010).  
Induction of apoptosis through PKCδ cleavage and Caspase-3 activation results in UPS degradation 
of C/EBPα in AML cells (Zhao et al., 2009). PKCδ was identified to mediate phosphorylation of 
C/EBPα, disrupting C/EBPα nuclear localisation resulting in proteasomal degradation (Wu et al., 
2013). Alternatively activated JNK1 in response to stress signals was identified to bind C/EBPα 
resulting in phosphorylation through an unidentified site, mediating a decrease in levels of C/EBPα 
ubiquitination and increasing protein stability, whilst inactive JNK1 which does not phosphorylate 
C/EBPα resulted in an increase in the levels of ubiquitinated protein (Trivedi et al., 2006).  
TRIB proteins are often reported to function as scaffold or adaptor proteins as they facilitate the 
formation of multiprotein binding complexes. dTrbl mediates binding dependent ubiquitination of 
dSlbo in border cells of Drosophila (Rørth et al., 2000, Masoner et al., 2013). Evolutionary 
conservation of this relationship is evident by both TRIB1- and TRIB2- mediating proteasomal 
degradation of C/EBPαp42 but this proteolysis is dependent on TRIB E3 ligase binding (Yokoyama 
et al., 2010, Keeshan et al., 2010, Grandinetti et al., 2011). Overexpression of TRIB1 and TRIB2 in 
BMTs results in AML disease with TRIB leukaemogenecity dependent on the E3 ligase COP1. 
Loss of the COP1 binding site on TRIB1 and TRIB2 through deletion, mutation or expression of 
dominant negative isoforms of COP1 relieves TRIB1 and TRIB2 proteolytic effect on C/EBPα 
(Keeshan et al., 2010, Yokoyama et al., 2010, Yoshida et al., 2013). Overexpression of COP1 in the 
presence of TRIB1 expression was identified to mediate ubiquitination of C/EBPα inhibiting 
myeloid differentiation and reported to reduce the latency of TRIB1 mediated AML in BMTs 
(Yoshida et al., 2013). Knockdown of TRIB1 abrogated the effects of overexpressed COP1 in AML 
cells (Yoshida et al., 2013). Similarly TRIM21 was identified as an E3 ligase inducing degradation 
of C/EBPα in a TRIB2 dependent manner in NSCLS (Grandinetti et al., 2011). Overexpression of 
TRIM21 did not mediate degradation of ectopically expressed C/EBPα but co-expression of TRIB2 
and TRIM21 mediated degradation of C/EBPα (Grandinetti et al., 2011). Thus TRIB proteins 
facilitate ubiquitination and proteasomal degradation of C/EBPα through binding an E3 ligase and 
through direct binding to C/EBPα. To date there are no published reports on the effects of TRIB2 
on the ubiquitination status of C/EBPα. 
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C/EBP family members are highly homologous within their C-Terminal leucine zipper. The leucine 
zipper allows for formation of homo and heterodimers between C/EBP proteins and other proteins 
which contain leucine zippers such as C-fos and C-Jun (Williams et al., 1991, Hsu et al., 1994). 
Dimer formation was reported to stabilize C/EBPδ and C/EBPγ as it prevented ubiquitin-dependent 
degradation (Hattori et al., 2003). An intact leucine zipper region, mediating dimerisation, was 
identified to be essential for ubiquitination of C/EBPδ, however this ubiquitination was reported to 
not correlate with increased degradation (Zhou and Dewille, 2007). Thus there is not a consensus 
pattern of behaviour regarding C/EBP ubiquitination upon dimerisation. In frame C-Terminal 
C/EBPα AML patient mutations affecting the ability of C/EBPα to dimerise are frequently 
identified. Investigation of the functional role of monomeric C/EBPα revealed it inhibits C/EBPα 
ability to induce monopoiesis when ectopically expressed in lineage negative murine cells (Wang et 
al., 2006a). Thus monomeric C/EBPα does not function similarly to dimeric C/EBPα. C/EBPα 
dimer formation was also identified to vary with its nuclear localisation and in response to 
environmental stresses (Schaufele et al., 2003). There have been no reports to date investigating the 
ubiquitination and subsequent proteasomal degradation of monomeric C/EBPα or investigation of 
TRIB2 effect on monomeric C/EBPα. 
Aim 
TRIB2 has been reported to mediate proteasomal degradation of C/EBPα in an E3 ligase dependent 
manner. However there have been no investigations detailing the molecular biology of this 
proteolytic relationship. In this study I present the first reports of C/EBPα K48 ubiquitin-dependent 
degradation and of TRIB2-mediated K48 ubiquitination of C/EBPα identified by performing in 
vivo overexpression ubiquitination assays. I identified that TRIB2 and C/EBPα direct binding is 
essential for TRIB2-mediated ubiquitination having previously identified the amino acid features 
involved in the interaction as TRIB2-S227A/S229A/S231/K233A and C/EBPα-R339. In vivo 
ubiquitination assays identified TRIB2-S227A/S229A/S231/K233A was unable to mediate 
ubiquitination of WT-C/EBPα and C/EBPα-R339A was unable to be ubiquitinated by WT-TRIB2. 
I also verified that COP1 is the bona fida E3 ligase used by TRIB2 for ubiquitination of C/EBPα as 
TRIB2-VPM cannot mediate ubiquitination of C/EBPα. I propose that K313 is the potential site of 
ubiquitin conjugation on C/EBPα as K313R was unable to be ubiquitinate by TRIB2. I also 
determined TRIB2 preferentially ubiquitinates dimeric C/EBPα over monomeric C/EBPα despite 
the ability of TRIB2 to bind both monomeric and dimeric C/EBPα. 
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Result 4.2.1 Overexpression of TRIB2-mediates increased ubiquitination of 
overexpressed C/EBPα 
Previous data determined TRIB2-mediated the proteasomal degradation of C/EBPαp42 and this 
proteolytic relationship is dependent on COP1 E3 ligase binding to TRIB2, suggesting TRIB2 may 
mediate ubiquitin-dependent degradation of C/EBPα (Keeshan et al., 2006, Keeshan et al., 2010). 
However, it is incorrect to assume the proteasomal degradation process is ubiquitin-dependent. 
Recently a growing list of proteins have been identified which undergo proteasomal degradation in 
an ubiquitin-independent manner, e.g. ornithine decarboxylase, p21, and C/EBPδ (Hoyt et al., 2003, 
Chen et al., 2004, Zhou and Dewille, 2007). In order to determine if TRIB2 was in fact mediating 
ubiquitination of C/EBPα an in vivo ubiquitination assay was performed in HEK293t cells 
transiently transfected to overexpress C/EBPα-MYC, TRIB2-FLAG and Ubiquitin (Ub)-HA. Upon 
treatment with the proteasome inhibitor MG-132 the levels of ubiquitinated C/EBPα increased as 
determined by immunoblotting for HA and evident by the polyubiquitinated smear in lane 3 versus 
the untreated ubiquitination levels in lane 2 (Fig 4.2.1 top panel). Ubiquitination levels in lane 3 
determine the basal ubiquitination status of C/EBPα in the cell, suggesting ubiquitination may serve 
to control protein turnover of C/EBPα in a wildtype environment. Overexpression of TRIB2 in the 
presence of MG-132 (Fig 4.2.1 lane 5) increased the ubiquitination of C/EBPα versus C/EBPα in 
the absence of TRIB2 (Fig 4.2.1 lane 3). Immunoblotting for TRIB2 and C/EBPα confirm input 
protein expression and equal Actin levels confirmed equal protein loading (Fig 4.2.1 bottom panel). 
Overexpression of TRIB2 does not mediate degradation of overexpressed C/EBPα as detected in 
protein inputs in HEK293t cells in the in vivo ubiquitination assay, highlighting a limitation of this 
assay. In all cell systems/murine models with endogenous C/EBPα expression TRIB2-mediates 
proteasomal degradation (Keeshan et al., 2006, Keeshan et al., 2010, Rishi et al., 2014). This is 
proposed to be due to highly expressive nature of the HEK293t cells, transfection of highly 
expressive constructs and perhaps due to a protein overload of the proteasome. The in vivo 
ubiquitination assay is optimised and published for identifying ubiquitination (Carmody et al., 
2007). Thus it may now be stated that TRIB2-mediates increased ubiquitination of C/EBPα.  
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Fig 4.2.1 TRIB2-mediates increased ubiquitination of C/EBPα HEK293t cells were transfected 
to overexpress Ub-HA, TRIB2, C/EBPα and PHMA served as an empty vector control. Indicated 
samples were treated with 10 μM MG-132 5 hrs prior to harvesting lysates. C/EBPα was 
immunoprecipitated and an in vivo ubiquitination assay was performed. Lysates were separated by 
SDS-PAGE and immunoblotted for anti HA. Immunoblotting for anti TRIB2 and anti C/EBPα 
detects input levels and Actin serves as a loading control (bottom panel). Representative molecular 
weight markers in kDa are presented for ubiquitination blots and TRIB2, C/EBPα and Actin 
immunoblots presented herein. Data presented is representative of three independent transfection 
experiments. The mean fold increase in C/EBPα ubiquitination in the presence of TRIB2 is 3.4 +/- 
0.43 SEM. 
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Result 4.2.2 TRIB2-mediates K48 specific ubiquitination of C/EBPα as determined 
by ubiquitin polychain specific antibodies  
In order to determine the type of ubiquitination mediated by TRIB2, immunoprecipitates were 
immunoblotted using antibodies specific to K48 and K63 polychains of ubiquitination. K48 
ubiquitination polychains target the substrate protein for proteasomal degradation (Pickart, 1997), 
while K63 ubiquitination induces endocytosis, regulates protein localisation and protein-protein 
interactions (Arnason and Ellison, 1994, Mukhopadhyay and Riezman, 2007). An in vivo 
ubiquitination assay was performed in HEK293t cells transiently transfected to overexpress 
C/EBPα, TRIB2 and Ub-HA. C/EBPα was immunoprecipitated and lysates were immunoblotted 
with an antibody specific to K48 ubiquitin polychain (Fig 4.2.2 A). Additionally the membrane 
from Fig 4.2.1 was stripped and incubated with an antibody specific to K63 ubiquitin polychain 
(Fig 4.2.2 A and B). Overexpression of TRIB2 mediated an increase in K48 ubiquitination of 
C/EBPα (Fig 4.2.2 A lane 4 and 5 top panel). K48 ubiquitination signal was stronger than detection 
of ubiquitination through immunoblotting for HA from the overexpression WT-Ub-HA construct as 
K48 antibody detects both endogenous K48 ubiquitination and K48 ubiquitination expressed from 
the WT-Ub-HA expression construct. Immunoblotting for K63 antibody determined that TRIB2 
was not mediating an increase in K63 ubiquitination (Fig 4.2.2 B). TRIB2 thus mediates K48 
specific ubiquitin-dependent degradation of C/EBPα.  
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Fig 4.2.2 TRIB2 mediates increased K48 ubiquitination of C/EBPα. HEK293t cells were 
transfected to overexpress Ub-HA, TRIB2, C/EBPα and PHMA empty vector control. Indicated 
A 
B 
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samples were treated with 10 μM MG-132 5 hrs prior to harvesting lysates. C/EBPα was 
immunoprecipitated and an in vivo ubiquitination assay was performed. Lysates were separated by 
SDS-PAGE and immunoblotted for A) anti K48 and B) anti K63 species of ubiquitination. 
Immunoblotting input lysates confirms expression of TRIB2 and C/EBPα and Actin confirmed 
equal protein loading. Data presented is representative of three independent transfection 
experiments. 
Result 4.2.3 TRIB2-mediates K48 specific ubiquitination of C/EBPα as determined 
by ubiquitin polychain mutants 
In order to confirm the TRIB2 mediated K48- and not K63- specific ubiquitination of C/EBPα by 
another method an in vivo ubiquitination assay was performed including ubiquitin mutants which 
do not express the K48 ubiquitin polychain (K48R) and the K63 ubiquitin polychain (K63R). 
Immunoprecipitation of C/EBPα in cells transfected to expression UB/K63R alone produced a very 
strong background signal subsequent to immunoblotting for anti HA (Fig 4.2.3 lane 3). 
Immunoprecipitation of C/EBPα in cells transfected to express WT-Ub-HA and UB/K48R did not 
produce any background signal upon immunoblotting for anti HA. Thus when characterising the 
effect of UB/K63R on C/EBPα ubiquitination changes relative to the background signal in lane 3 
were assessed. Overexpression of UB/K48R was unable to mediate ubiquitination of C/EBPα in the 
presence of TRIB2 (Fig 4.2.3 lane 8). Both WT-Ub and UB/K63R mediated increased 
ubiquitination of C/EBPα in the presence of TRIB2 versus C/EBPα alone (Fig 4.2.3 lane 4 and lane 
6, lane 7 and lane 9) as both ubiquitin constructs express the K48 polychain. Overexpression of 
TRIB2-mediated an increase in C/EBPα ubiquitination in the presence of WT-Ub (lane 7) and 
UB/K63R (lane 9) but not in the presence of UB/K48R (lane 8) (Fig 4.2.3 top panel). 
Immunoblotting for anti TRIB2 and anti C/EBPα confirmed equal input expression and 
immunoblotting for Actin confirmed equal protein loading (Fig 4.2.3 bottom panel). Thus this 
validates TRIB2-mediates K48 and not K63 specific ubiquitination of C/EBPα resulting in its 
proteasomal-dependent degradation.  
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Fig 4.2.3 TRIB2-mediates increased K48 ubiquitination of C/EBPα. HEK293t cells were 
transfected to overexpress Ub-HA, UB/K48R-HA, UB/K63R-HA, TRIB2, C/EBPα and PHMA 
empty vector control. Cells were treated with 10 μM MG-132 5 hrs prior to harvesting lysates. 
C/EBPα was immunoprecipitated and an in vivo ubiquitination assay was performed. Lysates were 
separated by SDS-PAGE and immunoblotted for anti HA. Immunoblotting input lysates confirms 
expression of TRIB2 and C/EBPα and Actin confirms equal protein loading. Data presented is 
representative of one independent transfection experiments.  
 1      2    3    4     5   6    7    8    9 
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Result 4.2.4 TRIB2 is unable to mediate ubiquitination of C/EBPα-R339A 
R339 was identified as the TRIB2 binding site on C/EBPα (unpublished data, Ciaran Forde, Dr. 
Karen Keeshan, Appendix 8.4, Fig 3.2.8 B). Thus analysis of the ubiquitination profile of C/EBPα-
R339 in the presence of TRIB2 would determine if TRIB2 binding was essential for its ubiquitin-
dependent degradation of C/EBPα. An in vivo ubiquitination assay was performed overexpressing 
WT-Ub-HA, WT-C/EBPα, C/EBPα-R339A and C/EBPα-R343A in the presence of TRIB2 in 
HEK293t cells treated with MG-132. C/EBPα-R343A was identified as a potential TRIB2 binding 
site by SASSA however GST-IP verification revealed it retained the ability to bind GST-TRIB2 
(unpublished data, Ciaran Forde Appendix 8.4). WT-C/EBPα was ubiquitinated in the presence of 
TRIB2 as was R343A mutant which retained the ability to interact with TRIB2 (Fig 4.2.4 lane 1 
and lane 3 top panel), however R339A was not ubiquitinated in the presence of TRIB2 (Fig 4.2.4 
lane 2 top panel) indicating that TRIB2 and C/EBPα binding is essential for TRIB2-mediated 
ubiquitination and proteasomal degradation of C/EBPα. Immunoblotting for TRIB2 and C/EBPα 
confirmed equal input expression and immunoblotting for Actin confirmed equal protein loading 
(Fig 4.2.4 bottom panel).  
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Fig 4.2.4 TRIB2:C/EBPα binding is essential for mediating ubiquitination. HEK293t cells were 
transfected to overexpress WT-C/EBPα, C/EBPα-R339A and C/EBPα-R343A in the presence of 
overexpressed TRIB2 and Ub-HA. Cells were treated with 10 μM MG-132 5 hrs prior to harvesting 
lysates. C/EBPα was immunoprecipitated and an in vivo ubiquitination assay was performed. 
Lysates were separated by SDS-PAGE and immunoblotted for anti HA. Immunoblotting input 
lysates confirms expression of TRIB2 and C/EBPα and Actin confirmed equal protein loading. 
Data presented is representative of two independent transfection experiments. 
 
 
 
 
 
 1      2      3 
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Result 4.2.5 TRIB2-S277A/S229A/S231A/K233A is unable to mediate 
ubiquitination of C/EBPα 
Direct TRIB2 and C/EBPα binding was determined as a requisite for TRIB2-mediated 
ubiquitination of C/EBPα (Fig 4.2.4), thus in order to validate the identification of 
S227A/S229A/S231A/K233A (Fig 3.2.7) as a region responsible for C/EBPα interaction with 
TRIB2 an in vivo ubiquitination assay was performed. HEK293t cells were transfected to express 
WT-Ub-HA, WT-C/EBPα, WT-TRIB2, TRIB2-R77A, TRIB2-S227A/S229A/S231A/K233A and 
TRIB2-K322A and treated with MG-132 for 5 hrs. TRIB2-R77A and TRIB2-K322A retained the 
ability to directly bind C/EBPα (Fig 3.2.7). Immunoblotting for HA determined TRIB2-
S227A/S229A/S231A/K233A is unable to mediate ubiquitination of C/EBPα, unlike TRIB2-R77A 
and TRIB2-K322A mutants which both retained the ability to mediate ubiquitination of C/EBPα, 
similar to WT-TRIB2 (Fig 4.2.5 top panel). Immunoblotting protein inputs for C/EBPα expression 
determined overexpression of TRIB2-R77A and TRIB2-K322 mediated an increase in C/EBPαp30; 
however TRIB2-S227A/S229A/S231A/K233A did not increase C/EBPαp30 levels similar to WT-
TRIB2 (Fig 4.2.5 bottom panel). Thus TRIB2 and C/EBPα direct binding is essential for TRIB2-
mediated ubiquitination and proteasomal degradation of C/EBPαp42 and C/EBPαp30 generation. 
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Fig 4.2.5 TRIB2 binding to C/EBPα is essential for mediated ubiquitination. HEK293t cells 
were transfected to overexpress WT-TRIB2, TRIB2-R77A, TRIB2-S227A/S229A/S231A/K233A, 
TRIB2-K322A, C/EBPα and Ub-HA. Cells were treated with 10 μM MG-132 5 hrs prior to 
harvesting lysates. C/EBPα was immunoprecipitated and an in vivo ubiquitination assay was 
performed. Lysates were separated by SDS-PAGE and immunoblotted for HA. Immunoblotting 
protein input lysates confirms expression of TRIB2 and C/EBPα. Data presented is representative 
of three independent transfection experiments.  
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Result 4.2.6 Prediction of potential ubiquitination sites on C/EBPα 
Much debate surrounds the prediction of ubiquitination sites in substrate proteins. There has been 
consensus in the lack of a discernible ubiquitination site motif (Danielsen et al., 2011) however 
reports on the identity of the flanking amino acid sequences surrounding the ubiquitination site vary 
(Radivojac et al., 2010, Kim et al., 2011, Zhou et al., 2013, Udeshi et al., 2013). Ubpred online 
software was used to identify the probability of each lysine in C/EBPα acting as a ubiquitination 
site. Ubpred assigns probability scores based on the amino acid identity surrounding lysines, as it 
was trained on known ubiquitination sites (Radivojac et al., 2010). Ubpred analysis of C/EBPα 
identified six residues as potential ubiquitination sites K90, K92, K159, K169, K250 and K313 (Fig 
4.2.6 A). Annotation of the predicted lysines identified a recurrent C/EBPα mutation K313dup 
which has been reported in 10 % of C/EBPα mutated AMLs and was identified to have a shorter 
protein half life than wildtype C/EBPα as determined by cycloheximide (CHX) assay (Carnicer et 
al., 2008). K313dup mutation results in an extra lysine adjacent to K313, which I predict to be a 
potential ubiquitination site (Fig 4.2.6 A).  K313 is located in the C-Terminal region of C/EBPα 
between the DNA binding domain and the zipper region (Fig 4.2.6 B). Murine BMT and knock-in 
models report the ability of K313dup to induce AML (Bereshchenko et al., 2009, Kato et al., 2011). 
Investigations in the laboratory identified K90 and K92 were not essential lysines for C/EBPα 
ubiquitination (Personal communication, Dr. Karen Keeshan). K159 was previously identified as 
the site of C/EBPα sumoylation (Geletu et al., 2007). K313 was chosen as potential C/EBPα 
ubiquitination site to be investigated based on the leukaemogenecity of this mutation in AML.   
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Fig 4.2.6 Identification of C/EBPα ubiquitination site. A) Ubpred analysis of rat C/EBPα 
Ensembl ID ENSRNOG00000010918; displaying the probability of each lysine acting as an 
ubiquitin conjugation site. B) Schematic diagram displaying the localisation of K90/K92 and 
K313dup in terms of C/EBPα domains adapted from (Mueller and Pabst, 2006). 
 
 
 
A 
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Result 4.2.7 Identification of K313 as a site of C/EBPα ubiquitination 
C/EBPα-K313R mutant was produced by GenScript in order to investigate the role of this lysine in 
TRIB2-mediated ubiquitination of C/EBPα. Substitution of a lysine for an arginine residue is often 
performed as arginine is a positive amino acid and retains the electrostatic interactions performed 
by lysine, required for protein stability. However arginine lacks the required ε amino side chain for 
ubiquitin conjugation thus creation of K313R would assess the role of this lysine in the 
ubiquitination of C/EBPα without disrupting C/EBPα protein structure. An in vivo ubiquitination 
assay was performed in HEK293t cells overexpressing WT-Ub-HA, TRIB2, WT-C/EBPα, and 
C/EBPα-K313R and treated with MG-132 for 5 hrs. Immunoblotting for anti HA determined that 
mutation of K313R reduced basal ubiquitination levels of C/EBPα compared to WT-C/EBPα after 
equal immunoprecipitation of C/EBPα (Fig 4.2.7 top panel lane 3). Overexpression of TRIB2 was 
unable to mediate increased C/EBPα-K313R ubiquitination unlike WT-C/EBPα (Fig 4.2.7 top 
panel lane 4 and lane 5). Overexpression of TRIB2-mediated an increase in WT-C/EBPαp30 levels 
as expected (Fig 4.2.7 bottom panel lane 4). However TRIB2 was unable to mediate an increase in 
C/EBPα-K313Rp30 levels (Fig 4.2.7 bottom panel lane 5). Immunoblotting input protein lysates 
confirmed C/EBPαp42 and TRIB2 expression (Fig 4.2.7 bottom panel). This suggests that K313 
serves as the site of ubiquitin conjugation on C/EBPα in the presence and absence of TRIB2 and 
mutation of K313 abrogates TRIB2-mediated ubiquitin-dependent proteasomal degradation of 
C/EBPα. 
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Fig 4.2.7 C/EBPα-K313 is a site of ubiquitin conjugation. HEK293t cells were transfected to 
overexpress Ub-HA, WT-TRIB2, WT-C/EBPα and C/EBPα-K313R. Cells were treated with 10 μM 
MG-132 5 hrs prior to harvesting lysates. C/EBPα was immunoprecipitated and an in vivo 
ubiquitination assay was performed. Lysates were separated by SDS-PAGE and immunoblotted for 
anti HA after equal immunoprecipitation of C/EBPα. Immunoblotting protein inputs for anti TRIB2 
and anti C/EBPα detects TRIB2, WT-C/EBPα42, WT-C/EBPαp30, K313R-C/EBPαp42 and 
K313R-C/EBPαp30 levels (bottom panel). Data presented is representative of three independent 
transfection experiments. 
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Result 4.2.8 Mutation of the COP1 binding site and the kinase-like domain of 
TRIB2 abrogate its ability to mediate C/EBPα ubiquitination 
An intact COP1 binding site and kinase-like domain were reported to be essential for TRIB2 
oncogenicity (Keeshan et al., 2010). Mutation or deletion of the COP1 binding site abrogated 
TRIB2 ability to degrade C/EBPαp42 (Keeshan et al., 2010). In order to ascertain that COP1 was 
responsible for the conjugation of ubiquitin to C/EBPα through direct TRIB2 and C/EBPα binding 
an in vivo ubiquitination assay was performed overexpressing the TRIB2 mutant TRIB2-VPM 
which is unable to bind COP1 through mutation of the COP1 binding site DQVPL to AQLAA 
(Keeshan et al., 2010). Additionally an intact kinase domain was reported to be essential for 
TRIB2-mediated oncogenicity (Keeshan et al., 2010). Immunoblotting for anti HA determined that 
COP1 binding is essential for TRIB2-mediated ubiquitination of C/EBPαp42 as TRIB2-VPM was 
unable to mediate ubiquitination of C/EBPαp42 (Fig 4.2.8 A top panel lane 2). TRIB2-VPM was 
also unable to increase CEBPαp30 levels similarly to WT-TRIB2 (Fig 4.2.8 A bottom panel lane 
2). In order to assess the effect of mutating the TRIB2 kinase-like domain on C/EBPαp42 
ubiquitination an in vivo ubiquitination assay was performed using TRIB2-KDM. Immunoblotting 
for anti HA determined that mutation of TRIB2 to resemble a canonical kinase (TRIB2-KDM) 
abrogated its ability to mediate ubiquitination of C/EBPαp42 (Fig 4.2.8 B top panel). TRIB2-KDM 
was also unable to mediate an increase in C/EBPαp30 compared to WT-TRIB2 (Fig 4.2.8 B bottom 
panel). Immunoblotting input protein lysates confirmed TRIB2 and C/EBPαp42 protein expression 
while Actin confirmed equivalent protein loading.  
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Fig 4.2.8 TRIB2-VPM and TRIB2-KDM are unable to mediate ubiquitination of C/EBPα. A) 
HEK293t cells were transfected to overexpress Ub-HA, WT-C/EBPαp42, WT-TRIB2, TRIB2-
VPM. Note the TRIB2 sample was included in the same experiment however it was loaded several 
lanes down, the figure was cropped in order to display relevant data only. B) HEK293t cells were 
A 
B 
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transfected to overexpress Ub-HA, WT-C/EBPαp42, WT-TRIB2, and TRIB2-KDM. Cells were 
treated with 10 μM MG-132 5 hrs prior to harvesting lysates. C/EBPα was immunoprecipitated and 
an in vivo ubiquitination assay was performed. Lysates were separated by SDS-PAGE and 
immunoblotted for anti HA after equal immunoprecipitation of C/EBPα. Immunoblotting for anti 
C/EBPα confirms input protein expression and Actin confirms equal protein loading (bottom 
panel). Data presented is representative of three independent transfection experiments. 
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Result 4.2.9 TRIB2 preferentially ubiquitinates dimeric C/EBPα 
The C/EBP family of proteins are able to homo and heterodimerise via their highly conserved C-
Terminal leucine zipper dimerisation domains. It had previously been reported that formation of 
dimers increased C/EBP protein family stability (Hattori et al., 2003). Thus we sought to determine 
if monomeric C/EBPα is more susceptible to TRIB2-mediated ubiquitin-dependent degradation. 
Mutation of C/EBPα leucines 1 and 2 in the dimerisation domain (leucine 317 and 324) to valines 
(C/EBPα-L12V) abrogate C/EBPα ability to dimerise  (Liu et al., 2003). Previous work in the 
laboratory determined TRIB2 is able to bind both monomeric and dimeric C/EBPαp42 (Ciaran 
Forde, unpublished data, Appendix 8.5), thus an in vivo ubiquitination assay was performed to 
identify whether TRIB2 preferentially degrades monomeric or dimeric C/EBPαp42 (Fig 4.2.9 A). 
Immunoblotting for anti HA and anti K48 revealed WT-C/EBPαp42 is ubiquitinated more strongly 
than C/EBPα-L12V (Fig 4.2.9 A lane 2 vs. lane 3 top panel) indicating monomeric C/EBPα protein 
is more stable that dimeric C/EBPα. Overexpression of TRIB2-mediated an increase in dimeric 
C/EBPα ubiquitination as is evident by immunoblotting for HA and K48 ubiquitin polychain (Fig 
4.2.9 A lane 2 vs. lane 4 top panel). TRIB2 overexpression also mediated an increase in C/EBPα-
L12V ubiquitination (Fig 4.2.9 A lane 3 vs. lane 5) however the increase mediated was not 
equivalent to that of dimeric C/EBPαp42. Immunoblotting for K63 polychain revealed TRIB2 is 
not mediating a non degradative ubiquitination signal to C/EBPα-L12V (Fig 4.2.9 A top panel). 
Immunoblotting protein inputs lysates confirmed TRIB2, C/EBPαp42 and C/EBPα-L12V 
expression while Actin confirmed equal protein loading (Fig 4.2.9 A bottom panel). 
 
As the in vivo ubiquitination assay suggested that TRIB2 does not mediate ubiquitination of 
monomeric C/EBPα-L12V similar to dimeric C/EBPαp42 (Fig 4.2.9 A), CHX treatment was 
performed to determine the protein stability of monomeric versus dimeric C/EBPαp42 in the 
presence of TRIB2. HEK293t cells were transfected to overexpress TRIB2, C/EBPαp42 and 
C/EBPα-L12V for 24 hrs. Cells were treated with 100 ng/mL CHX for the indicated timepoints. 
Immunoblotting for C/EBPαp42 revealed WT-C/EBPαp42 had much reduced protein stability in 
the presence of TRIB2 than C/EBPα-L12V (Fig 4.2.9 B). WT-C/EBPα displayed 18% relative 
expression at 270 min post CHX vs C/EBPα-L12V displayed 86% relative expression at 270 min 
post CHX. Carnicer et al report expression of WT-C/EBPαp42 in HEK293t displays a relative 
decrease of 63 % in protein expression 270 min post CHX treatment (Carnicer et al., 2008). In the 
presence of TRIB2 immunoblotting for WT-C/EBPαp42 determined relative protein expression is 
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reduced by 72 % (Fig 4.2.9 B and C), indicating as expected that the half life of WT-C/EBPαp42 is 
reduced in the presence of TRIB2. TRIB2 itself displayed a half life of 180 minutes similar to 
reported literature (Fig 4.2.9 B and D) (Wang et al., 2013b). Thus despite TRIB2 having a shorter 
protein half life than WT-C/EBPαp42 it still exerts a proteolytic effect on C/EBPαp42 reducing its 
protein stability (Fig 4.2.9 B, C and D). Immunoblotting for C/EBPα determined C/EBPα-L12V 
relative protein expression at 270 min only decreased by 14 % in the presence of TRIB2 (Fig 4.2.9 
B and C), indicating that the dimeric C/EBPαp42 is more susceptible to TRIB2-mediated 
ubiquitin-dependent degradation resulting in a shorter protein half life than its monomeric form.  
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Fig 4.2.9 TRIB2-mediates increased ubiquitination of dimeric C/EBPαp42. A) HEK293t cells 
were transfected to overexpress Ub-HA, WT-TRIB2, WT-C/EBPαp42, C/EBPα-L12V and PHMA 
empty vector control. Cells were treated with 10 μM MG-132 5 hrs prior to harvesting lysates. 
C/EBPα was immunoprecipitated and an in vivo ubiquitination assay was performed. Lysates were 
separated by SDS-PAGE and immunoblotted for anti HA, anti K48 and anti K63 species of 
ubiquitin after equal immunoprecipitation of C/EBPα. Immunoblotting for anti TRIB2 and anti 
C/EBPα confirms input protein expression and Actin confirms equal protein loading (bottom 
A 
B 
C D 
B 
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panel). B) HEK293t cells were transfected to overexpress TRIB2, C/EBPαp42 and C/EBPα-L12V. 
Cells were treated with 100 ng/mL CHX for 0, 90, 180 and 270 mins. Lysates were collected 24 hrs 
post transfection, separated by SDS-PAGE and immunoblotted for anti C/EBPα and anti TRIB2. 
Relative expression normalised to expression at 0 mins is displayed. C) Graphical representation of 
WT-C/EBPα and C/EBPα-L12V relative expression over course of CHX treatment. D) Graphical 
representation of TRIB2 relative expression in WT-C/EBPα and C/EBPα-L12V transfected cells 
over course of CHX treatment. Data presented is representative of one independent transfection 
experiments. 
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4.3 Discussion 
TRIB2 mediates proteasomal degradation of C/EBPαp42 suggestive of ubiquitin involvement. This 
proteolytic relationship is a nexus in TRIB2-mediated AML disease. To date there are no published 
reports on TRIB2 and the subsequent ubiquitination status of C/EBPα. In this study in vivo 
ubiquitination assays offered the ability to assess the effect of TRIB2 function via mutational 
analysis on C/EBPα ubiquitination status. It was determined that TRIB2 overexpression mediated 
an increase in C/EBPαp42 ubiquitination. In order to unequivocally determine that TRIB2 mediates 
UPS degradation of C/EBPαp42 we immunoblotted for both the K48 and K63 polychain of 
ubiquitin. Immunoblotting for K48 proteasome degradation polychain of ubiquitin determined 
TRIB2-mediates an increase in K48 ubiquitination of C/EBPαp42, with no identifiable K63 
ubiquitination. K48 ubiquitination was identified as the sole type of ubiquitination mediated by 
TRIB2 through co-expression of ubiquitin mutant constructs which do not express the K48 
polychain of ubiquitin and do not express the K63 polychain of ubiquitin, K48R and K63R 
respectively. Expression of UB/K48R in the presence of TRIB2 was unable to mediate 
ubiquitination of C/EBPα, confirming TRIB2 meditates K48 ubiquitination of C/EBPαp42. 
Previously the E3 ligases FBXW7 and E6AP have been identified to directly bind C/EBPα 
mediating its ubiquitination, inhibiting both terminal adipocytic and granulocytic differentiation 
(Bengoechea-Alonso and Ericsson, 2010, Pal et al., 2013a, Pal et al., 2013b). In this study I 
determined that direct binding of TRIB2 and C/EBPα was essential for TRIB2-mediated proteolysis 
despite TRIB2 not possessing E3 functionality. Binding mutants C/EBPα-R339A and TRIB2-
S227A/S229A/S31A/K233A abrogated C/EBPαp42 ubiquitination. Previous reports elegantly 
determined that TRIB2 proteolytic effect was reliant on its ability to bind COP1 (Keeshan et al., 
2010). In order to confirm that COP1 is the bona fida E3 ligase responsible for C/EBPαp42 
ubiquitination in the presence of TRIB2 we assessed TRIB2-VPM ability to mediate ubiquitination 
of C/EBPαp42. TRIB2-VPM is unable to ubiquitinate C/EBPαp42. These data support the 
classification of TRIB2 as a adaptor or scaffold protein forming a multiprotein complex comprising 
of COP1:TRIB2:C/EBPα (Keeshan et al., 2006, Keeshan et al., 2010). Direct binding of TRIB2 and 
C/EBPα facilitates ubiquitin conjugation to C/EBPα through the action of the TRIB2 bound COP1. 
TRIB proteins have been proposed to function as both adaptor molecules and signalling modulators 
as they lack any discernible kinase activity (reviewed by (Lohan and Keeshan, 2013)). In this 
context TRIB2 provides a molecular platform, anchoring both C/EBPα and COP1. 
Lysines serve as the premier site of ubiquitin conjugation through thioester bond formation. To date 
there remains much debate regarding the identification of a lysine as an ubiquitination site based on 
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analysis of its surrounding amino acid environment. Zhou et al report an increase in hydrophobic 
and small residues, with a decrease in charged amino acids surrounding a ubiquitination site (Zhou 
et al., 2013). Kim et al report that there is a preference for an overall net negative charge 
surrounding the ubiquitination site and a disfavouritism toward arginines on the N-Terminal side 
and lysine and histidine on both sides (Kim et al., 2011). Radivojac et al concurred with Kim et al 
reporting an increase of polar charged amino acids especially negatively charged aspartic acid and 
glutamate, however disagreed with Kim et al reporting a depletion of hydrophobic residues 
isoleucine, leucine, phenylalanine and proline at ubiquitination sites (Radivojac et al., 2010). Using 
Ubpred online software the probability score of each lysine in C/EBPα to behave as an ubiquitin 
conjugation site was calculated based on knowledge of identified protein ubiquitination sites and 
their surrounding amino acids. Six potential ubiquitination sites were identified with medium-high 
probability scores. K90 and K92 were identified as lysines with medium probability scores of 
behaving as C/EBPα sites of ubiquitin conjugation. Interestingly these lysines are unique to the 
C/EBPαp42 isoform and were thought to perhaps provide a mechanism by which TRIB2 mediates 
degradation of C/EBPαp42 alone. However, investigation in the laboratory revealed K90R/K92R 
mutants are ubiquitinated similarly to WT-C/EBPα and therefore do not act as sites of 
ubiquitination (Personal communication, Dr. Karen Keeshan). Annotation of site K159 revealed it 
acts as a sumoylation site as it has been shown that C/EBPαp30 mediates increased sumoylation of 
C/EBPαp42 on K159 via Ubc9 (Geletu et al., 2007).  
Annotation of K313 revealed it is found mutated in ~ 10 % of mutated C/EBPα patient AMLs 
resulting in a duplication K313dup (Carnicer et al., 2008). Analysis of K313 surrounding amino 
acids sequence revealed it was neighboured by hydrophobic amino acids at n+1 n+2 and n+4 with 
polar glutamine present at n-1 and n-2, there was a disfavouritism for lysine, histidine and arginine 
with no surrounding charged amino acids (data not shown). In order to assess the role of K313 as 
an ubiquitin conjugation site in C/EBPα a K313R mutant was created and an in vivo ubiquitination 
assay was performed. TRIB2 was unable to mediate ubiquitination of C/EBPα-K313R thus 
identifying K313 as the potential ubiquitination site. C/EBPα-K313R was also ubiquitinated less 
than WT-C/EBPα in the absence of TRIB2 suggesting K313 may also govern homeostatic control 
of C/EBPα protein stability. The K313dup mutation results in an additional lysine beside a lysine 
which we suggest serves as an ubiquitination site, thus K313dup may result in enhanced 
ubiquitination of C/EBPα, increased degradation, resulting in a block in myeloid differentiation and 
AML. This hypothesis is supported by data indicating that K313dup protein is less stable than WT-
C/EBPα despite displaying higher expression levels (Carnicer et al., 2008). K313dup murine 
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knockin studies report induction of AML in 25 % of mice, the remaining 75 % developing 
leukaemia with erythroid involvement (Bereshchenko et al., 2009). K313dup mice displayed 
increased HSC expansion through an increase in cell proliferation and a decrease in genes 
associated with stem cell quiescence (Bereshchenko et al., 2009).  K313dup mice also lacked 
GMPs (Bereshchenko et al., 2009). Further studies involving C/EBPα-304-323dup, encompassing 
K313, reported this mutant blocked granulocytic differentiation and also gained self-renewal 
capacity (Kato et al., 2011). Analysis of cell marker expression revealed AML patients with 
K313dup mutation expressed CD7 a T-Cell marker (Carnicer et al., 2008). HSC expansion, 
decreased HSC quiescence, reduction in GMPs and increased CD7 expression have all been 
associated with C/EBPα null and K313dup genotypes (Zhang et al., 2004, Wouters et al., 2007, Ye 
et al., 2013). Investigation of K313dup in knockin murine models deciphering the role of C/EBPα 
in keratinocyte biology revealed, this lysine duplication increased keratinocyte proliferation, 
resulting in subsequent defects in cell commitment and differentiation and loss of the barrier 
function of epithelial cells (Lopez et al., 2009). K313dup mutation has been identified to abrogate 
C/EBPα ability to bind DNA and also to mediate E2F repression (Lopez et al., 2009). Thus the 
phenotypes observed in K313dup mice may be due to both the loss of C/EBPα transactivation 
capacity through its inability to bind DNA, loss of its ability to couple exit of the cell cycle with 
differentiation through loss of E2F repression and now I propose through reduced protein stability 
mediated by enhanced C/EBPα ubiquitination. Thus the identification of K313 as the site of 
ubiquitin conjugation on C/EBPα may provide further understanding into the molecular biology 
behind the phenotype of this K313dup mutation, in patient and murine AMLs.  
TRIB proteins retain a highly conserved kinase-like domain. As mentioned previously an intact 
kinase domain is essential for TRIB2 leukaemogenecity (Keeshan et al., 2010). Mutation of TRIB2 
to resemble a canonical kinase TRIB2-KDM was identified to abrogate TRIB2 differentiation 
inhibition and self-renewal enhancing effects as determined by differentiation assays and colony 
reforming assays (Keeshan et al., 2010). TRIB2-KDM lost the ability to mediate degradation of 
C/EBPα while still retaining the ability to bind COP1 (unpublished data and (Keeshan et al., 2010). 
In vivo ubiquitination assays performed using TRIB2-KDM confirmed this mutant is unable to 
mediate ubiquitination of C/EBPα and is also unable to generate increased C/EBPαp30 levels 
similar to WT-TRIB2. Thus these amino acids within subdomain VIB remain crucial for TRIB2 
functionality, their exact role in TRIB2 biology remains to be determined. Perhaps mutation may 
result in reduced affinity for C/EBPα through conformational changes to the 3D structure of 
TRIB2.  
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C/EBP proteins exist as homo or heterodimers mediated via their C-Terminal domain leucine 
zipper domains. C/EBP dimerisation was reported to stabilize C/EBPΥ and C/EBPδ proteins, 
reducing ubiquitination and subsequent proteasomal degradation (Hattori et al., 2003). C/EBPδ was 
identified to require an intact leucine zipper to facilitate its ubiquitination however this was 
inversely related to its protein stability, the increase in C/EBPδ ubiquitination upon dimerisation 
did not result in increased proteasomal degradation (Zhou and Dewille, 2007). C/EBPα 
functionality is also controlled through dimerisation, alteration in the ratio of C/EBPαp30 isoform 
results in C/EBPαp42:C/EBPαp30 heterodimers which abrogate WT-C/EBPαp42 function in 
haematopoiesis (Pabst et al., 2001b, Cleaves et al., 2004). Further investigation into the functional 
consequence of monomeric C/EBPα revealed C/EBPα-L12V was able to stall cell cycle at G1 
similar to WT-C/EBPα however it was unable to promote granulocytic differentiation (Wang et al., 
2003, Liu et al., 2003). To our knowledge there have been no reports to date assessing the stability 
of monomeric C/EBPαp42. Here we report monomeric C/EBPαp42 is ubiquitinated similarly to 
dimeric C/EBPαp42. Thus it appears in the experimental context studied dimerisation does not 
greatly increase C/EBPα stability unlike its family members C/EBPΥ and C/EBPδ. TRIB2 was 
previously identified to bind both monomeric and dimeric C/EBPαp42 however I observe it 
preferentially mediates increased ubiquitination of dimeric C/EBPαp42. While there is an increase 
in C/EBPα-L12V ubiquitination in the presence of TRIB2 it is not equivalent to its effect on 
dimeric C/EBPαp42. Increased monomeric stability in the presence of TRIB2 was further 
confirmed by cycloheximide treatment. Cycloheximide treatment inhibits de novo protein synthesis 
thus allowing assessment of protein stability over time. Despite TRIB2 protein possessing a shorter 
half life that C/EBPαp42, expression of TRIB2 reduced WT-C/EBPαp42 protein stability compared 
to previously published reports documenting WT-C/EBPαp42 half life (Carnicer et al., 2008). 
Comparison of WT-C/EBPαp42 and C/EBPα-L12V protein stability revealed C/EBPα-L12V had 
increased stability compared to WT-C/EBPαp42 in TRIB2 expressing cells. Together these data 
strongly suggest TRIB2 preferentially mediates ubiquitination and proteasomal degradation of 
dimeric C/EBPαp42 despite possessing the ability to bind both monomeric and dimeric forms. This 
preference for dimeric degradation may be due to differential localisation of monomeric and 
dimeric C/EBPαp42 as it has been reported that differences in C/EBPα dimer structure exists 
between regions of euchromatin and heterochromatin in the nucleus (Schaufele et al., 2003). 
Similarly monomeric and dimeric C/EBPα may each occupy a distinct location within the cell. 
Alternatively I hypothesize dimeric C/EBPα may be structurally permissive for increased TRIB2-
mediated ubiquitination. 
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The data presented herein reports TRIB2-mediates K48 specific ubiquitination of C/EBPα via 
interaction with the E3 ligase COP1 and preferentially ubiquitinating dimeric C/EBPα. Elucidation 
of the molecular features of the TRIB2:C/EBPα interaction reveal direct TRIB2 and C/EBPα 
binding are required for ubiquitination and K313 within C/EBPα C-Terminus serves as the site of 
ubiquitin conjugation. These data indicate that inhibition of the proteolytic effect of TRIB2 on 
C/EBPαp42 would provide a good therapeutic target and suggest that proteasomal inhibition may 
provide a novel target approach to treat high TRIB2 disease and cases of mutC/EBPα-K313dup 
AML (investigated in chapter 6). 
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Chapter 5: Results 
TRIB2 preferentially binds phosphorylated Ser21-C/EBPα mediating 
ubiquitin-dependent proteasomal degradation 
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5.1 Introduction 
“Phosphorylation of a protein can alter its behaviour in almost every conceivable way (Cohen, 
2000).” Phosphorylation events may alter the 3D conformation of a protein, its subcellular 
localisation, protein half life, docking partners, ultimately changing the function of the protein. 
Phosphorylation may occur at multiple sites on a protein providing multiple pathways with the 
ability to regulate substrate protein function and often these multisite phosphorylation events have 
antagonistic effects on protein function (reviewed by (Cohen, 2002). Phosphorylation involves the 
reversible transfer of a phosphate group (PO4
3-
) from ATP to the hydroxyl group of the eukaryotic 
amino acids serine, threonine, tyrosine, lysine, arginine, aspartic acid/glutamate and cysteine. 
Phosphorylation mediated regulation of C/EBPα protein function has been widely studied 
particularly in the context of haematological malignancies due to the crucial role of C/EBPα in 
regulating myeloid differentiation (Zhang et al., 2004). C/EBPα to date has several identified 
phosphorylation sites serine Ser21, Ser193, Thr222/226, Ser230, Ser248, Ser266 and Ser277 each 
with their own function, kinases’ and predisposition toward occurrence in different tissues (Ross et 
al., 1999, Behre et al., 2002, Ross et al., 2004, Wang et al., 2004, Wu et al., 2013). This study will 
focus primarily on Ser21 and Thr222/226. Fig 5.1.1 summarises the C/EBPα phosphorylation 
events. 
 
5.1.1 Schematic summarising localisation, kinases and biological consequences of C/EBPα 
phosphorylation events.  
145 
 
To date phosphorylation of C/EBPα at Ser21 in haematopoietic cells is the most widely studied 
C/EBPα phosphorylation event, however a dichotomy exists regarding the effect of P-Ser21-
C/EBPα on its ability to regulate myeloid differentiation. Phosphorylation of C/EBPα at Ser21 by 
ERK1/2 was identified to change the dimer conformation of C/EBPα, separating the N-Terminal 
transactivation domains (Ross et al., 2004). This change in dimer conformation however did not 
alter the ability of C/EBPα to bind DNA at its target myeloid gene promoter binding sites (Ross et 
al., 2004, Fragliasso et al., 2012). Ross et al report expression of a phosphomimetic of C/EBPα at 
Ser21 (S21D) inhibits C/EBPα-mediated differentiation of K562 cell line measured by morphology, 
NBT reduction and expression of terminal differentiation gene targets G-CSFR and C/EBPε (Ross 
et al., 2004). Both WT and S21A-C/EBPα were able to mediate K562 granulocytic differentiation. 
Overexpression of S21D in U937 myeloid cell line treated with RA also blocked differentiation 
while WT and S21A-C/EBPα RA treated cells underwent granulocytic differentiation (Ross et al., 
2004). In addition, increased P-Ser21-C/EBPα was identified downstream of FLT3 mutations 
(Radomska et al., 2006). FLT3-ITD results in a constitutively active receptor which blocks 
differentiation, increases P-ERK1/2 with a resultant increase in P-Ser21-C/EBPα (Radomska et al., 
2006). FLT3-ITD and P-ERK1/2 pharmacological inhibition mediated the differentiation of AML 
cells via decreased P-Ser21 levels, corroborating the differentiation inhibitory role of P-Ser21 
reported by Ross et al (Radomska et al., 2006). Additionally, overexpression of S21A in FLT3-ITD 
mutant AML cells showed that it could relieve the differentiation block as it is unable to be 
phosphorylated (Radomska et al., 2006). The dichotomy exists where Fragliasso et al reported 
overexpression of S21D and S21A minimally effects C/EBPα-induced differentiation of K562 
cells. In fact they report that S21A exhibits a greater inhibitory effect on induction of granulocytic 
differentiation than S21D (Fragliasso et al., 2012). Both S21D and S21A displayed 
indistinguishable G-CSFR promoter binding from WT-C/EBPα (Fragliasso et al., 2012).  
C/EBPα induced differentiation is not only mediated by its ability to transactivate expression of 
genes necessary for terminal differentiation but also through its ability to inhibit cell proliferation, 
as a pause in the cell cycle permits cellular differentiation. C/EBPα stalls the cell cycle via 
inhibition of E2F, CDK2/4 and also through upregulation of p21 (Timchenko et al., 1996, Slomiany 
et al., 2000, Wang et al., 2001). Overexpression of S21A, which was identified to rescue the FLT3-
ITD differentiation block, coincided with a huge decrease in C-MYC mRNA, an E2F transcriptional 
target suppressed upon inhibition of the cell cycle (Johansen et al., 2001, Radomska et al., 2006). 
Overexpression of S21D which was unable to rescue differentiation did not decrease C-MYC 
mRNA levels (Radomska et al., 2006). However in this study it was not investigated if the 
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differential effects on C-MYC mRNA were as of a direct result of differential S21D and S21A 
inhibition of E2F. Fragliasso et al investigated S21D and S21A inhibition of an E2F driven 
promoter and determined S21D inhibited E2F to a lesser extent than WT-C/EBPα and also 
displayed reduced binding to both E2F2 and E2F3. However S21A which displayed similar E2F 
inhibitory effects to WT-C/EBPα displayed increased E2F3 binding (Fragliasso et al., 2012). Thus 
despite the discrepancies between the studies perhaps the S21D inhibitory effects observed by Ross 
et al may be explained by the reduction in E2F binding observed by Franliasso et al. Ultimately the 
three studies hypothesised the existence of phosphorylation specific interacting partners, which are 
responsible for exerting the differential effects of phosphorylated and unphosphorylated C/EBPα.  
Phosphorylation of C/EBPα at Thr222/226 was also identified to exert an effect on haematopoiesis 
through skewing granulocyte lineage commitment (Buitenhuis et al., 2008). Inhibition of PI3K and 
of its downstream effector PKB results in a block in neutrophil differentiation with an increase in 
eosinophil differentiation in human CD34
+
 BM cells (Buitenhuis et al., 2008). PKB is thought to 
regulate lineage commitment through inactivation of GSK3 which was previously identified to 
phosphorylate C/EBPα at Thr222/226 (Ross et al., 1999, Buitenhuis et al., 2008). When C/EBPα is 
unphosphorylated at Thr222/226 it promotes neutrophil differentiation however inactivation of 
PKB results in active GSK3 mediating P-Thr222/226-C/EBPα and blocks neutrophil differentiation 
with a concomitant increase in eosinophils observed. It is postulated that the differences observed 
in differentiation outcomes are mediated by co-factor associations with phosphorylated and 
unphosphorylated C/EBPα at Thr222/226 (Buitenhuis et al., 2008). P-Thr222/226 C/EBPα was first 
identified as a GSK3 phosphorylation site in adipocytes, and pharmacological GSK3 inhibition 
decreased P-Thr222/226-C/EBPα and inhibited preadipocytic differentiation (Ross et al., 1999). 
Phosphorylation of C/EBPα at Thr222/226 was identified to change the structural confirmation of 
C/EBPα similarly to phosphorylation at Ser21 (Ross et al., 1999, Ross et al., 2004). P-Thr222/226-
C/EBPα in hepatocytes was reported to not effect C/EBPα functionality, thus suggesting functional 
effects of P-Thr222/226 are cell type specific (Liu et al., 2006). 
A crosstalk between phosphorylation and ubiquitination often results in phosphorylation acting as 
an ubiquitination trigger (reviewed by (Hunter, 2007)). Phosphorylation of a protein may facilitate 
ubiquitination by multiple mechanisms; regulation of E3 ligase activity, regulation of 
substrate/ligase complexes through alteration of subcellular localisation or through the creation of 
phosphodegron motifs which are recognised by E3 ligases (reviewed by (Hunter, 2007)). 
Phosphorylation of C/EBPα has been reported to affect both its half life through creation of a 
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phosphodegron and its nuclear and subcellular localisations (Schaufele et al., 2003, Bengoechea-
Alonso and Ericsson, 2010).  
PKCδ activation results in ubiquitin-dependent proteasomal degradation of C/EBPα in leukaemic 
cells, in response to induction of apoptosis as a result of DNA damage (Zhao et al., 2009). PKCδ 
was identified to mediate phosphorylation of C/EBPα at 3 sites (Ser21, Ser266 and Ser277) 
however this was not due to direct PKCδ and C/EBPα binding (Zhao et al., 2009, Wu et al., 2013). 
Activation of PKCδ increased phosphorylation of C/EBPα and cytoplasmically sequestered 
C/EBPα resulting in its ubiquitination and proteasomal degradation (Zhao et al., 2009, Wu et al., 
2013). Phosphorylation of C/EBPα at Thr222/226 also serves to increase C/EBPα ubiquitination. P-
Thr222/226 creates a phosphodegron motif recognised by the E3 ligase FBXW7 mediating 
ubiquitination and proteasomal degradation of C/EBPα in adipocytes (Bengoechea-Alonso and 
Ericsson, 2010). In contrast phosphorylation of C/EBPα by JNK1 was identified to decrease levels 
of ubiquitinated C/EBPα and to increase C/EBPα protein half life (Trivedi et al., 2006).  
This brief summary on the phosphorylation of C/EBPα at Ser21 and Thr222/226 highlights the 
complexity of the functional effect of this post-translational modification on C/EBPα function. 
Phosphorylation of C/EBPα at Ser21 by ERK1/2 is reported to both inhibit and not effect 
granulocytic differentiation and exert preferences on interacting protein partners (Ross et al., 2004, 
Radomska et al., 2006, Fragliasso et al., 2012, Koleva et al., 2012). P-Thr222/226 is reported to 
skew granulocytic differentiation toward increased eosinophils at the cost of neutrophils while P-
Thr222/226-C/EBPα is an E3 ligase target mediating C/EBPα ubiquitination in adipocytes 
(Buitenhuis et al., 2008, Ross et al., 1999, Bengoechea-Alonso and Ericsson, 2010). Thus it appears 
the phosphorylation site of C/EBPα and the cell context all have different effects on C/EBPα 
protein function. 
Aim 
The aim of this study was to determine the effect of TRIB2 expression on C/EBPα phosphorylation 
and to investigate any crosstalk between TRIB2-mediated ubiquitination and C/EBPα 
phosphorylation. I show that TRIB2-mediated a decrease in C/EBPα phosphorylation at Ser21 and 
Thr222/226. TRIB2 mediates increased ubiquitination of the C/EBPα S21D phosphomimetic 
construct. Additionally TRIB2 was identified to preferentially bind S21D compared to the 
unphosphorylatible C/EBPα construct S21A. Thus I propose phosphorylation of C/EBPα at Ser21 
results in increased TRIB2 binding and ubiquitin-dependent proteasomal degradation. Retroviral 
overexpression of TRIB2 in U937 leukaemic cells was performed to assess the effect on 
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endogenous C/EBPα phosphorylation. Overexpression in vivo ubiquitination and co-IP assays were 
performed to determine TRIB2 effect on C/EBPα phosphomimetic ubiquitination and preference 
for protein binding.   
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Result 5.2.1 TRIB2 overexpression decreases P-Ser21 and P-Thr222/226 C/EBPα 
in U937 cells 
In order to determine the effect TRIB2 overexpression may have on the phosphorylation profile of 
C/EBPα and to optimise endogenous phosphorylated C/EBPα protein detection, the U937 cell line 
was transduced with MigR1-TRIB2-eGFP and MigR1-eGFP empty vector control. U937 cells are a 
promyelomonocytic cell line which express both TRIB2 and C/EBPα that can be readily detected at 
the protein level (Rishi et al., 2014). Viral transduction of U937 with TRIB2 recapitulates the 
cellular environment of high TRIB2 AML cell, enabling investigation of the effects of 
overexpressed TRIB2 on endogenous C/EBPα (Keeshan et al., 2006). Validation of TRIB2 
overexpression from these retroviral vectors has been previously published (Keeshan et al., 2006). 
In order to robustly assess growth factor induced phosphorylations in the presence and absence of 
TRIB2, U937 cells transduced and sorted for GFP positive population (48 hrs post transduction) 
were serum starved overnight in 1 % FBS followed by stimulation for 30 min with 20 % FBS. 
Direct lysates were collected and separated by SDS page to assess C/EBPα status. Stimulation 
following serum starvation was performed as it increases the levels of phosphorylated C/EBPα 
(Ross et al., 2004), thus if TRIB2-mediated an effect on phosphorylation levels it would be more 
evident. To date several C/EBPα phosphorylation sites have been identified however at the time of 
experimentation there were only antibodies commercially available recognising P-Ser21 and P-
Thr222/226. Lysates were immunoblotted for anti P-Ser21 and anti P-Thr222/226, the membrane 
was stripped and incubated with anti C/EBPα antibody to detect total C/EBPα protein levels. Serum 
stimulation increased the levels of phosphorylated C/EBPα at both phosphorylation sites as is 
evident for the MigR1 transduced cells (Fig 5.2.1 compare lane 1 and lane 3). Overexpression of 
TRIB2 decreased the levels of phosphorylated C/EBPα in the presence and absence of stimulation 
(Fig 5.2.1 lane 2 and lane 4). TRIB2 overexpression also decreased the levels of C/EBPαp42 as 
expected (Fig 5.2.1 lane 2 and lane 4). A non specific band frequently detected with anti C/EBPα 
antibody at ~75 kDa served as the protein loading control to confirm equal protein loading (Fig 
5.2.1). Thus the decrease in phosphorylated C/EBPα observed may be due to the decrease in total 
C/EBPα protein levels. These data show that TRIB2 promotes degradation of both the 
phosphorylated and total C/EBPα protein levels. 
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Fig 5.2.1 TRIB2 overexpression decreases P-Ser21 and P-Thr222/226 C/EBPα levels in U937 
cells. U937 cells were transduced with MigR1-TRIB2-eGFP and MigR1-eGFP, 48 hrs post 
transduction the cells were sorted for GFP positive population. Cells were serum starved overnight 
in 1 % FBS stimulated with 20 % FBS for 30 min. Direct lysates were collected, separated by SDS 
page and immunoblotted for anti P-Thr222/226 and anti P-Ser21. The membranes were stripped 
and incubated with anti C/EBPα. A nonspecific band detected by anti C/EBPα confirmed equal 
protein loading. Data presented is representative of two independent transfection experiments. 
  
     1              2          3            4 
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Result 5.2.2 Proteasomal inhibition rescues the TRIB2-mediated decrease of P-
Ser21 C/EBPα in U937 cells 
In order to determine if the decrease in phosphorylated C/EBPα observed was due to a signalling 
effect mediated by TRIB2 or due to proteasomal degradation, U937 cells transduced with TRIB2 
and MigR1 were treated with two different proteasomal inhibitors, MG-132 and 
Bortezomib/Velclade ™. Due to the documented role of P-Ser21-C/EBPα in blocking 
granulopoiesis I focused solely on this phosphorylation site for the rest of the study (Ross et al., 
2004, Radomska et al., 2006). TPA was used to stimulate an increase in P-Ser21-C/EBPα level as 
previously reported (Ross et al., 1999). U937 cells were serum staved in 1 % FBS overnight, treated 
with 10 μM MG-132 for 6 hrs and stimulated with 200 nM TPA for 30 mins. Direct lysates were 
collected and immunoblotted for P-Ser21. TPA stimulation increased P-Ser21 levels in control 
MigR1 cells as is evident in lane 3 compared to lane 1 (Fig 5.2.2 A). As expected, MG-132 
treatment rescued C/EBPα total levels in TRIB2 expressing cells. P-Ser21 levels are equivocal in 
both MigR1 and TRIB2 transduced U937 cells in the absence and presence of TPA induced 
stimulation indicating MG-132 treatment rescues TRIB2-mediated proteasomal degradation of P-
Ser21 (Fig 5.2.2 A). Furthermore, it indicates that TRIB2 does not abrogate the signalling 
mediated-induction of C/EBPα phosphorylation.  
In the absence of proteasomal inhibition TRIB2 decreased the levels of both P-Ser21-C/EBPα and 
total C/EBPα protein levels as seen in Fig 5.2.1. In order to validate proteasomal inhibition 
rescuing TRIB2-mediated decrease in P-Ser21-C/EBPα, cells were treated with a second 
proteasomal inhibitor Bortezomib. Upon treatment with Bortezomib in the absence of growth 
stimulation both P-Ser21-C/EBPα and total C/EBPα levels increased to MigR1 control cells level. 
Thus proteasomal inhibition abrogated the TRIB2-mediated decrease in P-Ser21-C/EBPα (Fig 5.2.2 
B). These data indicate that TRIB2-mediated decrease in P-Ser21-C/EBPα is proteasomal 
degradation dependent and not due to an alteration in cell signalling cascades perpetuated by 
TRIB2. 
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Fig 5.2.2 Proteasomal inhibition rescues TRIB2-mediated decrease in P-Ser21-C/EBPα. U937 
cells were transduced with MigR1-TRIB2-eGFP and MigR1-eGFP, 48 hrs post transduction the 
cells were sorted for GFP positive population. A) Cells were treated with 10 μM MG-132 for 6 hrs 
and stimulated with 200 nM TPA. Direct lysates were collected, separated by SDS page and 
immunoblotted for anti P-Ser21-C/EBPα. T-ERK1/2 served as loading control. B) Cells were 
treated with 10 nM Bortezomib for 6 hrs. Direct lysates were collected, separated by SDS page, 
immunoblotted for anti P-Ser21-C/EBPα the membrane were stripped and then incubated with anti-
C/EBPα.  
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Result 5.2.3 Expression of C/EBPα phosphomimetic mutants S21D and S21A 
In order to investigate the binding and ubiquitination relationship between TRIB2 and P-Ser21-
C/EBPα expression vectors were used that expressed the mutated forms of P-Ser21. pcDNA3.1-
C/EBPα-S21D and pcDNA3.1-C/EBPα-S21A were a kind gift from Dr. D. Tenen (Harvard 
Medical School) and previously published (Ross et al., 2004). Mutation of Ser21 to aspartic acid 
(S21D) produces a chemically similar substitution to a phosphorylated serine resulting in a 
constitutive phosphorylation signal, while mutation of Ser21 to alanine (S21A) results in abrogation 
of phosphorylation as alanine lacks –OH group necessary for phosphate transfer. Expression of 
S21D and S21A were analysed by transfection of HEK293t cells. Lysates were immunoblotted with 
anti P-Ser21, the membrane was stripped and immunoblotted with anti C/EBPα to detect total 
protein levels. As expected, P-Ser21 is strongly detected in cells transfected to express WT-C/EBPα 
and S21D while there is no detection of P-Ser21-C/EBPα in cells transfected with S21A (Fig 5.2.3 
top panel). Immunoblotting with anti C/EBPα against total C/EBPα confirms equivocal expression 
of total C/EBPα from S21D, S21A and WT-C/EBPα vectors (Fig 5.2.3 bottom panel). WT-C/EBPα 
runs at a slightly higher molecular weight as it is expressed from a different expression vector, 
PHMA. Thus these constructs may be used to model the interaction of TRIB2 with phosphorylated 
and unphosphorylated C/EBPα at Ser21.  
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Fig 5.2.3 Expression of WT-C/EBPα, S21D and S21A in HEK293t. HEK293t cells were 
transfected to overexpress WT-C/EBPα, S21D-C/EBPα and S21A-C/EBPα. Cells were lysed, 
separated by SDS PAGE immunoblotted for anti P-Ser21-C/EBPα and anti C/EBPα. 
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Result 5.2.4 TRIB2-VPM preferentially binds S21D-C/EBPα in HEK293t cells  
Several C/EBPα interacting proteins have been identified to preferentially interact with either the 
phosphorylated or unphosphorylated form of C/EBPα (Fragliasso et al., 2012, Koleva et al., 2012). 
This preference supports differential functions of phosphorylated and unphosphorylated C/EBPα. In 
order to determine if TRIB2 displays a preference for either phosphorylated or unphosphorylated 
C/EBPα, a co-IP was performed using C/EBPα mutants S21D and S21A (Ross et al., 2004). 
TRIB2-VPM-MYC was expressed in HEK293t cells as it is unable to degrade C/EBPα negating the 
use of MG-132. HEK293t cells were transfected to overexpress TRIB2-VPM-MYC in the presence 
of WT-C/EBPα, S21D-C/EBPα and S21A-C/EBPα. Untransfected cells served as the control. 
Twenty four hrs post-transfection cells were lysed and TRIB2 was immunoprecipitated overnight 
using an anti MYC tag antibody. Immunoblotting for C/EBPα revealed TRIB2 preferentially bound 
S21D as compared to WT-C/EBPα, whereas reduced binding to S21A-C/EBPα was observed. 
Equal immunoprecipitation was confirmed by immunoblotting for anti MYC expression as readout 
of TRIB2-VPM expression (Fig 5.2.4 top panel). Protein input lysates were immunoblotted for 
TRIB2 and C/EBPα confirming protein expression while β-Tubulin confirmed equal protein 
loading (Fig 5.2.4 bottom panel). Thus TRIB2 preferentially binds C/EBPα when phosphorylated at 
Ser21, while it could still bind unphosphorylated C/EBPα albeit at reduced levels.  
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Fig 5.2.4 TRIB2-VPM preferentially binds S21D over S21A. HEK293t cells were transfected to 
overexpress TRIB2-VPM-MYC, WT-C/EBPα, S21D-C/EBPα, S21A-C/EBPα. MYC was 
immunoprecipitated overnight; lysates were separated by 12 % SDS-PAGE and immunoblotted 
with anti C/EBPα and anti MYC (top panel). Protein inputs lysates were immunoblotted with anti 
C/EBPα, anti TRIB2 and anti β-Tubulin (bottom panel). Data presented is representative of three 
independent transfection experiments. Performed with the assistance of Mara Salome. 
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Result 5.2.5 TRIB2 preferentially ubiquitinates S21D-C/EBPa 
TRIB2 displayed preferential binding to S21D-C/EBPα thus in order to determine if TRIB2 
increased binding resulted in increased ubiquitination, an in vivo ubiquitination assay was 
performed. HEK293t cells were transfected to overexpress Ub-HA, TRIB2, WT-C/EBPα, S21D-
C/EBPα and S21A-C/EBPα and treated with 10 μM MG-132 for 5 hrs. Following 
immunoprecipitation of C/EBPα, lysates were immunoblotted for K48. As expected TRIB2-
mediated an increase in K48 ubiquitination of WT-C/EBPα (Fig 5.2.5 lane 2 compared to lane 5 
top panel). TRIB2 also mediated an increase in S21D-C/EBPα ubiquitination (Fig 5.2.5 lane 3 
compared to lane 6, top panel). However TRIB2 did not mediate increased ubiquitination of S21A-
C/EBPα (Fig 5.2.5 lane 4 compared to lane 7). These results show that TRIB2 preferentially 
ubiquitinates P-Ser21-C/EBPα. 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
 
Fig 5.2.5 TRIB2 mediates increased ubiquitination of S21D. HEK293t cells were transfected to 
overexpress Ub-HA, WT-TRIB2, WT-C/EBPα S21D-C/EBPα, S21A-C/EBPα and PHMA the 
empty vector control. Cells were treated with 10 μM MG-132 5 hrs prior to lysis. C/EBPα was 
immunoprecipitated and an in vivo ubiquitination assay was performed. Lysates were separated by 
SDS-PAGE and immunoblotted for anti K48 ubiquitin. Immunoblotting protein inputs for C/EBPα 
confirm input protein expression, while a high molecular weight nonspecific detected with C/EBPα 
antibody serves as a loading control (bottom panel). Data presented is representative of three 
independent transfection experiments. 
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5.3 Discussion 
In this study I report TRIB2-mediates ubiquitin-dependent proteasomal degradation of P-Ser21-
C/EBPα through preferentially binding the phosphorylated protein. This degradation may be 
relieved through treatment with proteasomal inhibitors Bortezomib and MG-132. 
TRIB2 is a pseudokinase and while retaining certain kinase-like features (as discussed in Chapter 
3), it does not possess the ability to transfer phosphate groups. In the context of TRIB2-mediated 
AML, we propose that TRIB2 is functioning as an adaptor protein facilitating the formation of a 
COP1:TRIB2:C/EBPα multiprotein complex ultimately resulting in C/EBPα ubiquitin-dependent 
proteasomal degradation. However in other cellular contexts TRIB proteins have been described as 
signalling modulators and decoy kinases. TRIB1 and TRIB3 up and downregulate MAPK 
signalling cascades (Kiss-Toth et al., 2004). Knockdown of TRIB2 results in decreased JNK and 
p38 signalling (Wei et al., 2012). TRIB1 leukaemogenicity and degradation of C/EBPα is reported 
to be P-ERK1/2 dependent (Yokoyama et al., 2010). Interestingly TRIB1 overexpression increases 
P-ERK1/2 signalling with no accompanying increase P-Ser21-C/EBPα despite Ser21-C/EBPα 
reported to be a P-ERK1/2 phosphorylation site (Ross et al., 2004, Yokoyama et al., 2010, 
Yokoyama et al., 2012). However some innate differences exist between TRIB1 and TRIB2-
mediated degradation of C/EBPα, as TRIB2 was reported to have no effect on P-ERK1/2 signalling 
in the context of both haematological cells and overexpression in HEK239t cells (Dedhia et al., 
2010, Wei et al., 2012). I observed a TRIB2-mediated decrease in P-Ser21-C/EBPα in myeloid 
cells, however this was due to increased ubiquitination and degradation of the P-Ser21-C/EBPα 
protein. Treatment with both proteasomal inhibitors Bortezomib and MG-132 rescued P-Ser21-
C/EBPα levels in the presence of TRIB2.  
Phosphorylation events are known to alter protein subcellular localisation (Cohen, 2000). 
Phosphorylation of C/EBPα by PKCδ at Ser21, Ser266 and Ser277 was identified to result in 
C/EBPα cytoplasmic translocation and ubiquitin-dependent proteasomal degradation (Zhao et al., 
2009, Wu et al., 2013). In the context of TRIB2 overexpression C/EBPα localisation does not 
change. TRIB2 and C/EBPα co-localise within the nucleus of HeLa cells as determined by 
immunofluorescence and analysis of nuclear and cytoplasmic protein fractions (Ciaran Forde, 
unpublished data, Appendix 8.6). Thus while TRIB2 does effect C/EBPα ability to bind DNA, this 
I believe is not as a result of TRIB2-mediating cytoplasmic sequestering of C/EBPα (Keeshan et al., 
2006). Rather TRIB2 binds C/EBPα at R339 which lies within its DNA binding domain, disrupting 
DNA binding. Therefore the results indicate that the increased ubiquitination of S21D-C/EBPα 
mediated by TRIB2 is as a direct result of increased binding and ubiquitination and not as a result 
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of C/EBPα mislocalisation within the cell. Additionally leukaemic proteasomes were identified to 
be abnormally highly expressed compared to normal mononuclear cells (Kumatori et al., 1990). 
Leukaemic proteasomes are localised within the nucleus unlike cytoplasmic localisation in normal 
cells (Kumatori et al., 1990). Thus the abundance of nuclear leukaemic proteasomes facilitates 
TRIB2-mediated proteasomal degradation of C/EBPαp42. 
When first identified by Ross et al both phosphorylation events P-Ser21 and P-Thr222/226 were 
identified to alter the 3D conformation of C/EBPα as determined by FRET, tryptic digestion and 
SDS-PAGE analysis (Ross et al., 1999, Ross et al., 2004). C/EBPα exists as a dimer and 
phosphorylation results in an increase in spatial separation between the N-Termini of the individual 
monomers (Ross et al., 2004). Stimulation with phorbol 12-myristate 13-acetate (PMA) also 
induced a conformational change in C/EBPα dimers (Schaufele et al., 2003). C/EBPα dimers were 
identified to cluster at pericentric heterochromatic nuclear regions. Stimulation with PMA resulted 
in a torsional rotation of the transactivation domains away from each other, similar to the effect 
reported by Ross et al upon phosphorylation of P-Ser21, probably owing to the PMA mediated 
phosphorylation of C/EBPα at Ser21 (Schaufele et al., 2003, Ross et al., 2004). In this study I 
propose that phosphorylation of C/EBPα at Ser21 results in a permissive C/EBPα dimer 
confirmation change, structurally favouring increased TRIB2 binding at R339. TRIB2 binding 
results in COP1 mediated conjugation of ubiquitin at K313 resulting in proteasomal degradation. 
Validation of the dynamics of this protein interaction awaits the deciphering of TRIB2 and C/EBPα 
crystallised structures. 
Murine studies investigating the leukaemogenicity of P-Ser21-C/EBPα revealed it does not possess 
the ability to induce leukaemic disease (Unpublished data, personal communication Dr. D. Tenen, 
Harvard Medical School). Reports from Ross et al and Ramdoska et al show the ability of P-Ser21-
C/EBPα to block granulopoiesis but suggest it may be co-factor dependent, or that another genetic 
hit or signalling disturbance is required for the final transformation (Ross et al., 2004, Radomska et 
al., 2006). Here I reported preferential binding of TRIB2 to P-Ser21-C/EBPα leading to its 
ubiquitin-dependent proteasomal degradation. Much investigation remains to be done in order to 
further elucidate the differential functions of P-Ser21 and unphosphorylated Ser21-C/EBPα. 
Perhaps different phosphorylation patterns of C/EBPα occur throughout haematopoiesis mediating 
differential regulation of C/EBPα target gene expression. While it has been reported that there is no 
difference in DNA binding capabilities of P-Ser21 and unphosphorylated Ser21-C/EBPα these 
analyses were confined to investigation of terminal granulocytic C/EBPε and G-CSFR promoter 
regions (Ross et al., 2004, Radomska et al., 2006, Fragliasso et al., 2012, Koleva et al., 2012). P-
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Thr222/226-C/EBPα has been reported to skew neutrophil differentiation toward eosinophil 
differentiation and P-Ser21-C/EBPα promotes monocytic differentiation at the expense of terminal 
granulocytic differentiation (Ross et al., 2004, Buitenhuis et al., 2008). Thus it may be hypothesised 
that phosphorylated C/EBPα may have different effects in regulating HSC self-renewal, erythroid 
gene expression and myeloid differentiation through its differential association with co-factors. 
Experimental investigation of early myelo/erythroid and lymphoid progenitor cells may identify 
different patterns of C/EBPα phosphorylation governing lineage fate decisions through differential 
association with interacting protein partners and transcriptional activation of lineage governing 
genes.  
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Chapter 6: Results 
Leukaemic cells expressing high levels of TRIB2 displayed increased 
sensitivity to Bortezomib induced cytotoxicity 
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6.1 Introduction 
Bortezomib/Velcade is a first class boronic dipeptide compound (C19H25BN4O4) which reversibly 
and selectively inhibits the proteasome. It binds a threonine residue within the 26Sl subunit of the 
proteasome inhibiting its chymotryptic activity necessary for controlled target protein degradation 
(Bonvini et al., 2007). Bortezomib received FDA approved for treatment of relapsed and refractory 
multiple myeloma and mantle cell lymphoma in 2003(Aghajanian et al., 2002, Richardson et al., 
2003, Jagannath et al., 2004, Orlowski et al., 2005, Kane et al., 2007). Bortezomib has also been 
trialed as an acute leukaemia therapeutic, used both as a single agent and in combination with AML 
induction chemotherapy in order to determine its efficacy in phase I and phase II clinical trials 
(Cortes et al., 2004, Orlowski et al., 2005, Attar et al., 2005, Attar et al., 2013, Sarlo et al., 2013). 
Modest anti-leukaemic activity was observed as a single agent treatment (Cortes et al., 2004). 
However encouraging and complete remission responses were reported when Bortezomib treatment 
was combined with standard AML induction therapy (Attar et al., 2005, Attar et al., 2013). CD74 
has been identified as a poor prognosis marker for AML patients (Attar et al., 2008). CD74 
expression on AML blast cells is proposed to serve as a novel biomarker capable of identifying 
patients associated with complete remission in response to Bortezomib treatment in combination 
with induction therapy (Attar et al., 2008, Attar et al., 2013). Despite promising results involving 
incorporation of Bortezomib into AML treatment regimes little is yet known about its mechanism 
of action at the molecular cell level. 
Investigations into the apoptosis inducing effects of Bortezomib suggest it mediates cytotoxicity by 
a variety of mechanisms. Inhibition of proteasomal mediated degradation ultimately results in an 
accumulation of K48 ubiquitin linked proteins. This acquired abundance of defective, misfolded 
and unwanted proteins results in ER stress, triggering autophagy and apoptosis (Obeng et al., 2006). 
Bortezomib treatment also stabilizes the expression of pro-apoptotic protein p53 while decreasing 
the expression of anti-apoptotic proteins c-FLIP and XIAP (Pei et al., 2003, Poulaki et al., 2007, 
Riccioni et al., 2007, Dijk et al., 2011). Bortezomib treatment stabilises cell cycle regulators p21 
and p27 inhibiting cell cycle progression and inhibits NFκB activation by stabilising IκB inhibitor 
levels (Bonvini et al., 2007, Colado et al., 2008). Aberrant NFκB signalling is prevalent in AML, 
particularly in the leukaemic stem cell and often observed in chemotherapeutic resistance AML 
(Guzman et al., 2001, Guzman et al., 2002). Apoptotic induction through proteasomal inhibition is 
ultimately dependent on cell proteasome expression levels. Malignant haematopoietic cell lines and 
primary leukaemic samples were identified to have very large number of proteasomes compared to 
normal peripheral blood mononuclear cells and hence display high sensitivity to proteasomal 
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inhibition induced cell death (Kumatori et al., 1990, Dijk et al., 2011). However, variation in 
sensitivities of AML cell lines and primary patient responses have been reported (Colado et al., 
2008, Matondo et al., 2010, Dijk et al., 2011). This difference in malignant haematopoietic cell 
response has been attributed to proteasome activity levels, proteasome subunit expression levels, 
mutation of Bortezomib binding pocket and FAB leukaemic subtypes (Riccioni et al., 2007, 
Matondo et al., 2010, Dijk et al., 2011, Fang et al., 2012).  
The 26S proteasome is composed of the 20S catalytic subunit and the 19S or the 11s regulatory 
subunits. The 20S subunit possesses three different types of catalytic activity; chymotrypsin-like, 
trypsin–like and peptidyl-glutamyl peptide hydrolyzing like activity, provided by the subunits β5 
(PSMB5), β2 (PSMB7) and β1 (PSMB6) respectively. Increased 20S proteasome content in the 
leukaemic cell line KG1 compared to U937 (FAB subtype M1 compared to M5) was identified to 
be responsible for the increased sensitivity of the KG1 cells to Bortezomib induced cell death 
(Matondo et al., 2010). Ex vivo treatment of AML patient samples also supported the increased 
sensitivity of samples with increased 20S content (Matondo et al., 2010). Two different types of 
proteasomes exist; immunoproteasomes and constitutive proteasomes, the difference being the 
catalytic subunits β5, β2 and β1 are replaced with β5i, β2i and β1i which can be activated by 
interferon γ. The resultant immunoproteasomes participate in MHC class I antigen presentation 
resulting in more efficient T-cell activation than constitutive proteasomes. It was identified that the 
ratio of immune to constitutive proteasomes also affected Bortezomib response in leukaemic cells 
(Niewerth et al., 2013). A higher ratio of immune to constitutive proteasomes resulted in increased 
sensitivity to Bortezomib induced cell death in paediatric acute leukaemic cells (Niewerth et al., 
2013). Interestingly it was also identified that Bortezomib resistance may be overcome by 
interferon γ stimulated increase in immunoproteasomes (Niewerth et al., 2014). Studies 
investigating acquired resistance to Bortezomib treatment have attributed chemoresistance to 
altered expression or mutation of proteasome subunit genes. Upregulation of PSMB5 or mutation of 
Bortezomib binding pocket was identified to abrogate Bortezomib mediated cell death (Oerlemans 
et al., 2008, Franke et al., 2012). Similarly knockdown of PSMA1 was identified to resensitise 
Bortezomib resistant leukaemic cell line (Fang et al., 2012). 
Bortezomib potential as an anti-leukaemic agent is supported by reports of Bortezomib selectively 
killing the leukaemic cell and having no significant cytotoxic effects on normal mononuclear bone 
marrow or cord blood derived CD34
+
 or aldehyde dehydrogenase (ALDH)
+
 cells (Riccioni et al., 
2007, Colado et al., 2008, Fang et al., 2012). Primary AML samples treated with Bortezomib were 
categorised as high or low responders based on induction of cell death (Riccioni et al., 2007). FAB 
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subtypes M4 and M5 were classified as high responders while M1 and M2 were classified as low 
responders. However there is no consensus regarding sensitivity of AML primary samples based on 
FAB subtype. Bortezomib was shown to mediate increased cytotoxicity to M1 subtype versus M5 
subtype based on cell line response (KG1 versus U937) and AML patient sample response 
(Matondo et al., 2010). The different outcome compared to earlier studies was suggested to be 
associated with difference in cell culture medium (Riccioni et al., 2007, Matondo et al., 2010).  
Aim 
Elevated TRIB2 expression was identified as a feature of a distinct cohort of 285 AML patient 
samples clustered into 16 groups based on gene expression (Valk et al., 2004, Keeshan et al., 2006). 
Within this cluster 4, elevated TRIB2 expression was associated with the cluster defining 
dysregulated C/EBPα signature which included both wild type and mutated C/EBPα, although high 
TRIB2 levels correlated with the WT-C/EBPα samples (Valk et al., 2004, Keeshan et al., 2006). 
Patients presented with leukaemias with a mixed myeloid lymphoid phenotype (Wouters et al., 
2007). Elucidation of the molecular mechanism of TRIB2-induced AML in murine models has 
shown that the proteolytic effect TRIB2 exerts on C/EBPαp42 is a key leukaemogenic driver 
(Keeshan et al., 2006, Keeshan et al., 2010). I have identified that TRIB2 mediates K48 ubiquitin-
dependent proteasomal degradation of C/EBPαp42 (Fig 4.2.2 and 4.2.3). Thus as Bortezomib 
functions as a clinically available proteasome inhibitor with high selectivity for the leukaemic cell 
and results in accumulation of K48 ubiquitinated proteins. I investigated whether Bortezomib may 
serve as a potential targeted therapy for elevated TRIB2 leukaemias. The data shows that 
overexpressing MigR1-TRIB2-eGFP in the U937 cell line led to increased sensitivity to 
Bortezomib induced cell death. The increased cytotoxicity associated with high TRIB2 expression 
was shown to be dependent on TRIB2-mediated ubiquitination of C/EBPαp42. The results were 
supported in AML primary samples categorised for their TRIB2 expression levels.  
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Result 6.2.1 Determination of optimum Bortezomib concentration to assess cell 
death in U937 cells. 
Previous reports determined that leukaemic cell lines are very sensitive to Bortezomib treatment in 
the 5-10 nanomolar range (Colado et al., 2008, Dijk et al., 2011). Bortezomib is proposed to induce 
cytotoxicity through several mechanisms, facilitating the accumulation of K48 ubiquitin linked 
proteins and also through stabilization of pro-apoptotic and cell cycle inhibitory proteins (Obeng et 
al., 2006, Riccioni et al., 2007, Colado et al., 2008, Dijk et al., 2011). U937 cells were treated with 
increasing concentrations of Bortezomib 0-15 nM in order to deduce the optimum Bortezomib 
concentration for U937 cell death. Cells were counted 24 hrs post treatment and plotted against the 
log of Bortezomib concentration. Nonlinear regression analysis was performed and the mean IC50 
of two independent 24 hr treatments calculated an IC50 of 8.45+/- 0.45 nM SEM (Fig 6.2.1 A). This 
supports a previously reported Bortezomib IC50 of 8.1 nM in U937 cells (Matondo et al., 2010). In 
order to assess the effect of Bortezomib on apoptosis induction, U937 cells were stained with 
Annexin V and Dapi following 24 hrs of treatment and analysed by FACs. Dual staining of Dapi 
and Annexin V permits assessment of apoptotic induction by presenting Annexin V on x-axis vs 
Dapi on y-axis (Fig 6.2.1 B gating strategy employed). Annexin V and Dapi negative cells 
represent the live population Q4, Annexin V+/Dapi- cells represent cells undergoing early stages of 
apoptosis Q3, Annexin V+/Dapi+ cells represent late apoptosis stage cells Q2. Q1 quadrant 
represents the dead cell population however in this assay dead cells are usually not present within 
this quadrant due to fragmentation of cells. Cells were treated with DMSO as the no drug control 
(NDC) in order to determine if cell death observed was due to the effect of the Bortezomib solvent. 
There was no change to the live cell population of untreated and NDC treated cells indicating any 
decrease in cell viability observed was not due to DMSO induced toxicity but due to specific 
Bortezomib drug effects (Fig 6.2.1 C and D). Bortezomib treated samples received DMSO at a 
concentration less than 0.0001 %. Increasing concentrations of Bortezomib treatment 5-15 nM 
resulted in decreased percentage of live cells in Q4 from 69.7 % to 41 % with a concomitant 
increase in cells staining positive for Annexin V and Dapi. There was near a twofold increase in 
late stage apoptotic cells with increasing Bortezomib treatment. 10 nM Bortezomib treatment 
resulted in an approximate 50 % decrease in cell viability with 55.7 % of cells remaining Annexin 
V and Dapi negative. Combining the IC50 determined from cell counts of 8.45 +/- 0.45 nM (Fig 
6.2.1 A) with the results from the apoptosis assay (Fig 6.2.1 B and C) and published literature on 
Bortezomib treatment on leukaemic cell lines, 10 nM was chosen as the optimum Bortezomib 
concentration for the remainder of this study (Dijk et al., 2011, Du et al., 2012, Fang et al., 2012). 
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Fig 6.2.1 10 nM optimum Bortezomib concentration to assess cell death in U937 cells. A) 5, 10 
and 15 nM Bortezomib treated U937 cell counts were normalised to untreated cell count and 
plotted against the log of Bortezomib concentration. Nonlinear regression calculated mean IC50 
8.45 nM. B) Apoptosis assay gating strategy. C) Apoptosis assay of U937 cells treated with 0, 5, 10 
and 15 nM Bortezomib and NDC DMSO for 24 hrs. Cells were stained with Annexin V and Dapi 
and analysed by FACs. D) Graphical representation of apoptosis assay.  
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Result 6.2.2 TRIB2 overexpression increases Bortezomib induced cell death in 
U937 cells 
Oncogenic perturbation perpetuated by high TRIB2 expression is dependent on its ability to 
mediate ubiquitin-dependent proteasomal degradation of C/EBPαp42 (Fig 4.2.1) (Keeshan et al., 
2006, Keeshan et al., 2010). In order to determine if the high TRIB2 leukaemic cell could be 
pharmacologically targeted, cells were treated with Bortezomib at the selected concentration of 10 
nM. U937 cells were transduced with bicistronic retroviral MigR1-eGFP control and MigR1-
TRIB2-eGFP. As mentioned previously overexpression of TRIB2 in U937 cells recapitulates the 
high TRIB2 AML cell (Keeshan et al., 2006). Cells were transduced for 48 hrs, sorted for the GFP 
positive population and treated for 24 hrs with 10 nM Bortezomib. GFP expression was measured 
as a marker of cell viability by FACs analysis. Bortezomib treatment resulted in a decrease in GFP 
levels in both MigR1 and TRIB2 transduced cells indicative of cell death (Fig 6.2.2 A). However 
the decrease in GFP expression in Bortezomib treated TRIB2 overexpressing cells was much 
greater than MigR1 Bortezomib treated cells (MigR1 mean 67.3 % +/-1.40 SD vs TRIB2 42.03 % 
+/-1.37 SD). In order to control for slight variation in GFP expression in the untreated cells (MigR1 
91.05 % +/-0.69 SD vs TRIB2 82.1 % +/-2.06 SD) GFP expression post-Bortezomib treatment was 
normalised to untreated mean GFP expression levels. TRIB2 overexpression results in a statistically 
significant decrease in cell viability, as determined by GFP expression, compared to MigR1 
transduced cells (MigR1 0.757 +/-0.014 SD, TRIB2 0.608 +/-0.003 SD, t-test, p=0.0002) (Fig 6.2.2 
B).  
Assessment of apoptosis revealed Bortezomib treatment resulted in a shift in cell distribution from 
the Q4 live cell quadrant largely to the Q2 late apoptotic cell quadrant (Fig 6.2.2 C). Graphical 
representation of the mean percentage cells +/- SD from the apoptosis assay depicts the 
concomitant increase in late apoptosis Q2 corresponding with the decrease in live cells in Q4 (Fig 
6.2.2 D). In order to validate the decrease in high TRIB2 cell viability observed through 
measurement of GFP upon Bortezomib treatment the cell viability was assessed through 
characterisation of live cells as those determined to be Annexin V-/Dapi-, thus assessing cell 
viability by two additional factors. Bortezomib treatment resulted in a decrease in cells in Q4 for 
both MigR1 and TRIB2 transduced cells, however the decrease observed for TRIB2 expressing 
cells was greater (MigR1 56.73 % +/- 1.12 SD, TRIB2 32.9 % +/- 1.20 SD). Bortezomib treated 
MigR1 cell viability was similar to Bortezomib treated untransduced U937 cell viability (55.7 %) 
(Fig 6.2.1 C and D), indicating empty vector MigR1 control did not differentially effect U937 cell 
response to Bortezomib treatment. Normalising treated Annexin-/Dapi- cell population to untreated 
169 
 
mean of Annexin-/Dapi- population to control for slight variation in MigR1 (93.25 % +/- 0.77 SD) 
and TRIB2 (85.2 % +/-2.17 SD) live populations revealed there was a statistically significant 
decrease in cell viability upon treatment in cells expressing TRIB2 (MigR1 0.608 +/- 0.012 SD, 
TRIB2 0.396 +/-0.014 SD, t-test p=0.0004) (Fig 6.2.2 E). These results show that the leukaemic 
cell line U937 transduced to express high levels of TRIB2 are more sensitive to Bortezomib 
induced cell death.  
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Fig 6.2.2 TRIB2 overexpression increases Bortezomib induced cell death. U937 cells were 
transduced with bicistronic retroviruses expressing TRIB2-eGFP and MigR1-eGFP empty vector 
control. 48 hrs post-transduction GFP positive cells were sorted and treated with 10 nM Bortezomib 
for 24 hrs. A) Percentage GFP expression was measured by FACS. B) GFP expression was 
normalised to untreated controls and plotted as the mean +/- SD, t-test p=0.0002. C) Apoptosis 
assay of cells stained with Annexin V and Dapi. D) Graphical representation of apoptosis assay 
plotting the mean +/- SD. E) Live cell population as measured by Annexin V-/Dapi- normalised to 
the untreated live population and plotted as the mean +/- SD, t-test p=0.0004. Data presented is 
representative of three independent transduction experiments containing 3 sample replicates.  
A B 
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Result 6.2.3 Loss of TRIB2-mediated ubiquitination of C/EBPαp42 abrogates 
TRIB2 sensitivity to Bortezomib-induced cell death 
Overexpression of TRIB2 was identified to decrease U937 cell viability upon Bortezomib treatment 
(Fig 6.2.2) and Bortezomib treatment was reported to mediate cytotoxicity through accumulation of 
K48 ubiquitin linked proteins (Obeng et al., 2006). In order to determine if the increased sensitivity 
of TRIB2 overexpressing cells was attributable to the ubiquitination of C/EBPαp42, the drug 
treatment assay was performed using TRIB2-VPM-GFP construct which is unable to mediate 
C/EBPα ubiquitination (Fig 4.2.8) and subsequent proteasomal degradation of C/EBPαp42 through 
loss of the E3 ligase COP1 binding site (Keeshan et al., 2010). U937 cells were transduced with 
MigR1-eGFP, MigR1-TRIB2-eGFP and MigR1-TRIB2-VPM-eGFP for 48 hrs. GFP positive cell 
population was sorted and treated for 24 hrs with 10 nM Bortezomib. GFP expression was 
measured as a marker of cell viability by FACs analysis. Bortezomib treatment resulted in a 
decrease in GFP levels in MigR1, TRIB2 and TRIB2-VPM transduced cells indicative of cell death 
(Fig 6.2.3 A). In order to control for variation in GFP expression in the untreated cells GFP 
expression post Bortezomib treatment was normalised to the untreated mean GFP expression levels 
(MigR1 0.605 +/-0.040 SD, TRIB2 0.475 +/-0.016 SD, TRIB2-VPM 0.567 +/-0.002 SD) (Fig 6.2.3 
B). TRIB2 overexpression resulted in a statistically significant decrease in cell viability as 
compared to MigR1 and TRIB2-VPM transduced cells (t-test MigR1 vs TRIB2 p=0.0041, TRIB2 
Vs TRIB2-VPM p=0.0046). There was no statistically significant difference between MigR1 and 
TRIB2-VPM transduced cells (MigR1 vs TRIB2-VPM p=0.207) (Fig 6.2.3 B). The percentage of 
live cells determined by Annexin-/Dapi- population was approximately similar amongst transduced 
untreated cells (MigR1 74.9 5% +/- 3.32 SD, TRIB2 74.9 % +/- 4.42 SD, TRIB2-VPM 67.45 % +/- 
10.39 SD) (Fig 6.2.3 C). Graphical representation of the mean percentage cells +/- SD in each 
quadrant from the apoptosis assay depicts the concomitant increase in both early apoptosis Q3 and 
late apoptosis Q2 corresponding with the decrease in live cells in Q4 (Fig 6.2.3 D). Bortezomib 
treatment resulted in a decrease in cells in Q4 for MigR1, TRIB2 and TRIB2-VPM transduced 
cells, however the decrease observed for WT-TRIB2 expressing cells was greater (MigR1 44.9 % 
+/- 1.41 SD, TRIB2 36.5 % +/- 2.80 SD, TRIB2-VPM 41.4 % +/- 0.60 SD) (Fig 6.2.3 D). 
Bortezomib treated Annexin V-/Dapi- cell population was normalised to untreated mean of 
Annexin V-/Dapi- population to control for slight variation in live populations (MigR1 0.599 +/- 
0.02 SD, TRIB2 0.487 +/- 0.037, TRIB2-VPM 0.614 +/- 0.009 SD) (Fig 6.2.3 E). A statistically 
significant decrease in cell viability upon treatment in cells expressing WT-TRIB2 as compared to 
MigR1 and TRIB2-VPM was evident (t-test TRIB2 vs MigR1 p=0.034, TRIB2 vs TRIB2-VPM 
p=0.0046 and MigR1 Vs TRIB2-VPM p=0.306) (Fig 6.2.3 E). These results show that the loss of 
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TRIB2 proteolytic effect on C/EBPαp42 abrogates the sensitivity to Bortezomib-induced cell death 
in TRIB2 expressing U937 cell 
 
 
 
Fig 6.2.3 TRIB2-VPM abrogates TRIB2 increased Bortezomib induced cell death. U937 cells 
were transduced with TRIB2-VPM-GFP TRIB2-GFP and MigR1-GFP empty vector control. 48 hrs 
post transduction GFP positive cells were sorted and treated with 10 nM Bortezomib for 24 hrs. A) 
Percentage GFP expression was measured by FACS. B) GFP expression was normalised to 
untreated controls and plotted as the mean +/- SD. Bortezomib treatment resulted in a statistically 
significant decrease in TRIB2 cell viability vs MigR1 control and TRIB2-VPM. C) Apoptosis assay 
A B 
C 
D 
E 
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of cells stained with Annexin V and Dapi. D) Graphical representation of Apoptosis assay plotting 
the mean +/- SD. E) Graphical representation of the live cell population as measured by Annexin 
V-/Dapi- normalised to the mean of the untreated Annexin V-/Dapi- population and plotted as the 
mean +/- SD. Bortezomib treatment does not result in a statistically significant decrease in TRIB2-
VPM cell viability vs MigR1 control. Data presented is representative of two independent 
transduction experiments containing 3 sample replicates. 
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Result 6.2.4 High TRIB2 AML patient samples display increased cell death in 
response to Bortezomib treatment 
To investigate if the high TRIB2 cell response to Bortezomib treatment observed in a leukaemic 
cell lines was evident in primary AML patient samples, peripheral blood derived mononuclear 
AML patient samples positive and negative for TRIB2 expression were treated with Bortezomib. 
Patient samples were genotyped on diagnoses as AML1 (JAK (anus kinase) V617F subtype M4), 
AML2 (karyotypically normal subtype M4) and AML3 (mutNPM1 mutDNMT3A no subtype 
available). AML samples 1 and 2 were kindly provided by Dr. M. Cahill (University College Cork) 
while AML sample 3 was kindly provided by Dr. R. Delwel (Erasmus University). AML3 sample 
was a sample identified in the Valk dataset where gene expression analysis was performed on 285 
AML patients and expression analysis identified high levels of TRIB2 expression associating with a 
cohort of patients with dysregulated C/EBPα signature (Valk et al., 2004, Keeshan et al., 2006). 
Cryopreserved primary AML patient samples 1 and 2 were characterised previously based on their 
TRIB2 expression levels (Rishi et al., 2014). There was no detectible TRIB2 protein expression in 
AML1 while AML2 and AML3 both had robust levels of TRIB2 protein expression (Fig 6.2.4 A 
top panel). AML1 expressed C/EBPαp42 protein while both AML2 and AML3 samples displayed 
low levels of C/EBPαp42 protein expression, coinciding with high TRIB2 expression status of 
these patients. Bortezomib treatment of AML3 restored C/EBPαp42 protein expression levels as 
confirmed by equal Actin expression confirming equal protein loading (Fig 6.2.4 A) Western 
blotting for AML samples 1 and 2 was performed by Dr. L. Rishi (Fig 6.2.4 A) (Rishi et al., 2014). 
AML samples were cultured in 10 nM Bortezomib for 24 hrs and cell death was measured by Dapi 
staining. Due to cell number limitations single replicates were collected for AML1 and AML2 
while two replicates were collected for AML3. AML1 displayed only a 1 % change in cell death as 
measured by Dapi upon treatment. AML2 displayed a 30 % increase in Dapi staining and AML3 
displayed a 49.70 % +/-1.4 SD increase (mean +/-SD) (Fig 6.2.4 B and C). Untreated AML 
samples displayed varying degrees of cell death indigenous to each sample (Fig 6.2.4 B and C). In 
order to normalise for background cell death the fold increase in cell death upon Bortezomib 
treatment was plotted. Bortezomib treatment did not result in a change in cell death in AML1, there 
was a 2.13 fold increase in AML2 cell death and a 8.17 +/-0.028 SD fold increase in cell death in 
AML3 treated with 10 nM Bortezomib (Fig 6.2.4 D). Therefore these data in primary patient 
samples show that the high TRIB2 cell is more sensitive to Bortezomib mediated cell death and 
strongly support the cell line data in the previous section.  
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Fig 6.2.4 High TRIB2 AML samples display increased cytotoxicity in response to Bortezomib 
treatment. A) AML patient sample lysates were immunoblotted with anti TRIB2, anti C/EBPα and 
with anti Actin which served as a loading control. AML lysates were all prepared by Fíona Lohan; 
immunoblotting for AML samples 1 and 2 was performed by Dr. L. Rishi. Western blot for TRIB2 
is published by (Rishi et al., 2014). B) AML samples were treated with 10 nM Bortezomib for 24 
hrs, stained with Dapi and cell death was analysed by FACs. C) Graphical representation of 
percentage cell death as measured by Dapi staining. D) Fold increase in cell death as determined by 
Dapi positive cells. Percentage Dapi positive Bortezomib treated samples were normalised to 
percentage cell death in untreated samples.   
A 
B 
C D 
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Result 6.2.5 Bortezomib treatment increased the percentage of CD14
+
 and/or 
CD11b
+
 cells in high TRIB2 AML samples  
Bortezomib treatment has been previously reported to mediate increased cytotoxicity to patients 
expressing high levels of granulocytic surface markers CD11b/CD14/CD15 than patients 
expressing lower levels of CD11b/CD14/CD15 (Riccioni et al., 2007). Additionally Bortezomib 
was identified to target the Aldehyde ALDH
++
 leukaemic stem cell (Riccioni et al., 2007). In order 
to determine the effect of Bortezomib exerted on the differentiated CD11b
+
 myeloid cell population 
in the presence and absence of TRIB2 expression, AML1, AML2 and AML3 were stained for the 
myeloid cell marker CD11b in the absence and presence of Bortezomib treatment. CD11b is 
expressed on leukocytes including monocytes, neutrophils, NK cells, macrophages and 
granulocytes. The change in CD11b expression was assessed in the viable cell population (Dapi 
negative population). AML3 was also stained for CD14. CD14
+
 is a marker of macrophages and 
monocytes. CD11b expression varies between individual leukaemias. AML1, AML2 and AML3 
contained 22.2 %, 19.1 % and 63.6 % CD11b
+ 
cells respectively (Fig 6.2.5 A). Upon Bortezomib 
treatment there is a 1 % decrease in AML1 CD11b
+
 population however there is a 22.3 % increase 
in CD11b
+
 AML2 population. Bortezomib treatment of AML3 resulted in a decrease in CD11b
+
 
cells, but an increase in CD14
+ 
cells (Fig 6.2.5 B). As this assay was performed over a 24 hr period 
and AML samples were not maintained in culture media permissive of inducing differentiation, the 
decrease in CD11b
-
/CD14
-
 cells is potentially due to Bortezomib preferentially promoting cell 
death of this high TRIB2 less mature myeloid cell population resulting in the increase in CD11b
+
 
/CD14
+
 cells observed. Thus ex vivo treatment of patients AML2 and AML3 resulted in an increase 
in terminally differentiated cell markers, while there was only a 1% change in CD11b
+
 in patient 
AML1 which was not sensitive to Bortezomib induced cytotoxicity.  
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Fig 6.2.5 Bortezomib targets an immature myeloid cell population. A) AML1, AML2 and 
AML3 were stained with CD11b and CD14 (AML3 only) and analysed by FACs. Cells were gated 
on the Dapi negative population. B) Graphical representation of percentage Dapi negative 
CD11b
+
/CD11b
-
 cells in the absence and presence of Bortezomib treatment in AML1 and AML2. 
C) Graphical representation of percentage Dapi negative CD11b
+
/CD11b
-
 and CD14
+
/CD14
-
 cells 
in the absence and presence of Bortezomib treatment in AML3. (Note AML samples 1 and 2 were 
investigated at the same time while AML3 was investigated at a later date hence the different 
CD11b FACS gates employed). 
 
 
 
 
 
 
 
 
 
A 
B C 
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6.3 Discussion 
AML is a vastly heterogeneous disease with many associated genetic lesions. Bortezomib has been 
tested for efficacy in the treatment of AML as a single agent, in combination with standard 
induction therapy and recently with sorafenib tosylate in an ongoing phase III trial (AAML1031) 
with varying successes (Cortes et al., 2004, Attar et al., 2005, Attar et al., 2008, Sarlo et al., 2013, 
Attar et al., 2013). Perhaps the differential response of AML patients may reflect the effect of 
Bortezomib on the underlying genetic abnormalities. One of the main issues with AML treatment is 
a high relapse rate, due to proposed aberrant signalling cascades, particularly NFκB activation in 
the quiescent leukaemic stem cell (Guzman et al., 2001, Wang et al., 2011). There are several 
advantages to the clinical use of Bortezomib as a leukaemic treatment option. Leukaemic cells 
carry a large number of proteasomes and Bortezomib treatment results in low cytotoxicity to 
normal mononuclear CD34
+ 
cells, so it selectively targets the leukaemic cell (Kumatori et al., 1990, 
Riccioni et al., 2007, Colado et al., 2008, Attar et al., 2008, Fang et al., 2012). Bortezomib induced 
cell death, unlike cytrabine and Ara-C (induction therapy), does not require the cell to be actively 
cycling in order to induce cell death (online communication, Dr. E. Attar , Massachusetts General 
Hospital of http://www.dfhcc.harvard.edu/news/news/article/3287/,(Castaigne et al., 2004)). Thus 
Bortezomib treatment may prove to be an strong option to target the quiescent leukaemic stem cell 
(Attar et al., 2008). Additionally Bortezomib treatment has been proposed to act as a 
chemosensitiser. It is not a victim of the action of multi-drug resistant proteins, whose expression 
do not effect efflux of the drug (Oerlemans et al., 2008, Dijk et al., 2011, Wang et al., 2012). Thus 
in this manner Bortezomib treatment has been identified to sensitise leukaemic cells to many 
cytotoxic agents e.g. TRAIL, doxorubicin, idarubicin, valporic acid and cytrabine treatment 
(Colado et al., 2008, Dijk et al., 2011, Stapnes et al., 2014).  
TRIB2 induces transplantable murine AML through multiprotein complex formation with an E3 
ubiquitin conjugating ligase COP1, resulting in K48 ubiquitin-dependent proteasomal degradation 
of C/EBPαp42 as shown in chapter 4 (Keeshan et al., 2006, Keeshan et al., 2010). Additionally, I 
have shown that loss of the COP1 binding site on TRIB2 (TRIB-VPM) abrogates its ability to 
mediate ubiquitination of C/EBPαp42, and to induce murine AML (Keeshan et al., 2010). TRIB2-
mediated degradation of C/EBPαp42 was inhibited by treatment with both proteasomal inhibitors 
MG-132 and Bortezomib as shown in chapter 5. To date, studies of TRIB2 expression in AML 
patients have identified elevated mRNA expression in a specific subset of AML patients with 
dysregulated C/EBPαp42 signatures (Valk et al., 2004, Keeshan et al., 2006). A recent study 
identified elevated TRIB2 mRNA and protein expression in AML cell lines and AML patient 
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samples (Rishi et al., 2014). This provided the rational to investigate Bortezomib as a potential 
targeted therapy for high TRIB2 leukaemic cells. 
In this chapter I have determined that TRIB2 overexpression in U937 cells resulted in increased 
cytotoxicity to Bortezomib treatment versus MigR1 transduced control cells. Additionally I 
confirmed that the increased cytotoxicity mediated by TRIB2 was dependent on its E3 ligase 
binding capabilities. TRIB2-VPM transduced cells displayed similar reduction in cell viability to 
Bortezomib treatment of MigR1 control cells. Thus it may be postulated that loss of TRIB2-
mediated ubiquitination, through loss of its COP1 binding site, served to inhibit the increased 
cytotoxicity observed. As TRIB2 is proposed to function as an adaptor protein with E3 ligase 
binding capabilities I propose elevated TRIB2 expression increases Bortezomib cytotoxicity due to 
the increased accumulation of K48 ubiquitinated proteins, specifically C/EBPαp42. As previously 
reported the accumulation of K48 ubiquitinated proteins is thought to mediate Bortezomib 
cytotoxicity on a cellular level through triggering ER stress, autophagy and apoptosis (Obeng et al., 
2006, Fang et al., 2012). Bortezomib mediated cytotoxicity may be caused by more than an 
increase in K48 ubiquitinated proteins. Inhibition of proteasomal degradation in the presence of 
TRIB2 ultimately results in an increase in C/EBPαp42 protein levels. Tamoxifen mediated cell 
death was attributed to an increase in C/EBPαp42 protein levels through its association with p21 
(Cheng et al., 2007). Also ER stress results in expression of pro-apoptotic BIM (Puthalakath et al., 
2007). This induction of BIM is mediated by CHOP and C/EBPαp42 transcriptional activation of 
BIM (Puthalakath et al., 2007). Thus Bortezomib treatment results in accumulation of K48 
ubiquitinated proteins maintaining C/EBPαp42 protein levels and potentially also triggering 
apoptosis through activation of BIM and through its association with p21 (Cheng et al., 2007, 
Poulaki et al., 2007).  
Bortezomib treatment also induces cell death in AML patient samples identified to express TRIB2 
protein supporting the U937 cell line data. Bortezomib treatment of an AML1 patient sample 
negative for TRIB2 expression did not result in an increase in cytotoxicity. AML1 patient 
possessed JAKV617F mutation, occurrence of which results in aberrant STAT activation 
(Kundranda et al., 2012). I propose the large cytotoxicity observed by AML2 and AML3 compared 
to AML1 is due to the high levels of TRIB2 expression in those samples. However one would 
expect a small degree of cytotoxicity upon Bortezomib treatment in AML1 sample. The presence of 
JAKV617F mutation may provide resistance to Bortezomib cytotoxicity through aberrant STAT 
pathway activation (reviewed by (Lee et al., 2013)). Furthermore there is great variation in AML 
primary sample response to Bortezomib treatment. Analysis of the literature identifies reports of 0-
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10 % increase in apoptotic cells in AML samples upon Bortezomib treatments of 20-100 nM 
(Matondo et al., 2010). Assessment of additional AML samples response to Bortezomib is thus 
warranted.  
The ability of Bortezomib to inhibit NFκB aberrant signalling through stabilisation of inhibitory 
IκB suggests proteasomal inhibition may preferentially target specific haematopoietic cells, as 
aberrant NFκB signalling is a hallmark of a leukaemic stem cell (Guzman et al., 2001, Guzman et 
al., 2002). Bortezomib has been identified to show enhanced specificity for an immature CD34
+
 cell  
in comparison to doxorubicin (Colado et al., 2008). Indeed I identified Bortezomib induced 
cytotoxicity resulted in a decrease in CD11b
-
 cells in AML2 patient sample and decreased CD14
-
 
cells in AML3 patient sample. However Bortezomib treatment increased CD11b
- 
cells in AML3 
patient sample. A 1% change was identified in AML1 which exhibited no cytotoxicity to 
Bortezomib treatment. Thus perhaps the immature cell population targeted by Bortezomib is 
dependent on the individual leukaemia and the respective differentiation status of the leukaemias 
ultimately affecting the cell death response.  
As is often common with chemotherapeutics there are dose limiting side effects. In the case of 
Bortezomib these include peripheral neuropathy and thrombocytopenia (Argyriou et al., 2008). 
Development of second generation proteasomal inhibitors Carfilzomib and ONX 0912 which are 
epoxyketones may ameliorate these effects (Demo et al., 2007). Preclinical investigations 
determined both AML and ALL cells are sensitive to Carfilzomib and ONX and these second 
generation inhibitors may overcome Bortezomib resistance disease (Niewerth et al., 2013). 
Recently Carfilzomib has been identified to induce apoptosis in CML cells sensitive and resistant to 
tyrosine kinase inhibition and the CML cell immunoproteasomal load was identified to associate 
with Carfilzomib response (Crawford et al., 2014). Combinational treatment of CML cells with 
Carfilzomib and TKIs synergised, identifying a potential treatment regime for TKI resistant CML 
disease (Crawford et al., 2014). Here I have documented the first report of a targeted therapy for 
TRIB2 leukaemic disease. Additional to TRIB2 leukaemias Bortezomib may also selectively target 
high TRIB2 NSCLCs also identified to mediate degradation of C/EBPαp42 (Grandinetti et al., 
2011). In vivo murine model trials will be necessary to support the molecular data presented. 
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Chapter 7: General Discussion 
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7.1 Summary and overall conclusions 
TRIB2 is a potent oncogene driving fully penetrant transplantable murine AML in BMT models 
and shown to be elevated in a cohort of patient AMLs (Keeshan et al., 2006). TRIB2 
leukaemogenicity is intrinsically linked to its proteolytic relationship with C/EBPα (Keeshan et al., 
2006, Keeshan et al., 2010). Indeed TRIB2 is unable to induce murine AML in the absence of 
C/EBPα degradation and elevated TRIB2 expression in AML patients associate with a dysregulated 
C/EBPα signature (Keeshan et al., 2006, Keeshan et al., 2010). To date the information regarding 
TRIB2 effect on C/EBPα was limited to direct binding and proteasomal degradation of C/EBPαp42 
full length isoform (Keeshan et al., 2006). This project further elucidated the features of this 
molecular interaction and provided additional insight into the molecular biology of TRIB2-
mediated AML. TRIB2 is currently classified as a pseudokinase as it lacks demonstrable kinase-
like activity. In the context of our study TRIB2 is functionally defined as an adaptor or scaffold 
protein as it facilitates the formation of a multiprotein complex through multiple protein-binding 
domains. TRIB2 requires C/EBPα binding, its kinase-like domain and C-Terminal E3 ligase COP1 
binding in order to elicit its leukaemic effects (Keeshan et al., 2010). TRIB2 increased expression 
resulting in inhibition of C/EBPα fits the Gilliland two hit model of leukaemogenesis (Kelly and 
Gilliland, 2003). TRIB2 may be classified as type I mutation “a classic oncogene” resulting in loss 
of C/EBPα function, classified as a type II mutation halting differentiation.  
 
TRIB2 direct binding mediated K48 ubiquitin-dependent degradation of C/EBPαp42 
Molecular analysis performed within this study determined TRIB2 amino acids 
S227/S229/S231/K233 within subdomain VIII of the kinase-like domain are required for direct 
TRIB2 and C/EBPα binding. These amino acids were identified as a crucial site for C/EBPα 
binding initially in peptide arrays and subsequent SASSAs. The role of the specific amino acids 
was supported by in silico analysis using protein-protein interaction software PIPE which predicted 
TRIB2 amino acids 227-258 mediated C/EBPα binding. SDM of TRIB2-
S227A/S229A/S231A/K233A abrogated TRIB2 ability to bind C/EBPα in mammalian cells as 
determined by co-IP. Additionally, investigation into this TRIB2 region required for C/EBPα 
binding revealed it was rich in secondary structure permissive of protein-protein interactions. 
Identification of TRIB2-S227A/S229A/S231A/K233A supports the use of peptide array technology 
in the identification of protein interaction sites. To date no 3D structure exists for TRIB2, and 
predictive structural analysis has been performed in an attempt to get some idea of the structure of 
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this protein. TRIB2 has been modelled on PIM1 using Swiss Model homology modelling service 
and predicted to have a structure similar to that of an active kinase (Hegedus et al., 2007). TRIB 
proteins have been identified as phosphoproteins capable of being phosphorylated however the 
pseudokinase classification extends from their inability to mediate transfer of phosphates (Boylan et 
al., 2003, Hegedus et al., 2007, Wang et al., 2013b). Amino acids S227/S229/S231/K233 span a 
putative GSK3 phosphorylation site S/TXXXS/T. Mutation of S227A/S229A/S231A/K233A may 
alter the 3D structure of the TRIB2 protein, indeed upon SDS-PAGE analysis immunoblotting with 
anti TRIB2 antibody identified TRIB2-S227A/S229A/S231A/K233A runs at a slightly lower 
molecular weight than WT-TRIB2 and it loses the tight top doublet band detected by TRIB2 
antibody upon expression of WT-TRIB2. Perhaps mutation of this site results in loss of a 
phosphorylation site required for TRIB2 interaction with C/EBPα. Regardless of the molecular 
dynamics resulting from mutation of S227A/S229A/S231A/K233A, this region is essential for 
C/EBPα binding. Upon documentation of TRIB2 3D structure this may be fully elucidated. 
Previous investigation of TRIB2 family member TRIB1 and its site of C/EBPα binding was 
performed by creation of deletion constructs, generated by deletion of up to 180 amino acids which 
is ~ 1/3 of the protein, localising C/EBPα binding site in N-Terminal/N-Terminus of the kinase-like 
domain of TRIB1 (Yokoyama et al., 2010). These deletion constructs undoubtedly alter protein 3D 
structure. It is proposed that SDM of specific amino acids is the most conclusive and easily 
accessible option available for assessing sites of protein-protein interaction (Ofran and Rost, 2007). 
Interestingly homologous analysis revealed TRIB1 partially retains elements of SSSK binding 
sequence identified in TRIB2. TRIB1 contains T2572/T259/S261/K262 which also classifies as a 
putative GSK3 phosphorylation site and therefore may also exert a role in C/EBPα interaction. 
TRIB2 was identified to mediate proteasomal degradation of full length C/EBPαp42 suggestive of 
an ubiquitin-dependent mechanism. Indeed in vivo ubiquitination assays identified TRIB2 
expression in HEK293t cells, which endogenously express COP1, mediated K48 specific 
ubiquitination of C/EBPαp42. Loss of COP1:TRIB2 binding abrogated the ability of TRIB2 to 
mediate C/EBPα ubiquitination verifying it as the bona fida E3 ligase involved in ubiquitin 
conjugation. Analysis involving C/EBPαp42-R339A (previously identified as TRIB2 binding site 
on C/EBPα) revealed TRIB2 was unable to mediate its ubiquitination supporting the binding 
dependency for TRIB2-mediated ubiquitination of C/EBPα. This theory was validated as TRIB2-
S227A/S229A/S231A/K233A was also unable to mediate ubiquitination of C/EBPαp42 
additionally supporting its identification as a crucial site for C/EBPα binding.  
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Upon investigation of putative C/EBPα binding sites on TRIB2, R77 was identified in the analysis. 
This arginine is homologous to TRIB1-R107 identified mutated in an AML patient (Yokoyama et 
al., 2012). Molecular analysis of TRIB1-R107L revealed it had an increased proteolytic effect on 
C/EBPα compared to WT-TRIB1 (Yokoyama et al., 2012). The functions of TRIB1 and TRIB2 
slightly differ in that TRIB1 is identified as a modulator of MAPK signalling and its degradation of 
C/EBPα is dependent on MEK1 binding (Yokoyama et al., 2010, Dedhia et al., 2010). The authors 
report TRIB1 increases P-ERK1/2 and TRIB1-R107L further enhanced ERK1/2 phosphorylation, 
suggesting it may be due to either enhanced modulation of MAPK signalling pathway or 
alternatively due to a conformational change to TRIB1 protein that may alter its affinity for protein 
partners. However, examination of the data provided by the authors for the affect of TRIB1 and 
TRIB1-R107L on P-ERK1/2 reveals initially the increases mediated to P-ERK1/2 are equivocal and 
only upon IL-3 stimulation do TRIB1-R107L cells retain the enhanced increase in P-ERK1/2 while 
WT-TRIB1 cells do not (Yokoyama et al., 2012). This supports the notion of TRIB1-R107 
acquiring a conformational state which enhances increased MEK1 protein binding, propagating 
increased P-ERK1/2 and increased C/EBPα binding as increased degradation was observed 
(Yokoyama et al., 2012). Co-IP analysis of TRIB2-R77 revealed despite lower expression levels 
and a slightly lower molecular weight as observed during SDS-PAGE, that it had increased C/EBPα 
binding. Additional to this, ubiquitination assays revealed it also displayed increased ubiquitination 
of C/EBPαp42 compared to WT-TRIB2. Based on the observation that TRIB1-R107L increased 
degradation of C/EBPα (a binding dependent effect) and the observation herein of TRIB2-R77A 
displaying increased binding to C/EBPα and resultant increase in mediated C/EBPα ubiquitination, 
I propose loss of this homologous arginine facilitates TRIB proteins acquiring a structurally 
permissive state for increased protein binding. TRIB1-R017L reduced the latency of TRIB1 
induced AML and perhaps TRIB2-R77A may also result in a gain of functionality. 
Bortezomib treatment as a targeted therapy for TRIB2-mediated ubiquitination of dimeric P-
Ser21-C/EBP at K313 
C/EBPα is commonly referred to as the “master regulator of haematopoiesis” or as a “gatekeeper of 
AML”, indicative of its nonredudant role in haematopoiesis (Zhang et al., 2004). C/EBPα exists as 
two isoforms a full length C/EBPαp42 isoform and an N-Terminally truncated C/EBPαp30 isoform 
(Pabst et al., 2001b). C/EBPα is classified as a tumour suppressor whilst C/EBPαp30 is reported to 
have oncogenic potential through its ability to exert a dominant negative effect on C/EBPαp42 
function through repressive heterodimerisation and through Ubc9 mediated sumoylation of 
C/EBPαp42 (Pabst et al., 2001b, Cleaves et al., 2004, Geletu et al., 2007). TRIB2 mediates K48 
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ubiquitin-dependent proteasomal degradation of C/EBPαp42 resulting in a concomitant increase in 
C/EBPαp30 isoform. A leukaemic feedback loop has been identified whereby C/EBPαp30 can 
further drive TRIB2 expression through direct promoter binding in an E2F dependent manner (Rishi 
et al., 2014).  TRIB2 retains the ability to bind both C/EBPαp42 and C/EBPαp30 however its 
interaction with C/EBPαp30 does not require proteasomal inhibition unlike C/EBPαp42 (Keeshan 
et al., 2006). This suggests that TRIB2 binding to C/EBPαp30 does not mediate its degradation, 
also supported by the increase in C/EBPαp30 observed upon TRIB2 expression (Keeshan et al., 
2006). TRIB2-mediating proteasomal degradation of C/EBPαp42 but not C/EBPαp30 remains to be 
fully elucidated. It may be postulated that the increase in C/EBPαp30 observed is due to partial 
proteolysis of C/EBPαp42. Secondary structures and glycine rich regions (GRR) are known to 
proteolytically protect protein isoforms, e.g. generation of p50 from p105 is due to partial 
proteolysis and p50 was identify to be protected due to presence of a GRR which affects 
proteasomal processing (Lin and Ghosh, 1996). Alternatively TRIB2 may perturb ribosomal 
scanning and encourage eIF-2α translation from the alternative internal C/EBPαp30 translation start 
site. TRIB3 has been reported to regulate eIF-2α activity under conditions of cell stress (Ohoka et 
al., 2005). However in light of my work I propose an additional hypothesis. C/EBPα possesses 
several phosphorylation sites regulated by different kinases in response to cellular stresses, 
induction of apoptosis and activation of MAPK cascades. P-Ser21-C/EBPα was identified to inhibit 
C/EBPα induced differentiation and was identified to exert additional selectivity over protein 
partner binding (Ross et al., 2004, Radomska et al., 2006, Graham et al., 2009, Koleva et al., 2012). 
P-Ser21-C/EBPα and unphosphorylated-Ser21-C/EBPα were identified to differentially interact 
with specific protein partners (Koleva et al., 2012, Fragliasso et al., 2012). TRIB2 decreases the 
levels of P-Ser21 through preferentially binding the phosphorylated form and mediating increased 
ubiquitination. P-Ser21 was identified to result in a conformation change to C/EBPα dimer 
culminating in the TADs migrating away from each other ultimately increasing the space between 
the individual monomers which are homodimerised (Ross et al., 2004). I propose this 
phosphorylation event results in a sterically favourable confirmation for increased TRIB2 binding 
at C/EBPαR339 and increased ubiquitin conjugation. C/EBPαp30 lacks this P-Ser21 site and 
therefore cannot assume the structurally permissive confirmation resulting in the increased 
ubiquitination and proteasomal degradation. Provisional ubiquitination assays performed did 
suggest C/EBPαp30 ubiquitination levels do not increase in the presence of TRIB2 (data not 
shown). TRIB2 also exerts preferential degradation of C/EBPαp42 dimers. TRIB2 retains the 
ability to bind both monomeric and dimeric C/EBPαp42 however it preferentially ubiquitinates 
dimeric C/EBPαp42, reducing its protein half life. This suggests C/EBPα dimers are more 
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accessible to COP1:TRIB2 ubiquitination. TRIB2 and C/EBPα proteolytic relationship I propose is 
strongly influenced by steric factors such as protein dimerisation and 3D conformation in response 
to phosphorylation changes.  
Determination of the critical lysine residue for C/EBPα ubiquitination was performed using ubpred 
analysis which calculated the probability score for each lysine to act as the site of ubiquitin 
conjugation on C/EBPα. K313 among 6 other lysines were identified with med-high probability 
scores. Mutation of C/EBPα-K313R abrogated TRIB2-mediated ubiquitination of C/EBPαp42, 
identifying K313 as the ubiquitination site on C/EBPαp42. Expression of TRIB2 did not increase 
the levels of C/EBPαp30 in C/EBPα-K313R expressing cells indicating that ubiquitination of 
C/EBPαp42 was required for the increase in C/EBPαp30. Interestingly annotation of K313 revealed 
the occurrence of a C/EBPα mutation in patient AML, K313dup (Carnicer et al., 2008). C/EBPα-
K313dup protein displays reduced stability compared to WT-C/EBPαp42 and induces AML in 
murine models (Carnicer et al., 2008, Bereshchenko et al., 2009, Kato et al., 2011). K313dup 
mutation is associated with CD7 expression in AML patients, a phenotype observed in C/EBPαp42 
excised HSCs (Wouters et al., 2007, Carnicer et al., 2008). Thus I propose K313dup mutation 
results in increased ubiquitination, proteasomal degradation and subsequent loss of C/EBPαp42 
protein. AML is a vastly heterogeneous disease and knowledge of the molecular biology behind the 
genetic aberrations will further advance the treatment of the disease and help decipher targeted 
therapies for different causes.  
Due to TRIB2-mediated ubiquitin-dependent proteasomal degradation of C/EBPαp42, proteasomal 
inhibition was investigated as a putative treatment strategy. Bortezomib is reported to mediate cell 
death by a variety of mechanisms including induction of ER stress due to the accumulation of 
ubiquitinated proteins triggering apoptosis (Obeng et al., 2006, Fang et al., 2012). Indeed leukaemic 
cells overexpressing TRIB2 were more sensitive to Bortezomib induced proteasomal inhibition 
mediated cell death than control cells. Ex vivo AML patient samples response further supported the 
increased sensitivity of high expressing TRIB2 AMLs to Bortezomib treatment. Ectopic expression 
of C/EBPα has also been identified to induce apoptosis and inhibit cellular proliferation in liver 
cancers cells, thus restoration of C/EBPα expression may also mediate Bortezomib mediated cell 
death (Wang et al., 2013a). Leukaemic cell sensitivity to Bortezomib induced cytotoxicity has been 
linked to expression of proteasomal subunits and their respective phenotypes: either immune or 
constitutive (Oerlemans et al., 2008, Franke et al., 2012, Fang et al., 2012, Niewerth et al., 2013). 
TRIB2 sensitivity to Bortezomib treatment may also be mediated by alterations in proteasomal 
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subunit expression levels. Bortezomib targets PSMB5 and the TRIB2 leukaemic cell may possess 
altered PSMB5 proteasome subunit expression (Oerlemans et al., 2008). 
Aside from elevated TRIB2 AMLs, Bortezomib may serve as a targeted treatment for mutC/EBPα-
K313dup AMLs, potentially restoring differentiation arrest and inducing cytotoxicity to leukaemic 
cells. Identification of elevated TRIB2 expression in AML patients is associated with biphenotypic 
disease as they display both myeloid and lymphoid signatures (Wouters et al., 2007). Biphenotypic 
AMLs respond poorly to current therapeutics (Zhang et al., 2009, Matutes et al., 2011). 
Interestingly the subset of elevated TRIB2 AMLs levels displayed CD7 expression, similar to 
K313dup AMLs potentially identifying CD7 as a biomarker for increased Bortezomib sensitivity to 
induced cell death and potentially improved survival for such biphenotypic patients (Wouters et al., 
2007).  
7.2 Future perspectives 
Exploitation of the increased sensitivity of TRIB2 expressing leukaemic cells may provide 
opportunities for treatment of other high TRIB2 expressing malignancies. TRIB2 was identified to 
be elevated in 30 % of NSCLC tumours and indeed TRIB2 was identified to mediate proteasomal 
degradation of C/EBPα (Grandinetti et al., 2011). Bortezomib has shown efficacy in the treatment 
of NSCLC in both a phase I trial and in phase II trial combined with gemcitabine and carboplatin 
(Aghajanian et al., 2002, Davies et al., 2009). Aberrant Wnt signalling is prevalent in gastro-
intestinal and liver cancers resulting in increased TRIB2 expression, which was identified to be 
essential for survival and transformation of hepatocellular carcinoma cells (Wang et al., 2013a). 
TRIB2 oncogenicity has been linked to its negative impact of C/EBPα protein expression, and 
indeed TRIB2 knockdown increased C/EBPα levels revealing an inhibitory C/EBPα effect on target 
genes required for transformation (Wang et al., 2013a). Thus in this context Bortezomib may also 
provide a treatment option for the emerging role of TRIB2 or dysregulated Wnt signalling in liver 
cancers through facilitation of C/EBPα transformation-dependent-target gene repression. Ultimately 
elucidating the molecular mechanism of a disease enables the use of targeted therapy approaches. 
Binding dependent TRIB2-mediated K48 ubiquitin-specific proteasomal degradation of 
C/EBPαp42 via ubiquitin conjugation at K313, may be a relationship also conserved in different 
tissues and subsequent dysregulation may occur in other malignancies as mentioned above.  What 
is learnt here in the leukaemic cell has wider implications for TRIB2 and C/EBPα molecular 
biology mediating malignant disease.  
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7.3 Proposed Model 
COP1 binds TRIB2 via its C-Terminal binding site. A) Phosphorylation of C/EBPα at Ser21 results 
in a structurally favourable confirmation for TRIB2 binding through dimer separation. B) COP1 
bound TRIB2 mediates K48 ubiquitination of C/EBPα via conjugation of polyubiquitin chain at 
K313 in C/EBPα C-terminus. C) The C/EBPα K48 polyubiquitin chain is recognised by the 
proteasome resulting in degradation of C/EBPαp42. D) Bortezomib treatment inhibits proteasomal 
activity resulting in accumulation of K48 polyubiquitinated C/EBPα resulting in cell death in the 
presence of high TRIB2 expression. 
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Secondary Structure:  
                   *         *         *         *         *          
Query 1   MNIHRSTPITIARYGRSRNKTQDFEELSSIRSAEPSQSFSPNLGSPSPPETPNLSHCVSC 60  
Helix 1                      HHHHHHHHHHHHHH                        HHH 60  
Sheet 1      EEEEEEEEEE       EEE                              EEEEEEE 60  
Turns 1       T          T  T  T            T T   T   T   T  T         60  
 
                   *         *         *         *         *          
Query 61  IGKYLLLEPLEGDHVFRAVHLHSGEELVCKVFDISCYQESLAPCFCLSAHSNINQITEII 120  
Helix 61  HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH      HHHHHHHHHHHHH 120  
Sheet 61  EEEEEEEEE     EEEEE       EEEEEEEEEEEEEEEEEEEE      EEEEEEEE 120  
Turns 61             T           TT             T           T          120  
 
                   *         *         *         *         *          
Query 121 LGETKAYVFFERSYGDMHSFVRTCKKLREEEAARLFYQIASAVAHCHDGGLVLRDLKLRK 180  
Helix 121 HHHHHHHHHH     HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH    HHHHHHHHHH 180  
Sheet 121 EEEEEEEEE       EEEEEEEEEE        EEEEEEEEEE      EEEEEEEEEE 180  
Turns 121   T        T                TT                  T            180  
 
                   *         *         *         *         *          
Query 181 FIFKDEERTRVKLESLEDAYILRGDDDSLSDKHGCPAYVSPEILNTSGSYSGKAADVWSL 240  
Helix 181 HHHHHHHHHHHHHHHHHHHHH                 HH            HHHHHHHH 240  
Sheet 181 EE      EEEEEEEEEEEEE             EEEEEEEEEEE           EEEE 240  
Turns 181     T T          T     T  T   T         T      T   T         240  
 
                   *         *         *         *         *          
Query 241 GVMLYTMLVGRYPFHDIEPSSLFSKIRRGQFNIPETLSPKAKCLIRSILRREPSERLTSQ 300  
Helix 241 HHHHHHHH     HHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHH     HHHHH 300  
Sheet 241 EEEEEEEEEEEEEE       EEEEEEEEEEEEEEE      EEEEEE        EEEE 300  
Turns 241                   TT       TT     T   T           T   T   TT 300  
 
                   *         *         *         *    
Query 301 EILDHPWFSTDFSVSNSAYGAKEVSDQLVPDVNMEENLDPFFN 343  
Helix 301 HHHHHHHHHHHH     HHHHHHHHHHHHHHHHHHHHH      343  
Sheet 301 EEEEEEEEEEEEEE         EEEEEEEEE     EEEE   343  
Turns 301     T    T     TT        T         T        343  
 
 
Total Residues: H: 235   E: 197   T: 45    
       Percent: H: 68.5  E: 57.4  T: 13.1  
  
Fig 8.1 Chou Fasman secondary structure prediction server analysis of TRIB2 amino acid 
sequence. Highlighted in red are S227/S229/S231/K233 sequence and the prediction of Turns (T).  
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Fig 8.1.2  Net TURN P prediction of Beta Turns in proteins. Prediction of the presence of Beta 
turns in TRIB2 protein, output was edited for ease of represenation to analyse amino acids 224-235. 
S227-S331 are all expected Beta turn regions. 
 
 
 
Fig 8.2 PIPE prediction of TRIB2 and C/EBPα protein interaction sites. Q92519 UnitProt 
accession for hTRIB2, P497515 UniProt accession for hC/EBPα  
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Fig 8.3 Sarpred analysis Real Value prediction of surface accessibility of TRIB2. Prediction of 
solvent-accessible surface area amino acids (ASA). ASA scores of S227-39, S229-23, S231-35, 
K233-55.  
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Fig 8.4 Identification of R339 as the TRIB2 binding site on C/EBPα. (Performed by Ciaran 
Forde, Dr. Karen Keeshan) (A) Peptide arrays of immobilized overlapping 18-mer peptides each 
shifted to the right by 3 amino acids encompassing C/EBPα were generated as described in 
Materials and Methods 2.2.7.  Identical peptide arrays were probed with GST-TRIB2 and GST 
respectively. Eight binding spots unique to GST-TRIB2 were identified. The table displays the 
amino acid identity of these spots and reveals that GST-TRIB2 binds to amino acids within the C-
Terminus of C/EBPα. This array is representative of two independent arrays. Dark spots are 
indicative of peptide binding. (B) Specific Alanine Scanning Substitution Arrays (SASSAs) on a 
region spanning the C-Terminus of C/EBPα were probed with GST-TRIB2. A decrease in the 
intensity of the spots upon alanine substitution is indicative of decreased binding of GST-TRIB2 to 
CEBPα. The binding of GST-TRIB2 to each alanine substituted peptide was quantified by 
densitometry and presented as a percentage of the control unmutated WT sequence, with an 
underlay identifying the amino acid which was substituted with an alanine. The intensities of spots 
corresponding to mutated R333, R339, and R343 show a greater than 50% reduction in intensity 
relative to the un-mutated peptide control spot.  (C) Western blot analysis of HEK293t cell lysates 
equally expressing wild type C/EBPα and C/EBPα mutants (left panel). GST pull-down carried out 
using GST-TRIB2 followed by Western blot analysis for GST (right top and bottom panels) and 
C/EBPα (right middle panel), identify R339 as the TRIB2 binding site on C/EBPα.  
8.4 
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Fig 8.5 The C-Terminal LZ domain of C/EBPα is required for its interaction with TRIB2. 
(Performed by Ciaran Forde, Dr. Karen Keeshan). GST pull down using HEK293t lysates 
expressing C/EBPαp42, L12V and GZ proteins. Left panel represents Western blot for C/EBPαp30 
in HEK293t cell lysates. Right panels represent IP for GST followed by western blot for GST (top 
and bottom panels) and C/EBPα (middle panel).  
 
 
Figure 8.6: TRIB2 co-localises with C/EBPα in the nucleus. (Performed by Ciaran Forde, Dr. 
Karen Keeshan) (A) HeLa cells were transfected with vector only control, C/EBPα-Ha alone, 
TRIB2-MYC alone and C/EBPα and TRIB2-MYC together. 16 hrs post transfection cells were 
fractionated into cytoplasmic and soluble nuclear fractions. Protein expression of the each fraction 
was assessed by Western blot. TRIB2-MYC and C/EBPα were both detectable in the nuclear 
fraction when co-expressed. (B) HeLa cells co-expressing TRIB2-MYC (green) and C/EBPα (red) 
were visualised using confocal microscopy. Distinct areas of co-localisation (yellow) were seen to 
occur exclusively within the nucleus (arrows).  
8.5 
8.6 
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